


**CUMULATIVE
SUPPLEMENT 3
March 2024**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2024

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**Cumulative Supplement 3
March 2024**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**CUMULATIVE SUPPLEMENT 3
March 2024**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)

GLENMARK GENERICS INC USA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LIMITED (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD INDIA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
LUPIN LTD (LUPIN LTD)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
VERTICE PHARMA MANAGEMENT CORP (VERTICE)	ENCUBE ETHICALS PRIVATE LTD (ENCUBE)
ZYDUS WORLDWIDE DMCC (ZYDUS)	ZYDUS LIFESCIENCES GLOBAL FZE (ZYDUS LIFESCIENCES)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination

product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2023</u>	<u>MAR</u> <u>2024</u>	<u>JUN</u> <u>2024</u>	<u>SEP</u> <u>2024</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23099 2784 (12.1%)	23058 2802 (12.2%)			
MULTISOURCE	20315 (87.9%)	20256 (87.8%)			
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)	20198 (87.6%)			
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)	58 (0.3%)			
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)			
NEW MOLECULAR ENTITIES APPROVED	8	18			
NUMBER OF APPLICANTS	1214	1219			

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

		TABLET;ORAL		ABACAVIR SULFATE AND LAMIVUDINE					
AB	!	CIPLA	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Jan	CHRS	
		EPZICOM							
	+	@ VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004	Jan	DISC	
		TABLET, FOR SUSPENSION;ORAL		ABACAVIR SULFATE AND LAMIVUDINE					
	+	@ MYLAN LABS LTD	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Jan	DISC	

ACETAMINOPHEN; BUTALBITAL

		TABLET;ORAL		BUTALBITAL AND ACETAMINOPHEN					
AA		QUAGEN	300MG;50MG	A214305	001	Feb 01, 2024	Jan	NEWA	
AA			325MG;50MG	A214291	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

		CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA		QUAGEN	300MG;50MG;40MG	A214288	001	Feb 08, 2024	Jan	NEWA	
>A>	AA		325MG;50MG;40MG	A216376	001	Mar 12, 2024	Mar	NEWA	
	AA	SENORES PHARMS	300MG;50MG;40MG	A214087	001	Aug 13, 2021	Feb	CAHN	
	AA		325MG;50MG;40MG	A214087	002	Aug 13, 2021	Feb	CAHN	
		TABLET;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA		QUAGEN	325MG;50MG;40MG	A214287	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; CODEINE PHOSPHATE

		SOLUTION;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE					
	@	AKORN	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	Feb	DISC	
		TABLET;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE					
	@	SUN PHARM INDS LTD	300MG;30MG	A085868	001		Jan	DISC	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

		TABLET;ORAL		HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
>D>	AA	PRINSTON INC	325MG;5MG	A214928	001	Dec 30, 2021	Mar	DISC	
>A>	@		325MG;5MG	A214928	001	Dec 30, 2021	Mar	DISC	
>D>	AA		325MG;7.5MG	A214928	002	Dec 30, 2021	Mar	DISC	
>A>	@		325MG;7.5MG	A214928	002	Dec 30, 2021	Mar	DISC	
>D>	AA		325MG;10MG	A214928	003	Dec 30, 2021	Mar	DISC	
>A>	@		325MG;10MG	A214928	003	Dec 30, 2021	Mar	DISC	

ACETAZOLAMIDE

		TABLET;ORAL		ACETAZOLAMIDE					
	@	AJANTA PHARMA LTD	125MG	A211151	001	Sep 11, 2023	Feb	DISC	
	@		250MG	A211151	002	Sep 11, 2023	Feb	DISC	
	@	TORRENT	125MG	A213706	001	Jan 26, 2024	Jan	DISC	
AB			125MG	A213706	001	Jan 26, 2024	Jan	NEWA	
	@		250MG	A213706	002	Jan 26, 2024	Jan	DISC	
AB			250MG	A213706	002	Jan 26, 2024	Jan	NEWA	

ACETYLCYSTEINE

		SOLUTION;INHALATION, ORAL		ACETYLCYSTEINE					
	@	EXELA PHARMA	20%	A205643	001	Nov 01, 2023	Feb	DISC	

ACETYLCYSTEINE LYSINE

		FOR SOLUTION;ORAL		LEGUBETI					
	+	GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Feb	NEWA	
	+		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Feb	NEWA	

ACYCLOVIR

OINTMENT; TOPICAL

ACYCLOVIR

>D>	AB	COSETTE	5%	A205591	001	Nov 13, 2017	Mar	DISC
>A>		@	5%	A205591	001	Nov 13, 2017	Mar	DISC

SUSPENSION; ORAL

ACYCLOVIR

>D>	AB	HIKMA	200MG/5ML	A077026	001	Jun 07, 2005	Mar	DISC
>A>		@	200MG/5ML	A077026	001	Jun 07, 2005	Mar	DISC
>D>		@ VISTAPHARM	200MG/5ML	A213951	001	Jan 11, 2021	Mar	CAHN
>A>		@ VISTAPHARM LLC	200MG/5ML	A213951	001	Jan 11, 2021	Mar	CAHN

ADENOSINE

SOLUTION; INTRAVENOUS

ADENOSINE

		@ HOSPIRA	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Feb	DISC
		@	90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Feb	DISC

ALBUTEROL SULFATE

SYRUP; ORAL

ALBUTEROL SULFATE

>D>	AA	HIKMA	EQ 2MG BASE/5ML	A074749	001	Jan 30, 1998	Mar	DISC
>A>		@	EQ 2MG BASE/5ML	A074749	001	Jan 30, 1998	Mar	DISC

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED; INHALATION

AIRSUPRA

+!		ASTRAZENECA	EQ 0.09MG BASE/INH; 0.08MG/INH	N214070	001	Jan 10, 2023	Jan	CPOT
----	--	-------------	--------------------------------	---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

>D>	AB	BRECKENRIDGE	0.25MG	A207507	001	Jul 09, 2018	Mar	CAHN
>D>	AB		0.5MG	A207507	002	Jul 09, 2018	Mar	CAHN
>D>	AB		1MG	A207507	003	Jul 09, 2018	Mar	CAHN
>D>	AB		2MG	A207507	004	Jul 09, 2018	Mar	CAHN
>A>	AB	CHARTWELL RX	0.25MG	A207507	001	Jul 09, 2018	Mar	CAHN
>A>	AB		0.5MG	A207507	002	Jul 09, 2018	Mar	CAHN
>A>	AB		1MG	A207507	003	Jul 09, 2018	Mar	CAHN
>A>	AB		2MG	A207507	004	Jul 09, 2018	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

>D>	AB	ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011	Mar	DISC
>A>		@	0.5MG	A078469	001	Sep 29, 2011	Mar	DISC
>D>	AB		1MG	A078469	002	Sep 29, 2011	Mar	DISC
>A>		@	1MG	A078469	002	Sep 29, 2011	Mar	DISC
>D>	AB		2MG	A078469	003	Sep 29, 2011	Mar	DISC
>A>		@	2MG	A078469	003	Sep 29, 2011	Mar	DISC
>D>	AB		3MG	A078469	004	Sep 29, 2011	Mar	DISC
>A>		@	3MG	A078469	004	Sep 29, 2011	Mar	DISC

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

		@ GENUS	50MG/5ML	A076352	001	Sep 10, 2004	Jan	CAHN
--	--	---------	----------	---------	-----	--------------	-----	------

AMCINONIDE

LOTION; TOPICAL

AMCINONIDE

!		GENUS	0.1%	A076329	001	Nov 06, 2002	Jan	CAHN
---	--	-------	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

AMCINONIDE

AB	!	GENUS	0.1%	A076096	001	Nov 19, 2002	Jan	CAHN
----	---	-------	------	---------	-----	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

>A>	AP	QILU	EQ 250MG BASE/ML	A218146	001	Mar 19, 2024	Mar	NEWA
-----	----	------	------------------	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SOLUTION; ORAL

>D>		AMICAR						
>D>	AA	+! HIKMA	0.25GM/ML	N015230	002			Mar DISC
>A>		+ @	0.25GM/ML	N015230	002			Mar DISC
		AMINOCAPROIC ACID						
>D>	AA	TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020		Mar CHRS
>A>	AA	!	0.25GM/ML	A212494	001	Aug 11, 2020		Mar CHRS
>D>		@ VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020		Mar CAHN
>A>		@ VISTAPHARM LLC	0.25GM/ML	A212814	001	Feb 26, 2020		Mar CAHN
		TABLET; ORAL						
>D>		AMICAR						
>D>	AB	+ HIKMA	500MG	N015197	001			Mar DISC
>A>		+ @	500MG	N015197	001			Mar DISC
>D>	AB	+	1GM	N015197	002	Jun 24, 2004		Mar DISC
>A>		+ @	1GM	N015197	002	Jun 24, 2004		Mar DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

		@ AIPING PHARM INC	EQ 2.5MG BASE	A077759	001	Jul 09, 2007		Feb CAHN
		@	EQ 5MG BASE	A077759	002	Jul 09, 2007		Feb CAHN
		@	EQ 10MG BASE	A077759	003	Jul 09, 2007		Feb CAHN
		@ SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007		Jan DISC
		@	EQ 5MG BASE	A077974	002	Jul 09, 2007		Jan DISC
		@	EQ 10MG BASE	A077974	003	Jul 09, 2007		Jan DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB		SCIEGEN PHARMS INC	EQ 5MG BASE; 20MG	A209010	001	Dec 03, 2018		Feb CMFD
AB			EQ 5MG BASE; 40MG	A209010	002	Dec 03, 2018		Feb CMFD
AB			EQ 10MG BASE; 20MG	A209010	003	Dec 03, 2018		Feb CMFD
AB			EQ 10MG BASE; 40MG	A209010	004	Dec 03, 2018		Feb CMFD

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

>D>	AB	DAVA PHARMS INC	125MG/5ML	A062927	001	Nov 25, 1988		Mar DISC
>A>		@	125MG/5ML	A062927	001	Nov 25, 1988		Mar DISC
>D>	AB		250MG/5ML	A062927	002	Nov 25, 1988		Mar DISC
>A>		@	250MG/5ML	A062927	002	Nov 25, 1988		Mar DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB1	+	TAKEDA PHARMS USA	2.5MG; 2.5MG; 2.5MG; 2.5MG	N021303	001	Oct 11, 2001		Jan CTEC
		ADDERALL XR 15						
AB1	+	TAKEDA PHARMS USA	3.75MG; 3.75MG; 3.75MG; 3.75MG	N021303	006	May 22, 2002		Jan CTEC
		ADDERALL XR 20						
AB1	+	TAKEDA PHARMS USA	5MG; 5MG; 5MG; 5MG	N021303	002	Oct 11, 2001		Jan CTEC
		ADDERALL XR 25						
AB1	+	TAKEDA PHARMS USA	6.25MG; 6.25MG; 6.25MG; 6.25MG	N021303	004	May 22, 2002		Jan CTEC
		ADDERALL XR 30						
AB1	+!	TAKEDA PHARMS USA	7.5MG; 7.5MG; 7.5MG; 7.5MG	N021303	003	Oct 11, 2001		Jan CTEC
		ADDERALL XR 5						
AB1	+	TAKEDA PHARMS USA	1.25MG; 1.25MG; 1.25MG; 1.25MG	N021303	005	May 22, 2002		Jan CTEC
		DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE						
AB1		ACTAVIS ELIZABETH	1.25MG; 1.25MG; 1.25MG; 1.25MG	A077302	001	Jun 22, 2012		Jan CTEC
AB1			2.5MG; 2.5MG; 2.5MG; 2.5MG	A077302	002	Jun 22, 2012		Jan CTEC
AB1			3.75MG; 3.75MG; 3.75MG; 3.75MG	A077302	003	Jun 22, 2012		Jan CTEC
AB1			5MG; 5MG; 5MG; 5MG	A077302	004	Jun 22, 2012		Jan CTEC
AB1			6.25MG; 6.25MG; 6.25MG; 6.25MG	A077302	005	Jun 22, 2012		Jan CTEC
AB1			7.5MG; 7.5MG; 7.5MG; 7.5MG	A077302	006	Jun 22, 2012		Jan CTEC
AB1		ANI PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A205401	001	Jan 22, 2019		Jan CTEC
AB1			2.5MG; 2.5MG; 2.5MG; 2.5MG	A205401	002	Jan 22, 2019		Jan CTEC
AB1			3.75MG; 3.75MG; 3.75MG; 3.75MG	A205401	003	Jan 22, 2019		Jan CTEC
AB1			5MG; 5MG; 5MG; 5MG	A205401	004	Jan 22, 2019		Jan CTEC
AB1			6.25MG; 6.25MG; 6.25MG; 6.25MG	A205401	005	Jan 22, 2019		Jan CTEC
AB1			7.5MG; 7.5MG; 7.5MG; 7.5MG	A205401	006	Jan 22, 2019		Jan CTEC
AB1		ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214959	001	Sep 29, 2021		Jan CTEC

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214959	002	Sep 29, 2021	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214959	003	Sep 29, 2021	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A214959	004	Sep 29, 2021	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214959	005	Sep 29, 2021	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214959	006	Sep 29, 2021	Jan CTEC
AB1	ELITE LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A212037	001	Dec 11, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A212037	002	Dec 11, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A212037	003	Dec 11, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A212037	004	Dec 11, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A212037	005	Dec 11, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A212037	006	Dec 11, 2019	Jan CTEC
AB1	GRANULES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A217027	006	Jan 23, 2023	Jan CTEC
AB1	IMPAX LABS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076852	001	Feb 16, 2016	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A076852	002	Feb 16, 2016	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A076852	003	Feb 16, 2016	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A076852	004	Feb 16, 2016	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A076852	005	Feb 16, 2016	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A076852	006	Feb 16, 2016	Jan CTEC
AB1	LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A214403	004	Nov 26, 2021	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214403	005	Nov 26, 2021	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214403	006	Nov 26, 2021	Jan CTEC
AB1	RHODES PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210651	001	May 17, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210651	002	May 17, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210651	003	May 17, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A210651	004	May 17, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210651	005	May 17, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210651	006	May 17, 2019	Jan CTEC
AB1	SPECGX LLC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211547	001	Apr 22, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211547	002	Apr 22, 2019	Jan CTEC
AB2		3.125MG; 3.125MG; 3.125MG; 3.125MG	A211546	001	Aug 31, 2023	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211547	003	Apr 22, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A211547	004	Apr 22, 2019	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211546	002	Aug 31, 2023	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211547	005	Apr 22, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211547	006	Apr 22, 2019	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A211546	003	Aug 31, 2023	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A211546	004	Aug 31, 2023	Jan CTEC
AB2	SUN PHARM INDS INC	3.125MG; 3.125MG; 3.125MG; 3.125MG	A215997	001	Sep 27, 2023	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A215997	002	Sep 27, 2023	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A215997	003	Sep 27, 2023	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A215997	004	Sep 27, 2023	Jan CTEC
AB1	SUN PHARM INDUSTRIES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Jan CTEC
AB2	TEVA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	A210876	001	Jan 31, 2022	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210876	002	Jan 31, 2022	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A210876	003	Jan 31, 2022	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A210876	004	Jan 31, 2022	Jan CTEC
	MYDAYIS					
AB2	+ TAKEDA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	N022063	001	Jun 20, 2017	Jan CTEC
AB2	+	6.25MG; 6.25MG; 6.25MG; 6.25MG	N022063	002	Jun 20, 2017	Jan CTEC
AB2	+	9.375MG; 9.375MG; 9.375MG; 9.375MG	N022063	003	Jun 20, 2017	Jan CTEC
AB2	+	12.5MG; 12.5MG; 12.5MG; 12.5MG	N022063	004	Jun 20, 2017	Jan CTEC

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb CAHN	
AA		10MG	A212901	002	May 22, 2020	Feb CAHN	
>D>	AA	SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Mar DISC
>A>	@	5MG	A214574	001	Jan 27, 2021	Mar DISC	

TABLET;ORAL

AMPHETAMINE SULFATE

>D>	AA		10MG	A214574	002	Jan 27, 2021	Mar	DISC
>A>		@	10MG	A214574	002	Jan 27, 2021	Mar	DISC
		EVEKEO						
>D>	AA	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar	CAHN
>D>	AA	!	10MG	A200166	002	Aug 09, 2012	Mar	CAHN
>A>	AA	AZURITY	5MG	A200166	001	Aug 09, 2012	Mar	CAHN
>A>	AA	!	10MG	A200166	002	Aug 09, 2012	Mar	CAHN

APIXABAN

TABLET;ORAL

APIXABAN

AB		APOTEX	2.5MG	A210091	001	Feb 16, 2024	Feb	NEWA
AB			5MG	A210091	002	Feb 16, 2024	Feb	NEWA

APREMILAST

TABLET;ORAL

APREMILAST

AB		MANKIND PHARMA	10MG	A211734	001	Feb 07, 2024	Jan	NEWA
AB			20MG	A211734	002	Feb 07, 2024	Jan	NEWA
AB			30MG	A211734	003	Feb 07, 2024	Jan	NEWA

>A> APROCITENTAN

>A> TABLET;ORAL

>A> TRYVIO

>A>		+! IDORSIA	12.5MG	N217686	001	Mar 19, 2024	Mar	NEWA
-----	--	------------	--------	---------	-----	--------------	-----	------

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

ARFORMOTEROL TARTRATE

>A>	AN	PHARMAMAX	EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Mar	NEWA
-----	----	-----------	---------------------	---------	-----	--------------	-----	------

ARIPIPRAZOLE

TABLET;ORAL

ARIPIPRAZOLE

>A>	AB	LUPIN	2MG	A205589	001	Mar 18, 2024	Mar	NEWA
>A>	AB		5MG	A205589	002	Mar 18, 2024	Mar	NEWA
>A>	AB		10MG	A205589	003	Mar 18, 2024	Mar	NEWA
>A>	AB		15MG	A205589	004	Mar 18, 2024	Mar	NEWA
>A>	AB		20MG	A205589	005	Mar 18, 2024	Mar	NEWA
>A>	AB		30MG	A205589	006	Mar 18, 2024	Mar	NEWA

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA INITIO KIT

+	ALKERMES INC	675MG/2.4ML (281.25MG/ML)	N209830	001	Jun 29, 2018	Jan	CPOT
---	--------------	---------------------------	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

LANORINAL

AA	!	SANDOZ	325MG;50MG;40MG	A086996	002	Oct 11, 1985	Jan	CAHN
----	---	--------	-----------------	---------	-----	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

>D>	AB	APOTEX	10MG	A078983	001	May 30, 2017	Mar	CPOT
>A>	AB		EQ 10MG BASE	A078983	001	May 30, 2017	Mar	CPOT
>D>	AB		18MG	A078983	002	May 30, 2017	Mar	CPOT
>A>	AB		EQ 18MG BASE	A078983	002	May 30, 2017	Mar	CPOT
>D>	AB		25MG	A078983	003	May 30, 2017	Mar	CPOT
>A>	AB		EQ 25MG BASE	A078983	003	May 30, 2017	Mar	CPOT
>D>	AB		40MG	A078983	004	May 30, 2017	Mar	CPOT
>A>	AB		EQ 40MG BASE	A078983	004	May 30, 2017	Mar	CPOT
>D>	AB		60MG	A078983	005	May 30, 2017	Mar	CPOT
>A>	AB		EQ 60MG BASE	A078983	005	May 30, 2017	Mar	CPOT
>D>	AB		80MG	A078983	006	May 30, 2017	Mar	CPOT
>A>	AB		EQ 80MG BASE	A078983	006	May 30, 2017	Mar	CPOT
>D>	AB		100MG	A078983	007	May 30, 2017	Mar	CPOT
>A>	AB		EQ 100MG BASE	A078983	007	May 30, 2017	Mar	CPOT
>D>	AB	AUROBINDO PHARMA	10MG	A079016	001	May 30, 2017	Mar	CPOT
>A>	AB		EQ 10MG BASE	A079016	001	May 30, 2017	Mar	CPOT

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

>D>	AB		18MG	A079016	002	May 30, 2017	Mar	CPOT
>A>	AB		EQ 18MG BASE	A079016	002	May 30, 2017	Mar	CPOT
>D>	AB		25MG	A079016	003	May 30, 2017	Mar	CPOT
>A>	AB		EQ 25MG BASE	A079016	003	May 30, 2017	Mar	CPOT
>D>	AB		40MG	A079016	004	May 30, 2017	Mar	CPOT
>A>	AB		EQ 40MG BASE	A079016	004	May 30, 2017	Mar	CPOT
>D>	AB		60MG	A079016	005	May 30, 2017	Mar	CPOT
>A>	AB		EQ 60MG BASE	A079016	005	May 30, 2017	Mar	CPOT
>D>	AB		80MG	A079016	006	May 30, 2017	Mar	CPOT
>A>	AB		EQ 80MG BASE	A079016	006	May 30, 2017	Mar	CPOT
>D>	AB		100MG	A079016	007	May 30, 2017	Mar	CPOT
>A>	AB		EQ 100MG BASE	A079016	007	May 30, 2017	Mar	CPOT
>D>	AB	DR REDDYS	10MG	A090609	001	Feb 23, 2018	Mar	CPOT
>A>	AB		EQ 10MG BASE	A090609	001	Feb 23, 2018	Mar	CPOT
>D>	AB		18MG	A090609	002	Feb 23, 2018	Mar	CPOT
>A>	AB		EQ 18MG BASE	A090609	002	Feb 23, 2018	Mar	CPOT
>D>	AB		25MG	A090609	003	Feb 23, 2018	Mar	CPOT
>A>	AB		EQ 25MG BASE	A090609	003	Feb 23, 2018	Mar	CPOT
>D>	AB		40MG	A090609	004	Feb 23, 2018	Mar	CPOT
>A>	AB		EQ 40MG BASE	A090609	004	Feb 23, 2018	Mar	CPOT
>D>	AB		60MG	A090609	005	Feb 23, 2018	Mar	CPOT
>A>	AB		EQ 60MG BASE	A090609	005	Feb 23, 2018	Mar	CPOT
>D>	AB		80MG	A090609	006	Feb 23, 2018	Mar	CPOT
>A>	AB		EQ 80MG BASE	A090609	006	Feb 23, 2018	Mar	CPOT
>D>	AB		100MG	A090609	007	Feb 23, 2018	Mar	CPOT
>A>	AB		EQ 100MG BASE	A090609	007	Feb 23, 2018	Mar	CPOT
>D>	AB	GLENMARK PHARMS LTD	10MG	A079019	001	May 30, 2017	Mar	CPOT
>A>	AB		EQ 10MG BASE	A079019	001	May 30, 2017	Mar	CPOT
>D>	AB		18MG	A079019	002	May 30, 2017	Mar	CPOT
>A>	AB		EQ 18MG BASE	A079019	002	May 30, 2017	Mar	CPOT
>D>	AB		25MG	A079019	003	May 30, 2017	Mar	CPOT
>A>	AB		EQ 25MG BASE	A079019	003	May 30, 2017	Mar	CPOT
>D>	AB		40MG	A079019	004	May 30, 2017	Mar	CPOT
>A>	AB		EQ 40MG BASE	A079019	004	May 30, 2017	Mar	CPOT
>D>	AB		60MG	A079019	005	May 30, 2017	Mar	CPOT
>A>	AB		EQ 60MG BASE	A079019	005	May 30, 2017	Mar	CPOT
>D>	AB		80MG	A079019	006	May 30, 2017	Mar	CPOT
>A>	AB		EQ 80MG BASE	A079019	006	May 30, 2017	Mar	CPOT
>D>	AB		100MG	A079019	007	May 30, 2017	Mar	CPOT
>A>	AB		EQ 100MG BASE	A079019	007	May 30, 2017	Mar	CPOT
>D>	AB	HETERO LABS LTD V	10MG	A202682	001	Mar 11, 2021	Mar	CPOT
>A>	AB		EQ 10MG BASE	A202682	001	Mar 11, 2021	Mar	CPOT
>D>	AB		18MG	A202682	002	Mar 11, 2021	Mar	CPOT
>A>	AB		EQ 18MG BASE	A202682	002	Mar 11, 2021	Mar	CPOT
>D>	AB		25MG	A202682	003	Mar 11, 2021	Mar	CPOT
>A>	AB		EQ 25MG BASE	A202682	003	Mar 11, 2021	Mar	CPOT
>D>	AB		40MG	A202682	004	Mar 11, 2021	Mar	CPOT
>A>	AB		EQ 40MG BASE	A202682	004	Mar 11, 2021	Mar	CPOT
>D>	AB		60MG	A202682	005	Mar 11, 2021	Mar	CPOT
>A>	AB		EQ 60MG BASE	A202682	005	Mar 11, 2021	Mar	CPOT
>D>	AB		80MG	A202682	006	Mar 11, 2021	Mar	CPOT
>A>	AB		EQ 80MG BASE	A202682	006	Mar 11, 2021	Mar	CPOT
>D>	AB		100MG	A202682	007	Mar 11, 2021	Mar	CPOT
>A>	AB		EQ 100MG BASE	A202682	007	Mar 11, 2021	Mar	CPOT
>D>	AB	@ STRIDES PHARMA	10MG	A079021	001	Feb 18, 2021	Mar	CPOT
>A>	AB		EQ 10MG BASE	A079021	001	Feb 18, 2021	Mar	CPOT
>D>	AB		18MG	A079021	002	Feb 18, 2021	Mar	CPOT
>A>	AB		EQ 18MG BASE	A079021	002	Feb 18, 2021	Mar	CPOT
>D>	AB		25MG	A079021	003	Feb 18, 2021	Mar	CPOT
>A>	AB		EQ 25MG BASE	A079021	003	Feb 18, 2021	Mar	CPOT
>D>	AB		40MG	A079021	004	Feb 18, 2021	Mar	CPOT
>A>	AB		EQ 40MG BASE	A079021	004	Feb 18, 2021	Mar	CPOT
>D>	AB		60MG	A079021	005	Feb 18, 2021	Mar	CPOT
>A>	AB		EQ 60MG BASE	A079021	005	Feb 18, 2021	Mar	CPOT
>D>	AB		80MG	A079021	006	Feb 18, 2021	Mar	CPOT
>A>	AB		EQ 80MG BASE	A079021	006	Feb 18, 2021	Mar	CPOT
>D>	AB		100MG	A079021	007	Feb 18, 2021	Mar	CPOT
>A>	AB		EQ 100MG BASE	A079021	007	Feb 18, 2021	Mar	CPOT
>D>	AB	TEVA PHARMS USA	10MG	A079022	001	May 30, 2017	Mar	CPOT
>A>	AB		EQ 10MG BASE	A079022	001	May 30, 2017	Mar	CPOT
>D>	AB		18MG	A079022	002	May 30, 2017	Mar	CPOT
>A>	AB		EQ 18MG BASE	A079022	002	May 30, 2017	Mar	CPOT

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

>D>	AB		25MG	A079022	003	May 30, 2017	Mar	CPOT
>A>	AB		EQ 25MG BASE	A079022	003	May 30, 2017	Mar	CPOT
>D>	AB		40MG	A079022	004	May 30, 2017	Mar	CPOT
>A>	AB		EQ 40MG BASE	A079022	004	May 30, 2017	Mar	CPOT
>D>	AB		60MG	A079022	005	May 30, 2017	Mar	CPOT
>A>	AB		EQ 60MG BASE	A079022	005	May 30, 2017	Mar	CPOT
>D>	AB		80MG	A079022	006	May 30, 2017	Mar	CPOT
>A>	AB		EQ 80MG BASE	A079022	006	May 30, 2017	Mar	CPOT
>D>	AB		100MG	A079022	007	May 30, 2017	Mar	CPOT
>A>	AB		EQ 100MG BASE	A079022	007	May 30, 2017	Mar	CPOT
>D>	AB	ZYDUS PHARMS USA INC	10MG	A079017	007	Apr 05, 2023	Mar	CPOT
>A>	AB		EQ 10MG BASE	A079017	007	Apr 05, 2023	Mar	CPOT
>D>	AB		18MG	A079017	001	Sep 16, 2010	Mar	CPOT
>A>	AB		EQ 18MG BASE	A079017	001	Sep 16, 2010	Mar	CPOT
	AB		18MG	A079017	001	Sep 16, 2010	Jan	CMS1
>D>	AB		25MG	A079017	002	Sep 16, 2010	Mar	CPOT
>A>	AB		EQ 25MG BASE	A079017	002	Sep 16, 2010	Mar	CPOT
	AB		25MG	A079017	002	Sep 16, 2010	Jan	CMS1
>D>	AB		40MG	A079017	003	Sep 16, 2010	Mar	CPOT
>A>	AB		EQ 40MG BASE	A079017	003	Sep 16, 2010	Mar	CPOT
	AB		40MG	A079017	003	Sep 16, 2010	Jan	CMS1
>D>	AB		60MG	A079017	004	Sep 16, 2010	Mar	CPOT
>A>	AB		EQ 60MG BASE	A079017	004	Sep 16, 2010	Mar	CPOT
	AB		60MG	A079017	004	Sep 16, 2010	Jan	CMS1
>D>	AB		80MG	A079017	005	Sep 16, 2010	Mar	CPOT
>A>	AB		EQ 80MG BASE	A079017	005	Sep 16, 2010	Mar	CPOT
	AB		80MG	A079017	005	Sep 16, 2010	Jan	CMS1
>D>	AB		100MG	A079017	006	Sep 16, 2010	Mar	CPOT
>A>	AB		EQ 100MG BASE	A079017	006	Sep 16, 2010	Mar	CPOT
	AB		100MG	A079017	006	Sep 16, 2010	Jan	CMS1

STRATTERA

>D>		@ LILLY	5MG	N021411	001	Nov 26, 2002	Mar	CPOT
>A>		@	EQ 5MG BASE	N021411	001	Nov 26, 2002	Mar	CPOT
>D>	AB	+	10MG	N021411	002	Nov 26, 2002	Mar	CPOT
>A>	AB	+	EQ 10MG BASE	N021411	002	Nov 26, 2002	Mar	CPOT
>D>	AB	+	18MG	N021411	003	Nov 26, 2002	Mar	CPOT
>A>	AB	+	EQ 18MG BASE	N021411	003	Nov 26, 2002	Mar	CPOT
>D>	AB	+	25MG	N021411	004	Nov 26, 2002	Mar	CPOT
>A>	AB	+	EQ 25MG BASE	N021411	004	Nov 26, 2002	Mar	CPOT
>D>	AB	+	40MG	N021411	005	Nov 26, 2002	Mar	CPOT
>A>	AB	+	EQ 40MG BASE	N021411	005	Nov 26, 2002	Mar	CPOT
>D>	AB	+	60MG	N021411	006	Nov 26, 2002	Mar	CPOT
>A>	AB	+	EQ 60MG BASE	N021411	006	Nov 26, 2002	Mar	CPOT
>D>	AB	+	80MG	N021411	007	Feb 14, 2005	Mar	CPOT
>A>	AB	+	EQ 80MG BASE	N021411	007	Feb 14, 2005	Mar	CPOT
>D>	AB	+	100MG	N021411	008	Feb 14, 2005	Mar	CPOT
>A>	AB	+	EQ 100MG BASE	N021411	008	Feb 14, 2005	Mar	CPOT

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

>D>	AB	ANBISON LAB	EQ 10MG BASE	A211886	001	Jan 25, 2024	Mar	CAHN
	AB		EQ 10MG BASE	A211886	001	Jan 25, 2024	Jan	NEWA
>D>	AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Mar	CAHN
	AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Jan	NEWA
>D>	AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Mar	CAHN
	AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Jan	NEWA
>D>	AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Mar	CAHN
	AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Jan	NEWA
	AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A217118	001	Feb 13, 2024	Feb	NEWA
	AB		EQ 20MG BASE	A217118	002	Feb 13, 2024	Feb	NEWA
	AB		EQ 40MG BASE	A217118	003	Feb 13, 2024	Feb	NEWA
	AB		EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb	NEWA
>D>	AB	INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC
>A>		@	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC
>D>	AB		EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
>A>		@	EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
>D>	AB		EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
>A>		@	EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
>D>	AB		EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
>A>		@	EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
	AB	LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan	NEWA

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan	NEWA
AB		EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan	NEWA
AB		EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan	NEWA
>A>	AB	SHANDONG XINHUA	EQ 10MG BASE	A211886	001	Jan 25, 2024	Mar CAHN
>A>	AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Mar CAHN
>A>	AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Mar CAHN
>A>	AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Mar CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>	AA	ANI PHARMS	0.025MG;2.5MG	A086727	001		Mar DISC
>A>		@	0.025MG;2.5MG	A086727	001		Mar DISC

AVACINCAPTAD PEGOL SODIUM

SOLUTION;INTRAVITREAL

IZERVAY

+!	AB	ASTELLAS	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023	Jan CAHN
----	----	----------	---------------------------------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

>D>	AB	HIKMA	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Mar DISC
>A>		@	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Mar DISC

AZITHROMYCIN

TABLET;ORAL

AZITHROMYCIN

@ YUNG SHIN PHARM

EQ 250MG BASE

A211317 001 Jul 26, 2022 Feb DISC

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

>D>	AT	AKORN	500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995	Mar CAHN
>A>	AT	SAPTALIS PHARMS	500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995	Mar CAHN

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

@ ACIC PHARMS

0.5MG/ML

A216309 001 Aug 10, 2023 Jan DISC

@

2MG/ML

A216309 002 Aug 10, 2023 Jan DISC

TABLET;ORAL

BACLOFEN

>D>	AB	IMPAX	5MG	A077971	003	Jul 07, 2021	Mar DISC
>A>		@	5MG	A077971	003	Jul 07, 2021	Mar DISC
>D>	AB		10MG	A077971	001	Oct 26, 2007	Mar DISC
>A>		@	10MG	A077971	001	Oct 26, 2007	Mar DISC
>D>	AB		20MG	A077971	002	Oct 26, 2007	Mar DISC
>A>		@	20MG	A077971	002	Oct 26, 2007	Mar DISC
	AB	RUBICON	15MG	A209102	004	Feb 05, 2024	Feb CTEC
			15MG	A209102	004	Feb 05, 2024	Jan NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

>D>	AB	ZYDUS	750MG	A217592	001	Jun 08, 2023	Mar CAHN
>A>	AB	ZYDUS LIFESCIENCES	750MG	A217592	001	Jun 08, 2023	Mar CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

>D>	AA	INVAGEN PHARMS	0.5MG	A090294	001	Mar 29, 2010	Mar DISC
>A>		@	0.5MG	A090294	001	Mar 29, 2010	Mar DISC
>D>	AA		1MG	A090294	002	Mar 29, 2010	Mar DISC
>A>		@	1MG	A090294	002	Mar 29, 2010	Mar DISC
>D>	AA		2MG	A090294	003	Mar 29, 2010	Mar DISC
>A>		@	2MG	A090294	003	Mar 29, 2010	Mar DISC

BERDAZIMER SODIUMGEL;TOPICAL
ZELSUVMI

+! LNHC EQ 10.3% BASE N217424 001 Jan 05, 2024 Jan NEWA

BETAMETHASONE DIPROPIONATELOTION, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE>D> AB HIKMA EQ 0.05% BASE A208849 001 Oct 11, 2019 Mar DISC
>A> @ EQ 0.05% BASE A208849 001 Oct 11, 2019 Mar DISCOINTMENT, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE>A> AB AUROBINDO PHARMA LTD EQ 0.05% BASE A218289 001 Apr 10, 2024 Mar NEWA
@ PADAGIS US EQ 0.05% BASE A206118 001 Nov 09, 2017 Jan CAHNBICALUTAMIDETABLET;ORAL
BICALUTAMIDEAB CHARTWELL RX 50MG A091011 001 Jun 10, 2015 Jan CAHN
@ RISING 50MG A079185 001 Jul 06, 2009 Feb CAHNBIMATOPROSTSOLUTION/DROPS;TOPICAL
BIMATOPROST>D> AT HIKMA 0.03% A203051 001 Oct 09, 2018 Mar DISC
>A> @ 0.03% A203051 001 Oct 09, 2018 Mar DISCBIRCH TRITERPENESGEL;TOPICAL
FILSUVEZ

+! CHIESI 10% N215064 001 Dec 18, 2023 Jan CAHN

BISOPROLOL FUMARATETABLET;ORAL
BISOPROLOL FUMARATEAB HARMAN FINOCHEM 5MG A217617 001 Jan 18, 2024 Jan NEWA
AB 10MG A217617 002 Jan 18, 2024 Jan NEWABLEOMYCIN SULFATEINJECTABLE;INJECTION
BLEOMYCIN SULFATE@ TEVA PHARMS USA EQ 15 UNITS BASE/VIAL A065033 001 Jun 27, 2000 Jan DISC
@ EQ 30 UNITS BASE/VIAL A065033 002 Jun 27, 2000 Jan DISCBRIMONIDINE TARTRATESOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE

AB SANDOZ 0.1% A203172 001 Mar 04, 2024 Feb NEWA

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

AB LUPIN LTD EQ 0.075% ACID A211239 001 Feb 02, 2024 Jan NFTG

BROMSITE
AB +! SUN PHARM EQ 0.075% ACID N206911 001 Apr 08, 2016 Jan CFTGBUDESONIDESUSPENSION;ORAL
EOHILIA

+! TAKEDA PHARMS USA 2MG/10ML N213976 001 Feb 09, 2024 Feb NEWA

BUPIVACAINE HYDROCHLORIDEINJECTABLE;INJECTION
BUPIVACAINE HYDROCHLORIDE>A> AP ASPIRO 0.25% A217821 001 Mar 27, 2024 Mar NEWA
>A> AP 0.5% A217821 002 Mar 27, 2024 Mar NEWA
>A> AP 0.75% A217821 003 Mar 27, 2024 Mar NEWA

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATEINJECTABLE; INJECTION
VIVACAINE

! SEPTODONT 0.5%;0.0091MG/ML A077250 001 Sep 27, 2006 Jan CTNA

BUPRENORPHINE HYDROCHLORIDEINJECTABLE; INJECTION
BUPRENORPHINE HYDROCHLORIDE

@ AM REGENT EQ 0.3MG BASE/ML A078331 001 Mar 27, 2007 Jan DISC

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

>D> AB INVAGEN PHARMS 75MG A207389 001 Sep 18, 2017 Mar DISC

>A> @ 75MG A207389 001 Sep 18, 2017 Mar DISC

>D> AB 100MG A207389 002 Sep 18, 2017 Mar DISC

>A> @ 100MG A207389 002 Sep 18, 2017 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@ ANCHEN PHARMS 100MG A091459 001 Jun 09, 2011 Feb DISC

@ 150MG A091459 002 Jun 09, 2011 Feb DISC

@ 150MG A091520 001 Jun 09, 2011 Feb DISC

@ 200MG A091459 003 Jun 09, 2011 Feb DISC

>D> AB1 INVAGEN PHARMS 100MG A206674 001 Feb 09, 2016 Mar DISC

>A> @ 100MG A206674 001 Feb 09, 2016 Mar DISC

>D> AB3 150MG A206556 001 Aug 26, 2016 Mar DISC

>A> @ 150MG A206556 001 Aug 26, 2016 Mar DISC

>D> AB1 150MG A206674 002 Feb 09, 2016 Mar DISC

>A> @ 150MG A206674 002 Feb 09, 2016 Mar DISC

>D> AB1 200MG A206674 003 Feb 09, 2016 Mar DISC

>A> @ 200MG A206674 003 Feb 09, 2016 Mar DISC

>D> AB3 300MG A206556 002 Aug 26, 2016 Mar DISC

>A> @ 300MG A206556 002 Aug 26, 2016 Mar DISC

>D> AB3 @ RISING 150MG A090941 001 May 03, 2010 Feb CAHN

>D> AB3 SCINOPHARM TAIWAN 150MG A210081 001 Nov 03, 2017 Mar CAHN

>D> AB3 300MG A210081 002 Nov 03, 2017 Mar CAHN

>A> AB3 TWI PHARMS 150MG A210081 001 Nov 03, 2017 Mar CAHN

>A> AB3 300MG A210081 002 Nov 03, 2017 Mar CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB AIPING PHARM INC 5MG A202087 001 Dec 16, 2015 Jan CAHN

AB 10MG A202087 002 Dec 16, 2015 Jan CAHN

AB 15MG A202087 003 Dec 16, 2015 Jan CAHN

AB 30MG A202087 004 Dec 16, 2015 Jan CAHN

>D> AB AMNEAL PHARMS CO 5MG A208829 001 May 24, 2017 Mar DISC

>A> @ 5MG A208829 001 May 24, 2017 Mar DISC

>D> AB 7.5MG A208829 002 May 24, 2017 Mar DISC

>A> @ 7.5MG A208829 002 May 24, 2017 Mar DISC

>D> AB 10MG A208829 003 May 24, 2017 Mar DISC

>A> @ 10MG A208829 003 May 24, 2017 Mar DISC

>D> AB 15MG A208829 004 May 24, 2017 Mar DISC

>A> @ 15MG A208829 004 May 24, 2017 Mar DISC

>D> AB 30MG A208829 005 May 24, 2017 Mar DISC

>A> @ 30MG A208829 005 May 24, 2017 Mar DISC

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

>D> AP NEXUS 6MG/ML A207794 001 Jan 14, 2019 Mar DISC

>A> @ 6MG/ML A207794 001 Jan 14, 2019 Mar DISC

CABAZITAXEL

SOLUTION; INTRAVENOUS

CABAZITAXEL

>A> +! ACTAVIS 60MG/6ML (10MG/ML) N207970 001 Mar 14, 2024 Mar NEWA

CALCIPOTRIENESOLUTION; TOPICAL
CALCIPOTRIENE

>D>	AT	HIKMA	0.005%	A077579	001	Nov 19, 2009	Mar	DISC
>A>		@	0.005%	A077579	001	Nov 19, 2009	Mar	DISC

CAPECITABINETABLET; ORAL
CAPECITABINE

AB		HETERO LABS LTD V	150MG	A210203	001	Mar 05, 2024	Feb	NEWA
AB			500MG	A210203	002	Mar 05, 2024	Feb	NEWA

CAPTOPRILTABLET; ORAL
CAPTOPRIL

>A>	AB	INNOGENIX	12.5MG	A074677	004	May 30, 1997	Mar	CAHN
>A>	AB		25MG	A074677	002	May 30, 1997	Mar	CAHN
>A>	AB		50MG	A074677	001	May 30, 1997	Mar	CAHN
>A>	AB		100MG	A074677	003	May 30, 1997	Mar	CAHN
>D>	AB	STASON PHARMS	12.5MG	A074677	004	May 30, 1997	Mar	CAHN
	AB		12.5MG	A074677	004	May 30, 1997	Feb	CAHN
>D>	AB		25MG	A074677	002	May 30, 1997	Mar	CAHN
	AB		25MG	A074677	002	May 30, 1997	Feb	CAHN
>D>	AB		50MG	A074677	001	May 30, 1997	Mar	CAHN
	AB		50MG	A074677	001	May 30, 1997	Feb	CAHN
>D>	AB		100MG	A074677	003	May 30, 1997	Mar	CAHN
	AB		100MG	A074677	003	May 30, 1997	Feb	CAHN

CARBAMAZEPINETABLET; ORAL
CARBAMAZEPINE

AB		BIONPHARMA	200MG	A218221	001	Feb 16, 2024	Feb	NEWA
		TABLET, EXTENDED RELEASE; ORAL						
		CARBAMAZEPINE						
		@ AMNEAL PHARMS	100MG	A212704	001	Sep 22, 2023	Feb	DISC
		@	200MG	A212704	002	Sep 22, 2023	Feb	DISC
		@	400MG	A212704	003	Sep 22, 2023	Feb	DISC
>A>	AB	APOTEX	100MG	A213159	001	Mar 08, 2024	Mar	NEWA
>A>	AB		200MG	A213159	002	Mar 08, 2024	Mar	NEWA
>A>	AB		400MG	A213159	003	Mar 08, 2024	Mar	NEWA

CARBINOXAMINE MALEATETABLET; ORAL
CARBINOXAMINE MALEATE

>D>	AA	INVAGEN PHARMS	4MG	A090435	001	Apr 15, 2010	Mar	DISC
>A>		@	4MG	A090435	001	Apr 15, 2010	Mar	DISC

CARBOPROST TROMETHAMINEINJECTABLE; INJECTION
CARBOPROST TROMETHAMINE

AP		ANI PHARMS	EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jan	NEWA
>A>	AP	MICRO LABS	EQ 0.25MG BASE/ML	A218013	001	Apr 03, 2024	Mar	NEWA

CARMUSTINEINJECTABLE; INJECTION
CARMUSTINE

@	INGENUS PHARMS LLC	100MG/VIAL	A211011	001	Jun 21, 2022	Feb	DISC
---	--------------------	------------	---------	-----	--------------	-----	------

CARVEDILOLTABLET; ORAL
CARVEDILOL

@	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Jan	DISC
@		6.25MG	A076989	002	Sep 05, 2007	Jan	DISC
@		12.5MG	A076989	003	Sep 05, 2007	Jan	DISC
@		25MG	A076989	004	Sep 05, 2007	Jan	DISC

CASPOFUNGIN ACETATEPOWDER; INTRAVENOUS
CASPOFUNGIN ACETATE

>A>	AP	AREVA PHARMS	50MG/VIAL	A211263	001	Oct 01, 2021	Mar	CAHN
>A>	AP		70MG/VIAL	A211263	002	Oct 01, 2021	Mar	CAHN
>D>	AP	UBI	50MG/VIAL	A211263	001	Oct 01, 2021	Mar	CAHN
>D>	AP		70MG/VIAL	A211263	002	Oct 01, 2021	Mar	CAHN

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM
QILU

EQ 3GM BASE/VIAL

A203661 003 Jan 24, 2024 Jan NEWA

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAMPOWDER; INTRAVENOUS
EXBLIFEP

+! ALLECRA THERAPS EQ 2GM BASE/VIAL; 0.5GM/VIAL

N216165 001 Feb 22, 2024 Feb NEWA

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CLAFORAN

+ @ STERIMAX EQ 500MG BASE/VIAL

N050547 001 Jan CAHN

+ @ EQ 1GM BASE/VIAL

N050547 002 Jan CAHN

+ @ EQ 2GM BASE/VIAL

N050547 003 Jan CAHN

+ @ EQ 10GM BASE/VIAL

N050547 004 Dec 29, 1983 Jan CAHN

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ STERIMAX EQ 20MG BASE/ML

N050596 002 May 20, 1985 Jan CAHN

@ EQ 40MG BASE/ML

N050596 004 May 20, 1985 Jan CAHN

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ STERIMAX EQ 20MG BASE/ML

N050596 001 May 20, 1985 Jan CAHN

@ EQ 40MG BASE/ML

N050596 003 May 20, 1985 Jan CAHN

CEFOTETAN DISODIUMINJECTABLE; INJECTION
CEFOTAN

AP + PAI HOLDINGS PHARM EQ 1GM BASE/VIAL

N050588 001 Dec 27, 1985 Feb CMFD

AP + EQ 2GM BASE/VIAL

N050588 002 Dec 27, 1985 Feb CMFD

CEFOTETAN

AP ! FRESENIUS KABI USA EQ 1GM BASE/VIAL

A065374 001 Aug 09, 2007 Feb CTEC

AP ! EQ 2GM BASE/VIAL

A065374 002 Aug 09, 2007 Feb CTEC

CEFPROZILTABLET; ORAL
CEFPROZIL

>A>	AB	ALKEM LABS LTD	250MG	A090857	001	Apr 09, 2024	Mar	NEWA
>A>	AB		500MG	A090857	002	Apr 09, 2024	Mar	NEWA

CEFTRIAZONE SODIUMINJECTABLE; INTRAMUSCULAR, INTRAVENOUS
CEFTRIAZONE

AP DEVA HOLDING AS EQ 250MG BASE/VIAL

A210197 001 Jan 12, 2024 Jan NEWA

AP EQ 500MG BASE/VIAL

A210197 002 Jan 12, 2024 Jan NEWA

AP EQ 1GM BASE/VIAL

A210197 003 Jan 12, 2024 Jan NEWA

AP EQ 2GM BASE/VIAL

A210197 004 Jan 12, 2024 Jan NEWA

CETIRIZINE HYDROCHLORIDESOLUTION; ORAL
CETIRIZINE HYDROCHLORIDE

		@ ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010	Feb	CDFR
AA		AMNEAL PHARMS	5MG/5ML	A090766	001	Oct 07, 2009	Feb	CDFR
		@ APOZEAL PHARMS	5MG/5ML	A078870	001	Apr 27, 2009	Feb	CDFR
		@ AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009	Feb	CDFR
AA		BAJAJ	5MG/5ML	A090191	001	Nov 12, 2009	Feb	CDFR
AA		BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	Feb	CDFR
AA		CHARTWELL MOLECULAR	5MG/5ML	A078876	001	May 11, 2012	Feb	CDFR
		@ LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	Feb	CDFR
AA	!	PADAGIS US	5MG/5ML	A078398	001	Jun 17, 2008	Feb	CDFR
AA		PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Feb	CDFR
		@ RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008	Feb	CDFR
AA		TARO	5MG/5ML	A076601	001	Jun 20, 2008	Feb	CDFR
>D>	AA	TEVA PHARMS	5MG/5ML	A077279	001	May 27, 2008	Mar	DISC

	SOLUTION;ORAL							
	CETIRIZINE HYDROCHLORIDE							
>A>	@	5MG/5ML	A077279	001	May 27, 2008	Mar	DISC	
AA		5MG/5ML	A077279	001	May 27, 2008	Feb	CDFR	
	@ WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Feb	CDFR	
	ZYRTEC							
	@ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CDFR	
	SYRUP;ORAL							
	CETIRIZINE HYDROCHLORIDE							
AA	PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Jan	CMFD	
	<u>CHLORAMPHENICOL SODIUM SUCCINATE</u>							
	INJECTABLE;INJECTION							
	CHLORAMPHENICOL SODIUM SUCCINATE							
	@ FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982	Feb	DISC	
	<u>CHLOROTHIAZIDE SODIUM</u>							
	INJECTABLE;INJECTION							
	CHLOROTHIAZIDE SODIUM							
>D>	AP	RK PHARMA	EQ 500MG BASE/VIAL	A202493	001	Jun 18, 2014	Mar	DISC
>A>	@		EQ 500MG BASE/VIAL	A202493	001	Jun 18, 2014	Mar	DISC
	<u>CHLORPROMAZINE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	CHLORPROMAZINE HYDROCHLORIDE							
>A>	AP	ZYDUS PHARMS	25MG/ML	A217275	001	Mar 13, 2024	Mar	NEWA
	TABLET;ORAL							
	CHLORPROMAZINE HYDROCHLORIDE							
AB	ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Feb	CAHN	
AB		25MG	A212630	002	Nov 29, 2021	Feb	CAHN	
AB		50MG	A212630	003	Nov 29, 2021	Feb	CAHN	
AB		100MG	A212630	004	Nov 29, 2021	Feb	CAHN	
AB		200MG	A212630	005	Nov 29, 2021	Feb	CAHN	
	<u>CHLORZOXAZONE</u>							
	TABLET;ORAL							
	CHLORZOXAZONE							
AA	HAVIX	500MG	A210961	001	Jan 22, 2024	Jan	NEWA	
AA	SENORES PHARMS	250MG	A215158	001	Jul 29, 2021	Feb	CAHN	
AA		500MG	A210961	001	Jan 22, 2024	Feb	CAHN	
	<u>CHOLINE FENOFIBRATE</u>							
	CAPSULE, DELAYED RELEASE;ORAL							
	FENOFIBRIC ACID							
>D>	AB	ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	Mar	DISC
>A>	@		EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	Mar	DISC
>D>	AB		EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	Mar	DISC
>A>	@		EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	Mar	DISC
AB	MACLEODS PHARMS LTD		EQ 45MG FENOFIBRIC ACID	A207796	001	Feb 08, 2024	Feb	NEWA
AB			EQ 135MG FENOFIBRIC ACID	A207796	002	Feb 08, 2024	Feb	NEWA
>D>	AB	SCINOPHARM TAIWAN	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar	CAHN
>D>	AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar	CAHN
>A>	AB	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar	CAHN
>A>	AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar	CAHN
	<u>CICLOPIROX</u>							
	CREAM;TOPICAL							
	CICLOPIROX							
AB	TARO	0.77%	A076790	001	Apr 12, 2005	Jan	CAHN	
	SOLUTION;TOPICAL							
	CICLOPIROX							
>D>	AT	HIKMA	8%	A078270	001	Sep 18, 2007	Mar	DISC
>A>	@		8%	A078270	001	Sep 18, 2007	Mar	DISC
	<u>CILOSTAZOL</u>							
	TABLET;ORAL							
	CILOSTAZOL							
	@ RISING	50MG	A077323	002	Apr 20, 2006	Feb	CAHN	
	@	100MG	A077323	001	Apr 20, 2006	Feb	CAHN	

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

@ PAI HOLDINGS PHARM	EQ 300MG BASE/5ML	A074664	001	Oct 28, 1997	Feb	DISC
@ PHARM ASSOC	EQ 300MG BASE/5ML	A074553	001	Jan 27, 1997	Feb	DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

>D>	@ AKORN	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Mar	CAHN
>A>	@ SAPTALIS PHARMS	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Mar	CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

>D>	!	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	Mar	DISC
>A>	@		212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	Mar	DISC
>D>	AB	!	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	Mar	DISC
>A>	@		425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	Mar	DISC
>D>	AB	DR REDDYS LABS LTD	425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CHRS
>A>	!		425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CTEC
>A>	AB	!	425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CHRS

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPROFLOXACIN; DEXAMETHASONE

>A>	AB	AMNEAL	0.3%;0.1%	A216501	001	Mar 22, 2024	Mar	NEWA
-----	----	--------	-----------	---------	-----	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

>A>	AP	HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Mar	NEWA
>A>	AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar	CMS1

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Jan	CAHN
AB		EQ 20MG BASE	A077046	002	Nov 24, 2004	Jan	CAHN
AB		EQ 40MG BASE	A077046	003	Nov 24, 2004	Jan	CAHN
	@ TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006	Jan	CAHN
	@	EQ 20MG BASE	A077278	002	Mar 22, 2006	Jan	CAHN
	@	EQ 40MG BASE	A077278	003	Mar 22, 2006	Jan	CAHN

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

@ NEW HEIGHTS	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Jan	CAHN
---------------	-------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

>A>	AB1	ALEMBIC	EQ 1% BASE	A212466	001	Apr 02, 2024	Mar	NEWA
	@ AMNEAL		EQ 1% BASE	A215219	001	Nov 03, 2022	Feb	DISC

GEL;VAGINAL

XACIATO

+!	ORGANON LLC	EQ 2% BASE	N215650	001	Dec 07, 2021	Jan	CAHN
----	-------------	------------	---------	-----	--------------	-----	------

CLOBAZAM

TABLET;ORAL

CLOBAZAM

@ BRECKENRIDGE	20MG	A209308	002	Oct 22, 2018	Jan	DISC
----------------	------	---------	-----	--------------	-----	------

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

>A>	AB2	TARO	0.05%	A208563	001	Mar 14, 2024	Mar	NEWA
-----	-----	------	-------	---------	-----	--------------	-----	------

CREAM;TOPICAL

CORMAX

>D>	AB1	HIKMA	0.05%	A074220	001	May 16, 1997	Mar	DISC
>A>	@		0.05%	A074220	001	May 16, 1997	Mar	DISC

	GEL;TOPICAL						
>D>	EMBELINE						
>D>	AB	HIKMA	0.05%	A076141	001	Apr 12, 2002	Mar DISC
>A>		@	0.05%	A076141	001	Apr 12, 2002	Mar DISC
	OINTMENT;TOPICAL						
>D>	EMBELINE						
>D>	AB	HIKMA	0.05%	A074221	001	Mar 31, 1995	Mar DISC
>A>		@	0.05%	A074221	001	Mar 31, 1995	Mar DISC
	SHAMPOO;TOPICAL						
	CLOBETASOL PROPIONATE						
>D>	AB	HIKMA	0.05%	A209871	001	Oct 27, 2017	Mar DISC
>A>		@	0.05%	A209871	001	Oct 27, 2017	Mar DISC
	SOLUTION;TOPICAL						
>D>	EMBELINE						
>D>	AT	HIKMA	0.05%	A074222	001	Dec 06, 1995	Mar DISC
>A>		@	0.05%	A074222	001	Dec 06, 1995	Mar DISC
>A>	SUSPENSION/DROPS;OPHTHALMIC						
>A>	CLOBETASOL PROPIONATE						
>A>	+!	FORMOSA	0.05%	N218158	001	Mar 04, 2024	Mar NEWA

CLOMIPRAMINE HYDROCHLORIDE

	CAPSULE;ORAL						
	CLOMIPRAMINE HYDROCHLORIDE						
>A>	AB	CHARTWELL RX	25MG	A074364	001	Mar 29, 1996	Mar CAHN
>A>	AB		50MG	A074364	002	Mar 29, 1996	Mar CAHN
>A>	AB		75MG	A074364	003	Mar 29, 1996	Mar CAHN
>D>	AB	RK PHARMA	25MG	A213221	001	Jun 22, 2020	Mar DISC
>A>		@	25MG	A213221	001	Jun 22, 2020	Mar DISC
>D>	AB		50MG	A213221	002	Jun 22, 2020	Mar DISC
>A>		@	50MG	A213221	002	Jun 22, 2020	Mar DISC
>D>	AB		75MG	A213221	003	Jun 22, 2020	Mar DISC
>A>		@	75MG	A213221	003	Jun 22, 2020	Mar DISC
>D>	AB	SANDOZ	25MG	A074364	001	Mar 29, 1996	Mar CAHN
>D>	AB		50MG	A074364	002	Mar 29, 1996	Mar CAHN
>D>	AB		75MG	A074364	003	Mar 29, 1996	Mar CAHN

CLONIDINE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL						
	CLONIDINE HYDROCHLORIDE						
>D>	AB1	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	Mar DISC
>A>		@	0.1MG	A202984	001	Sep 30, 2013	Mar DISC
		@ BLUEPHARMA INDUSTRIA	0.1MG	A211433	001	Oct 12, 2018	Jan CAHN

CLOTRIMAZOLE

	TROCHE/LOZENGE;ORAL						
	CLOTRIMAZOLE						
AB		THINQ PHARM-CRO PVT	10MG	A215641	001	Feb 29, 2024	Feb NEWA

COBICISTAT

	TABLET;ORAL						
	COBICISTAT						
AB		MYLAN LABS LTD	150MG	A209986	001	Feb 07, 2024	Jan NFTG
		TYBOST					
AB	+!	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Jan CFTG

COCAINE HYDROCHLORIDE

	SOLUTION;NASAL						
	GOPRELTO						
	+!	NODEN PHARMA	4%	N209963	001	Dec 14, 2017	Jan CAHN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

	SYRUP;ORAL						
	PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE						
>D>	AA	HIKMA	10MG/5ML;5MG/5ML;6.25MG/5ML	A040674	001	Dec 23, 2014	Mar DISC
>A>		@	10MG/5ML;5MG/5ML;6.25MG/5ML	A040674	001	Dec 23, 2014	Mar DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

>D>	AA	HIKMA	10MG/5ML; 6.25MG/5ML	A040151	001	Aug 26, 1997	Mar	DISC
>A>		@	10MG/5ML; 6.25MG/5ML	A040151	001	Aug 26, 1997	Mar	DISC

CORTICOTROPIN

INJECTABLE; INJECTION

ACTHAR GEL (AUTOINJECTOR)

>A>		+!	MALLINCKRODT ARD	40 UNITS/0.5ML	N008372	003	Feb 29, 2024	Mar	NEWA
>A>		+!		80 UNITS/ML	N008372	004	Feb 29, 2024	Mar	NEWA

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOPENTOLATE HYDROCHLORIDE

>D>		@	AKORN	0.5%	A205937	001	Dec 09, 2015	Mar	CAHN
>A>		@	SAPTALIS PHARMS	0.5%	A205937	001	Dec 09, 2015	Mar	CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP			HIKMA	500MG/VIAL	A216958	001	Dec 18, 2023	Jan	CAHN
AP				1GM/VIAL	A216958	002	Dec 18, 2023	Jan	CAHN
AP				2GM/VIAL	A216958	003	Dec 18, 2023	Jan	CAHN

SOLUTION; INTRAVENOUS

CYCLOPHOSPHAMIDE

		+ @	BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jan	CAHN
		+ @		1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jan	CAHN

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

		@	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Feb	DISC
--	--	---	-------------	---------	---------	-----	--------------	-----	------

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

ELCYS

		+ @	EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Jan	DISC
--	--	-----	--------------	-----------------------	---------	-----	--------------	-----	------

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

		+ @	RECORDATI RARE	0.5MG/VIAL	N050682	001		Jan	DISC
--	--	-----	----------------	------------	---------	-----	--	-----	------

DACTINOMYCIN

AP		!	EUGIA PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CHRS
----	--	---	--------------	------------	---------	-----	--------------	-----	------

>A> DANICOPAN

>A> TABLET; ORAL

>A> VOYDEYA

>A>		+	ALEXION PHARMS INC	50MG	N218037	001	Mar 29, 2024	Mar	NEWA
-----	--	---	--------------------	------	---------	-----	--------------	-----	------

>A>		+!		100MG	N218037	002	Mar 29, 2024	Mar	NEWA
-----	--	----	--	-------	---------	-----	--------------	-----	------

DAPSONE

GEL; TOPICAL

DAPSONE

		@	PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	Jan	DISC
--	--	---	----------------	----	---------	-----	--------------	-----	------

		@		7.5%	A212657	001	Nov 01, 2023	Jan	DISC
--	--	---	--	------	---------	-----	--------------	-----	------

DEFERASIROX

TABLET; ORAL

DEFERASIROX

>A>	AB		MYLAN	90MG	A211395	001	Mar 22, 2024	Mar	NEWA
-----	----	--	-------	------	---------	-----	--------------	-----	------

>A>	AB			180MG	A211395	002	Mar 22, 2024	Mar	NEWA
-----	----	--	--	-------	---------	-----	--------------	-----	------

>A>	AB			360MG	A211395	003	Mar 22, 2024	Mar	NEWA
-----	----	--	--	-------	---------	-----	--------------	-----	------

DEFLAZACORT

TABLET; ORAL

DEFLAZACORT

AB		AUROBINDO PHARMA LTD	6MG	A217123	001	Feb 09, 2024	Feb NFTG
AB			18MG	A217123	002	Feb 09, 2024	Feb NFTG
AB			30MG	A217123	003	Feb 09, 2024	Feb NFTG
AB			36MG	A217123	004	Feb 09, 2024	Feb NFTG
EMFLAZA							
AB	+	PTC THERAP	6MG	N208684	001	Feb 09, 2017	Feb CFTG
AB	+		18MG	N208684	002	Feb 09, 2017	Feb CFTG
AB	+		30MG	N208684	003	Feb 09, 2017	Feb CFTG
AB	+		36MG	N208684	004	Feb 09, 2017	Feb CFTG

DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS

KYBELLA

AP	+	ABBVIE	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Jan CAHN
----	---	--------	--------------------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

>A>	AB	CHARTWELL RX	10MG	A072103	002	May 24, 1988	Mar CAHN
>A>	AB		25MG	A072103	003	May 24, 1988	Mar CAHN
>A>	AB		50MG	A072103	004	May 24, 1988	Mar CAHN
>A>	AB		75MG	A072103	005	Jun 20, 1988	Mar CAHN
>A>	AB		100MG	A072103	001	Jun 20, 1988	Mar CAHN
>A>	AB		150MG	A072103	006	Jun 20, 1988	Mar CAHN
>D>	AB	SANDOZ	10MG	A072103	002	May 24, 1988	Mar CAHN
>D>	AB		25MG	A072103	003	May 24, 1988	Mar CAHN
>D>	AB		50MG	A072103	004	May 24, 1988	Mar CAHN
>D>	AB		75MG	A072103	005	Jun 20, 1988	Mar CAHN
>D>	AB		100MG	A072103	001	Jun 20, 1988	Mar CAHN
>D>	AB		150MG	A072103	006	Jun 20, 1988	Mar CAHN

DESLORATADINE

TABLET; ORAL

DESLORATADINE

@ CHARTWELL RX

5MG

A078364 001 Dec 03, 2010 Jan CAHN

DESMOPRESSIN ACETATE

TABLET; ORAL

DESMOPRESSIN ACETATE

@ ACTAVIS LABS FL INC

0.1MG

A076470 001 Jul 01, 2005 Feb DISC

@

0.2MG

A076470 002 Jul 01, 2005 Feb DISC

>A>	AB	AUROBINDO PHARMA	0.1MG	A213095	001	Mar 21, 2024	Mar NEWA
-----	----	------------------	-------	---------	-----	--------------	----------

>A>	AB		0.2MG	A213095	002	Mar 21, 2024	Mar NEWA
-----	----	--	-------	---------	-----	--------------	----------

DESONIDE

OINTMENT; TOPICAL

DESONIDE

>D>	AB	HIKMA	0.05%	A208836	001	Mar 27, 2017	Mar DISC
>A>		@	0.05%	A208836	001	Mar 27, 2017	Mar DISC

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

>D>	AB	COSETTE	0.25%	A209595	001	Mar 04, 2020	Mar DISC
>A>		@	0.25%	A209595	001	Mar 04, 2020	Mar DISC
		@ SAPTALIS PHARMS	0.05%	A203787	001	Jan 06, 2017	Feb CAHN
		@	0.25%	A203234	001	Jun 12, 2015	Feb CAHN

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

@ PANGEA

0.25MG

A088149 001 Apr 28, 1983 Jan CAHN

>A>	AB	ZYDUS LIFESCIENCES	0.5MG	A216282	001	Feb 07, 2024	Mar CAHN
>A>	AB		0.75MG	A216282	002	Feb 07, 2024	Mar CAHN
>A>	AB		1.5MG	A216282	003	Feb 07, 2024	Mar CAHN
>A>	AB		2MG	A216283	001	Feb 07, 2024	Mar CAHN
>A>	AB		4MG	A216282	004	Feb 07, 2024	Mar CAHN
>A>	AB		6MG	A216282	005	Feb 07, 2024	Mar CAHN

TABLET;ORAL

DEXAMETHASONE

>D>	AB	ZYDUS PHARMS	0.5MG	A216282	001	Feb 07, 2024	Mar	CAHN
	AB		0.5MG	A216282	001	Feb 07, 2024	Jan	NEWA
>D>	AB		0.75MG	A216282	002	Feb 07, 2024	Mar	CAHN
	AB		0.75MG	A216282	002	Feb 07, 2024	Jan	NEWA
>D>	AB		1.5MG	A216282	003	Feb 07, 2024	Mar	CAHN
	AB		1.5MG	A216282	003	Feb 07, 2024	Jan	NEWA
>D>	AB		2MG	A216283	001	Feb 07, 2024	Mar	CAHN
	AB		2MG	A216283	001	Feb 07, 2024	Jan	NEWA
>D>	AB		4MG	A216282	004	Feb 07, 2024	Mar	CAHN
	AB		4MG	A216282	004	Feb 07, 2024	Jan	NEWA
>D>	AB		6MG	A216282	005	Feb 07, 2024	Mar	CAHN
	AB		6MG	A216282	005	Feb 07, 2024	Jan	NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	@	GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML	A214891	001	Jul 28, 2023	Feb	DISC
	@		EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb	DISC
>A>	AP	MICRO LABS	EQ 10MG PHOSPHATE/ML	A217797	001	Mar 27, 2024	Mar	NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

>D>	AA	PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Mar	DISC
>A>		+ @	2MG/5ML	A088251	001	Mar 23, 1984	Mar	DISC
		POLMON						
>D>	AA	CAPELLON PHARMS LLC	2MG/5ML	A202520	001	Jul 16, 2018	Mar	CHRS
>A>		!	2MG/5ML	A202520	001	Jul 16, 2018	Mar	CTEC
>A>	AA	!	2MG/5ML	A202520	001	Jul 16, 2018	Mar	CHRS

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXLANSOPRAZOLE

	AB	MYLAN	30MG	A205205	001	Jan 19, 2024	Jan	NEWA
	AB		60MG	A205205	002	Jan 19, 2024	Jan	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

>D>	AA	ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Mar	CAHN
>D>	AA		5MG	A090533	002	Oct 25, 2011	Mar	CAHN
>D>	AA		7.5MG	A090533	003	Oct 25, 2011	Mar	CAHN
>D>	AA		10MG	A090533	004	Oct 25, 2011	Mar	CAHN
>D>	AA		15MG	A090533	005	Oct 25, 2011	Mar	CAHN
>D>	AA		20MG	A090533	006	Oct 25, 2011	Mar	CAHN
>D>	AA		30MG	A090533	007	Oct 25, 2011	Mar	CAHN
>A>	AA	AZURITY	2.5MG	A090533	001	Oct 25, 2011	Mar	CAHN
>A>	AA		5MG	A090533	002	Oct 25, 2011	Mar	CAHN
>A>	AA		7.5MG	A090533	003	Oct 25, 2011	Mar	CAHN
>A>	AA		10MG	A090533	004	Oct 25, 2011	Mar	CAHN
>A>	AA		15MG	A090533	005	Oct 25, 2011	Mar	CAHN
>A>	AA		20MG	A090533	006	Oct 25, 2011	Mar	CAHN
>A>	AA		30MG	A090533	007	Oct 25, 2011	Mar	CAHN
		@	TRIS PHARMA INC	A206095	001	Aug 18, 2022	Jan	DISC
		@		A206095	002	Aug 18, 2022	Jan	DISC

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

>A>	AP	AM REGENT	50MG/ML	A217263	001	Apr 08, 2024	Mar	NEWA
-----	----	-----------	---------	---------	-----	--------------	-----	------

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

	@	HIKMA	5MG/ML (5MG/ML)	A070311	002	Dec 16, 1985	Jan	NEWA
	@		10MG/2ML (5MG/ML)	A070311	003	Dec 16, 1985	Jan	NEWA
AP			50MG/10ML (5MG/ML)	A070311	001	Dec 16, 1985	Jan	CPO7

DICHLORPHENAMIDETABLET; ORAL
ORMALVI

AB	TORRENT	50MG	A215924	001	Dec 29, 2022	Feb	CTNA
----	---------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUMSOLUTION; TOPICAL
DICLOFENAC SODIUM

>D>	AB	LUPIN PHARMS	2%	A208021	001	Sep 20, 2022	Mar	CHRS
>A>	AB	!	2%	A208021	001	Sep 20, 2022	Mar	CHRS
>D>		PENNSAID						
>D>	AB	+! HORIZON	2%	N204623	001	Jan 16, 2014	Mar	DISC
>A>		+ @	2%	N204623	001	Jan 16, 2014	Mar	DISC

DIGOXINELIXIR; ORAL
DIGOXIN

AA	VISTAPHARM LLC	0.05MG/ML	A213000	001	Oct 04, 2019	Feb	CAHN
----	----------------	-----------	---------	-----	--------------	-----	------

DIHYDROERGOTAMINE MESYLATESPRAY, METERED; NASAL
DIHYDROERGOTAMINE MESYLATE

>D>	AB	AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Mar	DISC
>A>		@	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Mar	DISC
		TRUDHESA						
		+! JN BIDCO	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Feb	CAHN

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

@ SUN PHARM 360MG

A090492 005 Oct 28, 2011 Feb DISC

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

>A>	AP	HIKMA	5MG/ML	A078538	001	Dec 17, 2008	Mar	CAHN
>D>	AP	HIKMA FARMACEUTICA	5MG/ML	A202651	001	Aug 09, 2012	Mar	DISC
>A>		@	5MG/ML	A202651	001	Aug 09, 2012	Mar	DISC
>D>	AP	WEST-WARD PHARMS INT	5MG/ML	A078538	001	Dec 17, 2008	Mar	CAHN

DIPHENHYDRAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

>A>	AP	GLAND PHARMA LTD	50MG/ML	A218448	001	Mar 20, 2024	Mar	NEWA
-----	----	------------------	---------	---------	-----	--------------	-----	------

DIPYRIDAMOLETABLET; ORAL
DIPYRIDAMOLE

@	GENUS	25MG	A040898	001	Apr 23, 2008	Jan	CAHN
@		50MG	A040898	002	Apr 23, 2008	Jan	CAHN
@		75MG	A040898	003	Apr 23, 2008	Jan	CAHN

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

AP	ACIC PHARMS	80MG/4ML (20MG/ML)	A216677	002	Feb 28, 2024	Feb	NEWA
AP		20MG/ML (20MG/ML)	A216677	001	Feb 28, 2024	Feb	NEWA

SOLUTION; INTRAVENOUS
DOCETAXEL

+ @	AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jan	CAHN
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jan	CAHN
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jan	CAHN

DOLUTEGRAVIR SODIUMTABLET; ORAL
TIVICAY

+ @	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jan	DISC
+ @		EQ 25MG BASE	N204790	003	Jun 09, 2016	Jan	DISC

DONEPEZIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL
DONEPEZIL HYDROCHLORIDE

>D>	AB	MACLEODS PHARMS LTD	10MG	A201787	002	Dec 14, 2012	Mar	CHRS
>A>	AB	!	10MG	A201787	002	Dec 14, 2012	Mar	CHRS
>D>	AB	SANDOZ	5MG	A091198	001	May 10, 2011	Mar	DISC
>A>		@	5MG	A091198	001	May 10, 2011	Mar	DISC
>D>	AB	!	10MG	A091198	002	May 10, 2011	Mar	DISC
>A>		@	10MG	A091198	002	May 10, 2011	Mar	DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

>D>	AT	HIKMA	EQ 2% BASE	A077846	001	Oct 28, 2008	Mar	DISC
>A>		@	EQ 2% BASE	A077846	001	Oct 28, 2008	Mar	DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>D>	AT1	HIKMA	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	Mar	DISC
>A>		@	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	Mar	DISC

DOXAZOSIN MESYLATE

TABLET;ORAL
DOXAZOSIN MESYLATE

>D>		@ AUROBINDO PHARMA USA	EQ 1MG BASE	A075509	001	Oct 19, 2000	Mar	CMFD
>A>	AB		EQ 1MG BASE	A075509	001	Oct 19, 2000	Mar	CMFD
>D>		@	EQ 2MG BASE	A075509	002	Oct 19, 2000	Mar	CMFD
>A>	AB		EQ 2MG BASE	A075509	002	Oct 19, 2000	Mar	CMFD
>D>		@	EQ 4MG BASE	A075509	003	Oct 19, 2000	Mar	CMFD
>A>	AB		EQ 4MG BASE	A075509	003	Oct 19, 2000	Mar	CMFD
>D>		@	EQ 8MG BASE	A075509	004	Oct 19, 2000	Mar	CMFD
>A>	AB		EQ 8MG BASE	A075509	004	Oct 19, 2000	Mar	CMFD

DOXERCALCIFEROL

INJECTABLE;INJECTION
DOXERCALCIFEROL

		@ AMNEAL	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	Jan	DISC
		@	4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	Jan	DISC
AP			4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jan	CMFD

DOXYCYCLINE

CAPSULE;ORAL
DOXYCYCLINE

>A>	AB	DR REDDYS	40MG	A218034	001	Apr 08, 2024	Mar	NFTG
>A>	AB	LUPIN	40MG	A216631	001	Apr 08, 2024	Mar	NFTG
		ORACEA						
>D>		+! GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Mar	CFTG
>A>	AB	+!	40MG	N050805	001	May 26, 2006	Mar	CFTG

DOXYCYCLINE HYCLATE

CAPSULE;ORAL
ACTICLATE CAP
+ @ CHARTWELL RX
INJECTABLE;INJECTION
DOXYCYCLINE HYCLATE

		@ CHARTWELL RX	EQ 75MG BASE	N208253	001	Apr 26, 2016	Jan	CAHN
>A>	AP	LUPIN LTD	EQ 100MG BASE/VIAL	A217794	001	Mar 14, 2024	Mar	NEWA
		TABLET;ORAL ACTICLATE						
	AB	+ CHARTWELL RX	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jan	CAHN
	AB	+!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jan	CAHN
		TABLET, DELAYED RELEASE;ORAL DORYX						
		+ @ MAYNE PHARMA	EQ 75MG BASE	N050795	001	May 06, 2005	Feb	DISC
		+ @	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb	DISC

DRONABINOLCAPSULE;ORAL
DRONABINOL

>D>	AB	HIKMA	2.5MG	A079217	001	Jun 20, 2014	Mar	DISC
>A>		@	2.5MG	A079217	001	Jun 20, 2014	Mar	DISC
>D>	AB		5MG	A079217	002	Jun 20, 2014	Mar	DISC
>A>		@	5MG	A079217	002	Jun 20, 2014	Mar	DISC
>D>	AB		10MG	A079217	003	Jun 20, 2014	Mar	DISC
>A>		@	10MG	A079217	003	Jun 20, 2014	Mar	DISC

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

DRONEDARONE HYDROCHLORIDE

AB		LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan	NFTG
AB	+	! SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan	CFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

@	ANCHEN PHARMS	EQ 20MG BASE
@		EQ 30MG BASE
@		EQ 60MG BASE
@	MARKSANS PHARMA	EQ 20MG BASE
@		EQ 30MG BASE
@		EQ 60MG BASE

A090780	001	Oct 28, 2015	Feb	DISC
A090780	002	Oct 28, 2015	Feb	DISC
A090780	003	Oct 28, 2015	Feb	DISC
A090723	001	Dec 11, 2013	Feb	DISC
A090723	002	Dec 11, 2013	Feb	DISC
A090723	003	Dec 11, 2013	Feb	DISC

DUTASTERIDE

CAPSULE;ORAL

AVODART

>A>	AB	+	! WAYLIS THERAP	0.5MG	N021319	001	Nov 20, 2001	Mar	CAHN
>D>	AB	+	! WOODWARD	0.5MG	N021319	001	Nov 20, 2001	Mar	CAHN
			DUTASTERIDE						
>D>	AB		BIONPHARMA	0.5MG	A200899	001	Nov 20, 2015	Mar	CAHN
>A>	AB		CHARTWELL	0.5MG	A200899	001	Nov 20, 2015	Mar	CAHN
		@	VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Feb	DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>D>	AB		STRIDES PHARMA	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Mar	DISC
>A>		@		600MG;200MG;300MG	A201802	001	Oct 03, 2023	Mar	DISC

ENALAPRIL MALEATE

FOR SOLUTION;ORAL

EPANED KIT

>A>		+ @	AZURITY	1MG/ML	N204308	001	Aug 13, 2013	Mar	CAHN
>D>		+ @	SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013	Mar	CAHN

SOLUTION;ORAL

ENALAPRIL MALEATE

>D>		@	AMNEAL	1MG/ML	A212894	001	Jun 29, 2022	Mar	CMFD
>A>	AB			1MG/ML	A212894	001	Jun 29, 2022	Mar	CMFD

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

EPINEPHRINE

+	!	BPI LABS	30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Feb	NEWA
---	---	----------	--------------------	---------	-----	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

XYLOCAINE W/ EPINEPHRINE

+	@	FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003		Feb	CRLD
---	---	--------------------	--------------	---------	-----	--	-----	------

EPLERENONE

TABLET;ORAL

EPLERENONE

>D>	AB		PRASCO	25MG	A203896	001	Feb 02, 2017	Mar	DISC
>A>		@		25MG	A203896	001	Feb 02, 2017	Mar	DISC
>D>	AB			50MG	A203896	002	Feb 02, 2017	Mar	DISC
>A>		@		50MG	A203896	002	Feb 02, 2017	Mar	DISC
AB			SLATE RUN PHARMA	25MG	A212765	001	Aug 10, 2020	Feb	CAHN

	TABLET;ORAL							
	EPLERENONE							
AB		50MG		A212765	002	Aug 10, 2020	Feb	CAHN
	<u>EPLONTERSEN SODIUM</u>							
	SOLUTION;SUBCUTANEOUS							
	WAINUA (AUTOINJECTOR)							
	+	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Feb	CTNA
	+		EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Jan	CAHN
	<u>EPOPROSTENOL SODIUM</u>							
	INJECTABLE;INJECTION							
	EPOPROSTENOL SODIUM							
AP1	MEITHEAL		EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Jan	CAHN
AP1			EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Jan	CAHN
	<u>ERGOTAMINE TARTRATE</u>							
	TABLET;SUBLINGUAL							
	ERGOMAR							
	!	PANGEA	2MG	A087693	001	Feb 24, 1983	Feb	CAHN
	<u>ERIBULIN MESYLATE</u>							
	SOLUTION;INTRAVENOUS							
>A>	ERIBULIN MESYLATE							
>A>	AP	GLAND PHARMA LTD	1MG/2ML (0.5MG/ML)	A218047	001	Apr 05, 2024	Mar	NFTG
		HALAVEN						
>D>	+	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010	Mar	CFTG
>A>	AP	+	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010	Mar	CFTG
	<u>ERTAPENEM SODIUM</u>							
	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS							
	ERTAPENEM SODIUM							
	@	SUN PHARM	EQ 1GM BASE/VIAL	A209145	001	May 02, 2023	Jan	DISC
	<u>ERYTHROMYCIN</u>							
	CAPSULE, DELAYED REL PELLETS;ORAL							
	ERYTHROMYCIN							
>D>	AB	ARBOR PHARMS LLC	250MG	A062746	001	Dec 22, 1986	Mar	CAHN
>A>	AB	AZURITY	250MG	A062746	001	Dec 22, 1986	Mar	CAHN
	OINTMENT;OPHTHALMIC							
	ERYTHROMYCIN							
>D>	AT	BAUSCH AND LOMB	0.5%	A064067	001	Jul 29, 1994	Mar	CHRS
>A>	AT	!	0.5%	A064067	001	Jul 29, 1994	Mar	CHRS
>D>	AT	!	PADAGIS US	A062447	001	Sep 26, 1983	Mar	DISC
>A>		@	0.5%	A062447	001	Sep 26, 1983	Mar	DISC
	TABLET;ORAL							
	ERYTHROMYCIN							
>D>	AB	ARBOR PHARMS LLC	250MG	A061621	001		Mar	CAHN
>D>	AB		500MG	A061621	002		Mar	CAHN
>A>	AB	AZURITY	250MG	A061621	001		Mar	CAHN
>A>	AB		500MG	A061621	002		Mar	CAHN
	TABLET, DELAYED RELEASE;ORAL							
	ERY-TAB							
>D>	AB	ARBOR PHARMS LLC	250MG	A062298	001		Mar	CAHN
>D>	AB		333MG	A062298	003	Mar 29, 1982	Mar	CAHN
>D>	AB	!	500MG	A062298	002		Mar	CAHN
>A>	AB	AZURITY	250MG	A062298	001		Mar	CAHN
>A>	AB		333MG	A062298	003	Mar 29, 1982	Mar	CAHN
>A>	AB	!	500MG	A062298	002		Mar	CAHN
	<u>ERYTHROMYCIN ETHYLSUCCINATE</u>							
	TABLET;ORAL							
	E.E.S. 400							
>D>		@	ARBOR PHARMS LLC	EQ 400MG BASE	A061905	001		Mar
>D>	BX	!		EQ 400MG BASE	A061905	002	Aug 12, 1982	Mar
>A>		@	AZURITY	EQ 400MG BASE	A061905	001		Mar
>A>	BX	!		EQ 400MG BASE	A061905	002	Aug 12, 1982	Mar
	ERYTHROMYCIN ETHYLSUCCINATE							
>D>	BX	!	ARBOR PHARMS LLC	EQ 400MG BASE	A061904	001		Mar
>A>	BX	!	AZURITY	EQ 400MG BASE	A061904	001		Mar

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

>D>	@	ARBOR PHARMS LLC	EQ 125MG BASE	A 060359	002		Mar	CAHN
>D>	!		EQ 250MG BASE	A 060359	001		Mar	CAHN
>D>	@		EQ 500MG BASE	A 060359	003		Mar	CAHN
>A>	@	AZURITY	EQ 125MG BASE	A 060359	002		Mar	CAHN
>A>	!		EQ 250MG BASE	A 060359	001		Mar	CAHN
>A>	@		EQ 500MG BASE	A 060359	003		Mar	CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

>D>	AB	PHARM ASSOC	EQ 5MG BASE	A 077512	001	Sep 12, 2012	Mar	DISC
>A>	@		EQ 5MG BASE	A 077512	001	Sep 12, 2012	Mar	DISC
>D>	AB		EQ 10MG BASE	A 077512	002	Sep 12, 2012	Mar	DISC
>A>	@		EQ 10MG BASE	A 077512	002	Sep 12, 2012	Mar	DISC
>D>	AB		EQ 20MG BASE	A 077512	003	Sep 12, 2012	Mar	DISC
>A>	@		EQ 20MG BASE	A 077512	003	Sep 12, 2012	Mar	DISC

ESLICARBAZEPINE ACETATE

TABLET; ORAL

ESLICARBAZEPINE ACETATE

>A>	AB	LUPIN LTD	200MG	A 211246	001	Mar 27, 2024	Mar	NEWA
>A>	AB		400MG	A 211246	002	Mar 27, 2024	Mar	NEWA
>A>	AB		600MG	A 211246	003	Mar 27, 2024	Mar	NEWA
>A>	AB		800MG	A 211246	004	Mar 27, 2024	Mar	NEWA
>D>	AB	TORRENT	200MG	A 211227	001	Feb 27, 2024	Mar	DISC
>A>	@		200MG	A 211227	001	Feb 27, 2024	Mar	DISC
	AB		200MG	A 211227	001	Feb 27, 2024	Feb	NEWA
>D>	AB		400MG	A 211227	002	Feb 27, 2024	Mar	DISC
>A>	@		400MG	A 211227	002	Feb 27, 2024	Mar	DISC
	AB		400MG	A 211227	002	Feb 27, 2024	Feb	NEWA
>D>	AB		600MG	A 211227	003	Feb 27, 2024	Mar	DISC
>A>	@		600MG	A 211227	003	Feb 27, 2024	Mar	DISC
	AB		600MG	A 211227	003	Feb 27, 2024	Feb	NEWA
>D>	AB		800MG	A 211227	004	Feb 27, 2024	Mar	DISC
>A>	@		800MG	A 211227	004	Feb 27, 2024	Mar	DISC
	AB		800MG	A 211227	004	Feb 27, 2024	Feb	NEWA

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

LUNELLE

+	@	PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N 020874	001	Oct 05, 2000	Feb	CRLD
---	---	----------------------	-----------------------	----------	-----	--------------	-----	------

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

ETHACRYNATE SODIUM

>A>	AP	STERIMAX	EQ 50MG BASE/VIAL	A 208663	001	Jun 09, 2020	Mar	CAHN
>D>	AP	VPI PHARMS INC	EQ 50MG BASE/VIAL	A 208663	001	Jun 09, 2020	Mar	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

MINZOYA

AB3		LUPIN LTD	0.02MG; 0.1MG	A 217087	001	Feb 15, 2024	Feb	NEWA
-----	--	-----------	---------------	----------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>D>	AB	+	APIL	0.025MG; 0.8MG	N 022573	001	Dec 22, 2010	Mar	CAHN
>A>	AB	+	TEVA BRANDED PHARM	0.025MG; 0.8MG	N 022573	001	Dec 22, 2010	Mar	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

@		AMNEAL PHARMS	0.02MG; 1MG	A 214292	001	Jul 20, 2021	Feb	DISC
---	--	---------------	-------------	----------	-----	--------------	-----	------

ETHOSUXIMIDE

CAPSULE;ORAL
ETHOSUXIMIDE
AB EPIC PHARMA LLC 250MG A040686 001 May 28, 2008 Jan CAHN

EZETIMIBE; SIMVASTATIN

TABLET;ORAL
EZETIMIBE AND SIMVASTATIN
>D> @ AUROBINDO PHARMA USA 10MG;10MG A200082 001 Dec 17, 2020 Mar CMFD
>A> AB 10MG;10MG A200082 001 Dec 17, 2020 Mar CMFD
>D> @ 10MG;20MG A200082 002 Dec 17, 2020 Mar CMFD
>A> AB 10MG;20MG A200082 002 Dec 17, 2020 Mar CMFD
>D> @ 10MG;40MG A200082 003 Dec 17, 2020 Mar CMFD
>A> AB 10MG;40MG A200082 003 Dec 17, 2020 Mar CMFD
>D> @ 10MG;80MG A200082 004 Dec 17, 2020 Mar CMFD
>A> AB 10MG;80MG A200082 004 Dec 17, 2020 Mar CMFD

FAMOTIDINE

FOR SUSPENSION;ORAL
FAMOTIDINE
AB CEROVENE INC 40MG/5ML A217605 001 Jan 16, 2024 Jan NEWA

FAMOTIDINE; IBUPROFEN

TABLET;ORAL
FAMOTIDINE AND IBUPROFEN
>A> @ TORRENT 26.6MG;800MG A215925 001 Mar 18, 2024 Mar NEWA
FAMOTIDINE; IBUPROFEN
>A> AB PAR PHARM 26.6MG;800MG A203658 001 Mar 22, 2024 Mar NEWA
IBUPROFEN AND FAMOTIDINE
AB ! ALKEM LABS LTD 26.6MG;800MG A211890 001 Aug 03, 2021 Feb CHRS

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL
INREBIC
+! BRISTOL-MYERS EQ 100MG BASE N212327 001 Aug 16, 2019 Feb CAHN

FENOFIBRATE

CAPSULE;ORAL
FENOFIBRATE (MICRONIZED)
>A> AB CHARTWELL 67MG A211407 001 Jan 31, 2024 Mar CAHN
>A> AB 134MG A211407 002 Jan 31, 2024 Mar CAHN
>A> AB 200MG A211407 003 Jan 31, 2024 Mar CAHN
>D> AB INVAGEN PHARMS 67MG A207378 001 Mar 28, 2017 Mar DISC
>A> @ 67MG A207378 001 Mar 28, 2017 Mar DISC
>D> AB 134MG A207378 002 Mar 28, 2017 Mar DISC
>A> @ 134MG A207378 002 Mar 28, 2017 Mar DISC
>D> AB 200MG A207378 003 Mar 28, 2017 Mar DISC
>A> @ 200MG A207378 003 Mar 28, 2017 Mar DISC
>D> AB YOUNGTECH PHARMS INC 67MG A211407 001 Jan 31, 2024 Mar CAHN
AB 67MG A211407 001 Jan 31, 2024 Jan NEWA
>D> AB 134MG A211407 002 Jan 31, 2024 Mar CAHN
AB 134MG A211407 002 Jan 31, 2024 Jan NEWA
>D> AB 200MG A211407 003 Jan 31, 2024 Mar CAHN
AB 200MG A211407 003 Jan 31, 2024 Jan NEWA
TABLET;ORAL
FENOFIBRATE
>D> AB AUROBINDO PHARMA 145MG A205118 002 May 05, 2016 Mar CHRS
>A> AB ! 145MG A205118 002 May 05, 2016 Mar CHRS
TRICOR
>D> AB +! ABBVIE 145MG N021656 002 Nov 05, 2004 Mar DISC
>A> + @ 145MG N021656 002 Nov 05, 2004 Mar DISC

FIDAXOMICIN

TABLET;ORAL
DIFICID
AB +! CUBIST PHARMS LLC 200MG N201699 001 May 27, 2011 Jan CFTG
FIDAXOMICIN
AB ACTAVIS LABS FL 200MG A208443 001 Jan 16, 2024 Jan NEWA

FINASTERIDETABLET; ORAL
FINASTERIDE

>D>	AB	CIPLA	1MG	A077335	001	Nov 20, 2014	Mar	DISC
>A>		@	1MG	A077335	001	Nov 20, 2014	Mar	DISC

FINASTERIDE; TADALAFILCAPSULE; ORAL
ENTADFI

>D>		+!	BLUE WATER BIOTECH	5MG;5MG	N215423	001	Dec 09, 2021	Mar	CFTG
>A>	AB	+!		5MG;5MG	N215423	001	Dec 09, 2021	Mar	CFTG
>A>			FINASTERIDE AND TADALAFIL						
>A>	AB		ZYDUS	5MG;5MG	A218232	001	Mar 15, 2024	Mar	NFTG

FINGOLIMOD HYDROCHLORIDECAPSULE; ORAL
FINGOLIMOD HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 0.5MG BASE	A207983	001	Feb 28, 2024	Feb	NEWA
AB		BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Feb	CMFD

FLUDARABINE PHOSPHATEINJECTABLE; INJECTION
FLUDARABINE PHOSPHATE
@ RISING

50MG/VIAL

A200648 001 Oct 16, 2012 Feb CAHN

FLUOCINOLONE ACETONIDEOIL; TOPICAL
FLUOCINOLONE ACETONIDE

		@ SAPTALIS PHARMS	0.01%	A091514	001	Jun 25, 2015	Feb	CAHN
AT		TARO	0.01%	A209336	001	May 19, 2016	Jan	CAHN

OIL/DROPS; OTIC
FLUOCINOLONE ACETONIDE
@ SAPTALIS PHARMS

0.01%

A202705 001 Sep 09, 2016 Feb CAHN

FLUOCINONIDECREAM; TOPICAL
FLUOCINONIDE

@ PADAGIS ISRAEL 0.1%

A090256 001 Jan 14, 2014 Jan DISC

GEL; TOPICAL
FLUOCINONIDE

@ PADAGIS US 0.05%

A209030 001 Jun 19, 2018 Jan CAHN

FLUOXETINE HYDROCHLORIDECAPSULE; ORAL
FLUOXETINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 40MG BASE

A076990 001 Dec 13, 2004 Jan DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

>D>		@ AKORN	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002	Mar	CAHN
>A>		@ BAJAJ	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002	Mar	CAHN
>A>		@ SAPTALIS PHARMS	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002	Mar	CAHN
>D>		@ SPECGX LLC	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002	Mar	CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

>A>	AB	STRIDES PHARMA	EQ 10MG BASE	A212684	001	Apr 05, 2024	Mar	NEWA
>A>	AB		EQ 20MG BASE	A212684	002	Apr 05, 2024	Mar	NEWA
		@ TEVA	EQ 10MG BASE	A075872	001	Jan 29, 2002	Jan	DISC
		@	EQ 20MG BASE	A075872	002	Jan 04, 2019	Jan	DISC
		@ TEVA PHARMS USA	EQ 60MG BASE	A211051	001	Dec 03, 2018	Jan	DISC

FLUPHENAZINE HYDROCHLORIDETABLET; ORAL
FLUPHENAZINE HYDROCHLORIDE

		@ TORRENT	1MG	A217094	001	Jan 22, 2024	Jan	DISC
AB			1MG	A217094	001	Jan 22, 2024	Jan	NEWA
		@	2.5MG	A217094	002	Jan 22, 2024	Jan	DISC
AB			2.5MG	A217094	002	Jan 22, 2024	Jan	NEWA
		@	5MG	A217094	003	Jan 22, 2024	Jan	DISC
AB			5MG	A217094	003	Jan 22, 2024	Jan	NEWA
		@	10MG	A217094	004	Jan 22, 2024	Jan	DISC
AB			10MG	A217094	004	Jan 22, 2024	Jan	NEWA

		TABLET;ORAL							
		FLUPHENAZINE HYDROCHLORIDE							
AB	ZAMEER PHARMS	1MG		A215141	001	Oct 20, 2021	Feb	CAHN	
AB		2.5MG		A215141	002	Oct 20, 2021	Feb	CAHN	
AB		5MG		A215141	003	Oct 20, 2021	Feb	CAHN	
AB		10MG		A215141	004	Oct 20, 2021	Feb	CAHN	
		<u>FLUTICASONE PROPIONATE</u>							
		SPRAY, METERED;NASAL							
		FLUTICASONE PROPIONATE							
>D>	AB	HIKMA	0.05MG/SPRAY	A077570	001	Jan 16, 2008	Mar	DISC	
>A>	@		0.05MG/SPRAY	A077570	001	Jan 16, 2008	Mar	DISC	
		<u>FLUVOXAMINE MALEATE</u>							
		TABLET;ORAL							
		FLUVOXAMINE MALEATE							
AB	BIONPHARMA	25MG		A217917	001	Jan 22, 2024	Jan	NEWA	
AB		50MG		A217917	002	Jan 22, 2024	Jan	NEWA	
AB		100MG		A217917	003	Jan 22, 2024	Jan	NEWA	
		<u>FOSAMPRENAVIR CALCIUM</u>							
		TABLET;ORAL							
		FOSAMPRENAVIR CALCIUM							
AB	! MYLAN	EQ 700MG BASE		A204060	001	Apr 15, 2016	Jan	CHRS	
	LEXIVA								
	+ @ VIIV HLTHCARE	EQ 700MG BASE		N021548	001	Oct 20, 2003	Jan	DISC	
		<u>FOSCARNET SODIUM</u>							
		INJECTABLE;INJECTION							
		FOSCARNET SODIUM							
AP	AMNEAL	2.4GM/100ML		A216602	001	Mar 01, 2024	Feb	NEWA	
		<u>FOSFOMYCIN TROMETHAMINE</u>							
		FOR SOLUTION;ORAL							
		FOSFOMYCIN TROMETHAMINE							
>A>	AA	AMNEAL	EQ 3GM BASE/PACKET	A216600	001	Mar 25, 2024	Mar	NEWA	
		<u>FUROSEMIDE</u>							
		INJECTABLE;INJECTION							
		FUROSEMIDE							
>A>	AP	SABA ILAC SANAYIVE	10MG/ML	A215856	001	Apr 02, 2024	Mar	NEWA	
		<u>GABAPENTIN</u>							
		SOLUTION;ORAL							
		GABAPENTIN							
AA	ANNORA PHARMA	250MG/5ML		A217682	001	Jan 17, 2024	Jan	NEWA	
		TABLET;ORAL							
		GABAPENTIN							
AB1	ACI	600MG		A203244	002	Jul 12, 2013	Jan	CTEC	
AB1		800MG		A203244	001	Jul 12, 2013	Jan	CTEC	
AB1	ACTAVIS ELIZABETH	600MG		A075694	001	Oct 21, 2004	Jan	CTEC	
AB1		800MG		A075694	002	Oct 21, 2004	Jan	CTEC	
AB1	ALKEM LABS LTD	600MG		A206402	001	Dec 23, 2015	Jan	CTEC	
AB1		800MG		A206402	002	Dec 23, 2015	Jan	CTEC	
AB2	ANNORA PHARMA	300MG		A218075	001	Feb 26, 2024	Feb	NEWA	
AB2		600MG		A218075	002	Feb 26, 2024	Feb	NEWA	
AB1	APOTEX	100MG		A077894	001	Oct 10, 2006	Jan	CTEC	
AB1		300MG		A077894	002	Oct 10, 2006	Jan	CTEC	
AB1		400MG		A077894	003	Oct 10, 2006	Jan	CTEC	
AB1	ASCENT PHARMS INC	600MG		A214957	001	Oct 01, 2021	Jan	CTEC	
AB1		800MG		A214957	002	Oct 01, 2021	Jan	CTEC	
AB1	AUROBINDO PHARMA LTD	600MG		A200651	001	Oct 06, 2011	Jan	CTEC	
AB1		800MG		A200651	002	Oct 06, 2011	Jan	CTEC	
AB1	CSPC OUYI	600MG		A207057	001	Oct 26, 2017	Jan	CTEC	
AB1		800MG		A207057	002	Oct 26, 2017	Jan	CTEC	
AB1	GLENMARK PHARMS LTD	600MG		A077662	001	Aug 18, 2006	Jan	CTEC	
AB1		800MG		A077662	002	Aug 18, 2006	Jan	CTEC	
AB1	GRANULES	600MG		A217116	001	Mar 28, 2023	Jan	CTEC	
AB1		800MG		A217116	002	Mar 28, 2023	Jan	CTEC	
AB2	HUMANWELL	300MG		A216252	001	Feb 26, 2024	Feb	NEWA	
AB2		600MG		A216252	002	Feb 26, 2024	Feb	NEWA	
>D>	AB1	INVAGEN PHARMS	600MG	A202764	001	Oct 16, 2012	Mar	DISC	

TABLET; ORAL		GABAPENTIN							
>A>	@	600MG		A202764	001	Oct 16, 2012	Mar	DISC	
	AB1	600MG		A202764	001	Oct 16, 2012	Jan	CTEC	
>D>	AB1	800MG		A202764	002	Oct 16, 2012	Mar	DISC	
>A>	@	800MG		A202764	002	Oct 16, 2012	Mar	DISC	
	AB1	800MG		A202764	002	Oct 16, 2012	Jan	CTEC	
	AB1	100MG	IVAX SUB TEVA PHARMS	A076017	001	Apr 28, 2004	Jan	CTEC	
	AB1	300MG		A076017	002	Apr 28, 2004	Jan	CTEC	
	AB1	400MG		A076017	003	Apr 28, 2004	Jan	CTEC	
>A>	AB1	600MG	LAURUS	A217965	001	Apr 08, 2024	Mar	NEWA	
>A>	AB1	800MG		A217965	002	Apr 08, 2024	Mar	NEWA	
	AB1	600MG	RISING	A217995	001	Jul 19, 2023	Jan	CTEC	
	AB1	800MG		A217995	002	Jul 19, 2023	Jan	CTEC	
	AB1	600MG	RUBICON	A077661	004	Sep 13, 2006	Jan	CTEC	
	AB1	800MG		A077661	005	Sep 13, 2006	Jan	CTEC	
	AB1	600MG	SCIEGEN PHARMS INC	A205101	001	Feb 04, 2016	Jan	CTEC	
	AB1	800MG		A205101	002	Feb 04, 2016	Jan	CTEC	
	AB1	600MG	STRIDES PHARMA	A211313	001	Mar 04, 2024	Feb	NEWA	
	AB1	800MG		A211313	002	Mar 04, 2024	Feb	NEWA	
	AB1	600MG	SUN PHARM INDS LTD	A077525	001	Aug 24, 2006	Jan	CTEC	
	AB1	800MG		A077525	002	Aug 24, 2006	Jan	CTEC	
	AB2	300MG	ZYDUS PHARMS	A203934	001	Jan 24, 2024	Jan	NEWA	
	AB2	600MG		A203934	002	Jan 24, 2024	Jan	NEWA	
	AB1	600MG	ZYDUS PHARMS USA INC	A078926	001	Feb 11, 2011	Jan	CTEC	
	AB1	800MG		A078926	002	Feb 11, 2011	Jan	CTEC	
			GRALISE						
	AB2	+!	ALMATICA	N022544	001	Jan 28, 2011	Jan	CTEC	
	AB2	+		N022544	002	Jan 28, 2011	Jan	CTEC	
	BX	+		N022544	002	Jan 28, 2011	Jan	CHRS	
		+!		N022544	005	Apr 18, 2023	Jan	CHRS	
			NEURONTIN						
	AB1	+	VIATRIS	N020882	001	Oct 09, 1998	Jan	CTEC	
	AB1	+!		N020882	002	Oct 09, 1998	Jan	CTEC	
			<u>GADODIAMIDE</u>						
			INJECTABLE; INJECTION						
			OMNISCAN						
>D>	@	GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007	Mar	CRLD	
>A>	+	@	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007	Mar	CRLD	
>D>	+	!	28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007	Mar	DISC	
>A>	+	@	28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007	Mar	DISC	
			<u>GATIFLOXACIN</u>						
			SOLUTION/DROPS; OPHTHALMIC						
			GATIFLOXACIN						
>D>	AT		HIKMA	A203189	001	Sep 03, 2014	Mar	DISC	
>A>	@			A203189	001	Sep 03, 2014	Mar	DISC	
			<u>GENTAMICIN SULFATE</u>						
			SOLUTION/DROPS; OPHTHALMIC						
			GENTAK						
	@	SAPTALIS PHARMS	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb	CAHN	
>A>			<u>GIVINOSTAT HYDROCHLORIDE</u>						
>A>			SUSPENSION; ORAL						
>A>			DUVYZAT						
>A>	+	!	ITALFARMACO SPA	N217865	001	Mar 21, 2024	Mar	NEWA	
			<u>GLYBURIDE; METFORMIN HYDROCHLORIDE</u>						
			TABLET; ORAL						
			GLYBURIDE AND METFORMIN HYDROCHLORIDE						
AB		HERITAGE PHARMS	1.25MG; 250MG	A079009	001	Jun 03, 2009	Feb	CMFD	
AB			2.5MG; 500MG	A079009	002	Jun 03, 2009	Feb	CMFD	
AB			5MG; 500MG	A079009	003	Jun 03, 2009	Feb	CMFD	
			<u>GLYCOPYRROLATE</u>						
			INJECTABLE; INJECTION						
			GLYCOPYRROLATE						
AP		NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Feb	CAHN	

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATESOLUTION; INTRAVENOUS
PREVDUO

+!	AZURITY	0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb	CAHN
----	---------	---	---------	-----	--------------	-----	------

GRISEOFULVIN, MICROSIZETABLET; ORAL
FULVICIN-U/F

AB	CHARTWELL RX	250MG	A060569	002		Jan	CTEC
		250MG	A060569	002		Jan	CAIN
AB		500MG	A060569	001		Jan	CTEC
		500MG	A060569	001		Jan	CAIN
AB	SANDOZ	250MG	A091592	001	Aug 07, 2013	Jan	CTEC

GRISEOFULVIN, ULTRAMICROSIZETABLET; ORAL
FULVICIN P/G

AB	CHARTWELL RX	125MG	A061996	001		Jan	CTEC
		125MG	A061996	001		Jan	CAIN
AB		250MG	A061996	002		Jan	CTEC
		250MG	A061996	002		Jan	CAIN
	FULVICIN P/G 165						
	CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Jan	CAIN
	FULVICIN P/G 330						
	CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Jan	CAIN

GUANFACINE HYDROCHLORIDETABLET; ORAL
GUANFACINE HYDROCHLORIDE

AB	XIROMED	EQ 1MG BASE	A218326	001	Feb 23, 2024	Feb	NEWA
AB		EQ 2MG BASE	A218326	002	Feb 23, 2024	Feb	NEWA

HALCINONIDEOINTMENT; TOPICAL
HALOG

+ @	SUN PHARM INDS INC	0.1%	N017824	001		Jan	DISC
	SOLUTION; TOPICAL						
	HALOG						
+ @	SUN PHARM INDS INC	0.1%	N017823	001		Jan	DISC

HALOPERIDOLTABLET; ORAL
HALOPERIDOL

AB	CHARTWELL RX	0.5MG	A071209	002	Nov 17, 1986	Jan	CAHN
AB		1MG	A071209	003	Nov 17, 1986	Jan	CAHN
	@	2MG	A071209	004	Nov 17, 1986	Jan	CAHN
AB		5MG	A071209	001	Nov 17, 1986	Jan	CAHN
AB		10MG	A071210	001	Mar 11, 1988	Jan	CAHN
AB		20MG	A071211	001	Mar 11, 1988	Jan	CAHN

HALOPERIDOL DECANOATEINJECTABLE; INJECTION
HALOPERIDOL DECANOATE

@	TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jan	DISC
@		EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jan	DISC

HALOPERIDOL LACTATECONCENTRATE; ORAL
HALOPERIDOL

AA	RUBICON	EQ 2MG BASE/ML	A218371	001	Jan 31, 2024	Jan	NEWA
----	---------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

>A>	HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%						
>A>	+! FRESENIUS KABI USA	40 UNITS/ML	N017029	021	Aug 24, 2017	Mar	NEWA
>A>	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%						
>A>	+! FRESENIUS KABI USA	50 UNITS/ML	N017029	022	Aug 24, 2017	Mar	NEWA
>A>	+!	100 UNITS/ML	N017029	023	Aug 24, 2017	Mar	NEWA

INJECTABLE; INJECTION

>A>	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%							
>A>	+! FRESENIUS KABI USA	50 UNITS/ML	N017029	024	Aug 24, 2017	Mar	NEWA	
>A>	+!	100 UNITS/ML	N017029	025	Aug 24, 2017	Mar	NEWA	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

>D>	AA	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Mar	CHRS
>A>	AA	!	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Mar	CHRS
>D>	AA	! PAI HOLDINGS PHARM	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Mar	DISC
>A>		@	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Mar	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
----	--	------------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>D>	AA	INVAGEN PHARMS	10MG	A090255	001	Dec 15, 2008	Mar	DISC
>A>		@	10MG	A090255	001	Dec 15, 2008	Mar	DISC
>D>	AA		25MG	A090255	002	Dec 15, 2008	Mar	DISC
>A>		@	25MG	A090255	002	Dec 15, 2008	Mar	DISC
>D>	AA		50MG	A090255	003	Dec 15, 2008	Mar	DISC
>A>		@	50MG	A090255	003	Dec 15, 2008	Mar	DISC
>D>	AA		100MG	A090255	004	Dec 15, 2008	Mar	DISC
>A>		@	100MG	A090255	004	Dec 15, 2008	Mar	DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		I3 PHARMS	37.5MG; 20MG	A215988	001	Jan 17, 2024	Jan	NEWA
----	--	-----------	--------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>D>	AB	GRANULES	12.5MG; 50MG	A218015	001	Sep 29, 2023	Mar	DISC
>A>		@	12.5MG; 50MG	A218015	001	Sep 29, 2023	Mar	DISC
>D>	AB		12.5MG; 100MG	A218015	002	Sep 29, 2023	Mar	DISC
>A>		@	12.5MG; 100MG	A218015	002	Sep 29, 2023	Mar	DISC
>D>	AB		25MG; 100MG	A218015	003	Sep 29, 2023	Mar	DISC
>A>		@	25MG; 100MG	A218015	003	Sep 29, 2023	Mar	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB	INVAGEN PHARMS	12.5MG; EQ 10MG BASE	A201356	001	Apr 20, 2011	Mar	DISC
>A>		@	12.5MG; EQ 10MG BASE	A201356	001	Apr 20, 2011	Mar	DISC
>D>	AB		12.5MG; EQ 20MG BASE	A201356	002	Apr 20, 2011	Mar	DISC
>A>		@	12.5MG; EQ 20MG BASE	A201356	002	Apr 20, 2011	Mar	DISC
>D>	AB		25MG; EQ 20MG BASE	A201356	003	Apr 20, 2011	Mar	DISC
>A>		@	25MG; EQ 20MG BASE	A201356	003	Apr 20, 2011	Mar	DISC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

AP		+! FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Feb	CFTG
AP		+!	0.5MG/0.5ML	N019034	007	Feb 10, 2017	Feb	CFTG
		+!	0.5MG/0.5ML	N019034	007	Feb 10, 2017	Jan	NEWA

HYDROMORPHONE HYDROCHLORIDE

AP		HIKMA	0.2MG/ML	A216899	001	Feb 09, 2024	Feb	NFTG
AP			0.5MG/0.5ML	A216899	002	Feb 09, 2024	Feb	NFTG
AP			1MG/ML	A216899	003	Feb 09, 2024	Feb	NEWA
AP			2MG/ML	A216899	004	Feb 09, 2024	Feb	NEWA

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

@	GENUS		5MG/5ML	A207108	001	Apr 22, 2020	Jan	CAHN
---	-------	--	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@	GENUS		2MG	A077471	002	Dec 09, 2009	Jan	CAHN
@			4MG	A077471	003	Dec 09, 2009	Jan	CAHN
@			8MG	A077471	001	Dec 09, 2009	Jan	CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	SENORES PHARMS	200MG	A212902	001	May 14, 2020	Feb	CAHN
AB	TEVA PHARMS	200MG	A040081	001	Sep 30, 1994	Feb	CMFD

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

AB	QILU	500MG	A218021	001	Mar 06, 2024	Feb	NEWA
----	------	-------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>D>	AB	INVAGEN PHARMS	10MG	A040812	001	Mar 12, 2008	Mar	DISC
>A>		@	10MG	A040812	001	Mar 12, 2008	Mar	DISC
>D>	AB		25MG	A040812	002	Mar 12, 2008	Mar	DISC
>A>		@	25MG	A040812	002	Mar 12, 2008	Mar	DISC
>D>	AB		50MG	A040812	003	Mar 12, 2008	Mar	DISC
>A>		@	50MG	A040812	003	Mar 12, 2008	Mar	DISC

IBRUTINIB

TABLET; ORAL

IMBRUVICA

+	!	PHARMACYCLICS LLC	420MG	N210563	003	Feb 16, 2018	Jan	CHRS
---	---	-------------------	-------	---------	-----	--------------	-----	------

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

IBUTILIDE FUMARATE

>A>	AP	AVET LIFESCIENCES	0.1MG/ML	A204146	001	Apr 01, 2024	Mar	NEWA
-----	----	-------------------	----------	---------	-----	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYL

AB	ASCENT PHARMS INC	1GM	A216811	002	Feb 16, 2024	Feb	NEWA
----	-------------------	-----	---------	-----	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

@	RISING	1MG/ML	A200144	001	Oct 11, 2012	Feb	CAHN
---	--------	--------	---------	-----	--------------	-----	------

ILOPROST

SOLUTION; INHALATION

VENTAVIS

>D>	+	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Mar	DISC
>A>		+ @	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Mar	DISC
>D>	+	!	20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Mar	DISC
>A>		+ @	20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Mar	DISC

SOLUTION; INTRAVENOUS

AURLUMYN

+	!	EICOS SCI	100MCG/ML (100MCG/ML)	N217933	001	Feb 13, 2024	Feb	NEWA
---	---	-----------	-----------------------	---------	-----	--------------	-----	------

INDOMETHACIN

SUSPENSION; ORAL

INDOCIN

AB	+	!	ZYLA	25MG/5ML	N018332	001	Oct 10, 1985	Jan	CTEC
----	---	---	------	----------	---------	-----	--------------	-----	------

INDOMETHACIN

AB			NOVITIUM PHARMA	25MG/5ML	A217883	001	Jan 12, 2024	Jan	NEWA
----	--	--	-----------------	----------	---------	-----	--------------	-----	------

IOBENGUANE I-131

SOLUTION; INTRAVENOUS

AZEDRA

+	@	PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018	Feb	DISC
---	---	----------------------	----------	---------	-----	--------------	-----	------

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

>A>	AP	HAINAN POLY	51%	A217134	002	Apr 09, 2024	Mar	NEWA
>A>	AP		61%	A217134	003	Apr 09, 2024	Mar	NEWA
>A>	AP		76%	A217134	004	Apr 09, 2024	Mar	NEWA

INJECTABLE; INJECTION

ISOVUE-250

>D>	+	!	BRACCO	51%	N018735	007	Jul 06, 1992	Mar	CTEC
>A>	AP	+	!	51%	N018735	007	Jul 06, 1992	Mar	CTEC

ISOVUE-300

>D>	+	!	BRACCO	61%	N018735	002	Dec 31, 1985	Mar	CTEC
>A>	AP	+	!	61%	N018735	002	Dec 31, 1985	Mar	CTEC

ISOVUE-370

>D>	+	!	BRACCO	76%	N018735	003	Dec 31, 1985	Mar	CTEC
>A>	AP	+	!	76%	N018735	003	Dec 31, 1985	Mar	CTEC

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

>D>	AP		CIPLA	0.2MG/ML	A210322	001	Jun 12, 2018	Mar	DISC
>A>			@	0.2MG/ML	A210322	001	Jun 12, 2018	Mar	DISC

ISOSORBIDE MONONITRATE

TABLET; ORAL

MONOKET

AB	+		OMNIVIUM PHARMS	10MG	N020215	002	Jun 30, 1993	Jan	CAHN
AB	+	!		20MG	N020215	001	Jun 30, 1993	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

>D>	AB	!	CHARTWELL MOLECULAR	120MG	A075155	003	Aug 04, 2000	Mar	CHRS
>A>	AB			120MG	A075155	003	Aug 04, 2000	Mar	CHRS
>D>	AB		RICONPHARMA LLC	120MG	A210918	003	Nov 05, 2018	Mar	CHRS
>A>	AB	!		120MG	A210918	003	Nov 05, 2018	Mar	CHRS
	AB		SHANDONG	30MG	A214115	002	Feb 08, 2024	Feb	NEWA
	AB			60MG	A214115	003	Feb 08, 2024	Feb	NEWA
>D>		@		120MG	A214115	001	Apr 29, 2022	Mar	CMFD
>A>	AB			120MG	A214115	001	Apr 29, 2022	Mar	CMFD
	AB		ZYDUS PHARMS	30MG	A218255	001	Feb 15, 2024	Feb	NEWA
	AB			60MG	A218255	002	Feb 15, 2024	Feb	NEWA
	AB			120MG	A218255	003	Feb 15, 2024	Feb	NEWA

ISOTRETINOIN

CAPSULE; ORAL

ISOTRETINOIN

AB2			AUROBINDO PHARMA	10MG	A218194	001	Jan 29, 2024	Jan	NEWA
AB2				20MG	A218194	002	Jan 29, 2024	Jan	NEWA
AB2				25MG	A218194	003	Jan 29, 2024	Jan	NEWA
AB2				30MG	A218194	004	Jan 29, 2024	Jan	NEWA
AB2				35MG	A218194	005	Jan 29, 2024	Jan	NEWA
AB2				40MG	A218194	006	Jan 29, 2024	Jan	NEWA

IVERMECTIN

CREAM; TOPICAL

IVERMECTIN

>D>	AB		ZYDUS	1%	A215210	001	Aug 02, 2022	Mar	CAHN
>A>	AB		ZYDUS LIFESCIENCES	1%	A215210	001	Aug 02, 2022	Mar	CAHN

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA

	+	@	MYLAN	2%	N021738	001	Jun 12, 2007	Feb	DISC
--	---	---	-------	----	---------	-----	--------------	-----	------

KETOCONAZOLE

AB	!		XIROMED	2%	A213601	001	May 21, 2021	Feb	CHRS
----	---	--	---------	----	---------	-----	--------------	-----	------

TABLET; ORAL

KETOCONAZOLE

AB			SENORES PHARMS	200MG	A075912	001	Jan 10, 2002	Feb	CAHN
----	--	--	----------------	-------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

KETOROLAC TROMETHAMINE

>A>	AT		CAPLIN	0.5%	A218204	001	Mar 26, 2024	Mar	NEWA
-----	----	--	--------	------	---------	-----	--------------	-----	------

LACOSAMIDE

SOLUTION; INTRAVENOUS

LACOSAMIDE

>A>	AP	DR REDDYS	200MG/20ML (10MG/ML)	A217718	001	Mar 25, 2024	Mar	NEWA
	AP	HAINAN POLY	200MG/20ML (10MG/ML)	A217311	001	Feb 13, 2024	Feb	NEWA
>A>	AP	HIKMA	200MG/20ML (10MG/ML)	A216806	001	Apr 05, 2024	Mar	NEWA

SOLUTION; ORAL

LACOSAMIDE

>A>	AA	AMNEAL PHARMS	10MG/ML	A204839	001	Mar 27, 2024	Mar	NEWA
	AA	AUROBINDO PHARMA LTD	10MG/ML	A209224	001	Jan 24, 2024	Jan	NEWA

TABLET; ORAL

LACOSAMIDE

>A>	AB	MEDLEY PHARMS	50MG	A218014	001	Apr 02, 2024	Mar	NEWA
>A>	AB		100MG	A218014	002	Apr 02, 2024	Mar	NEWA
>A>	AB		150MG	A218014	003	Apr 02, 2024	Mar	NEWA
>A>	AB		200MG	A218014	004	Apr 02, 2024	Mar	NEWA

LACTULOSE

SOLUTION; ORAL

LACTULOSE

>D>	AA	! HIKMA	10GM/15ML	A074076	001	Jul 03, 1995	Mar	DISC
>A>		@	10GM/15ML	A074076	001	Jul 03, 1995	Mar	DISC
>D>	AA	PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	Mar	CHRS
>A>	AA	!	10GM/15ML	A074623	001	Jul 30, 1996	Mar	CHRS

SOLUTION; ORAL, RECTAL

LACTULOSE

		@ PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Feb	DISC
--	--	----------------------	-----------	---------	-----	--------------	-----	------

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

		@ MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Jan	DISC
		@	300MG	A078545	002	Mar 05, 2019	Jan	DISC

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

		+ @ VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	Jan	DISC
		LAMIVUDINE AND ZIDOVUDINE						
AB	!	HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015	Jan	CHRS

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

>D>	AB	GLENMARK GENERICS	25MG	A090169	001	May 12, 2012	Mar	CAHN
>D>	AB		100MG	A090169	002	May 12, 2012	Mar	CAHN
>D>	AB		150MG	A090169	003	May 12, 2012	Mar	CAHN
>D>	AB		200MG	A090169	004	May 12, 2012	Mar	CAHN
>A>	AB	GLENMARK PHARMS LTD	25MG	A090169	001	May 12, 2012	Mar	CAHN
>A>	AB		100MG	A090169	002	May 12, 2012	Mar	CAHN
>A>	AB		150MG	A090169	003	May 12, 2012	Mar	CAHN
>A>	AB		200MG	A090169	004	May 12, 2012	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

		@ ANCHEN PHARMS	25MG	A201374	001	Dec 26, 2012	Feb	DISC
		@	50MG	A201374	002	Dec 26, 2012	Feb	DISC
		@	100MG	A201374	003	Dec 26, 2012	Feb	DISC
		@	200MG	A201374	004	Dec 26, 2012	Feb	DISC
		@	250MG	A201374	005	Dec 26, 2012	Feb	DISC
		@	300MG	A201374	006	Dec 26, 2012	Feb	DISC

LENALIDOMIDE

CAPSULE; ORAL

LENALIDOMIDE

AB		QILU	2.5MG	A217265	001	Feb 22, 2024	Feb	NEWA
AB			5MG	A217265	002	Feb 22, 2024	Feb	NEWA
AB			10MG	A217265	003	Feb 22, 2024	Feb	NEWA
AB			15MG	A217265	004	Feb 22, 2024	Feb	NEWA
AB			20MG	A217265	005	Feb 22, 2024	Feb	NEWA
AB			25MG	A217265	006	Feb 22, 2024	Feb	NEWA

LEVAMLODIPINE MALEATETABLET; ORAL
CONJUPRI

>D>	+ @	CSPC OUYI	EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Mar	CMFD
>A>	+		EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Mar	CMFD
>D>	+ @		EQ 5MG BASE	N212895	003	Dec 19, 2019	Mar	CMFD
>A>	+!		EQ 5MG BASE	N212895	003	Dec 19, 2019	Mar	CMFD

LEVETIRACETAMINJECTABLE; INTRAVENOUS
LEVETIRACETAM

AP		ADRASTEA PHARMA	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
			LEVETIRACETAM IN SODIUM CHLORIDE					
AP		B BRAUN MEDICAL INC	500MG/100ML (5MG/ML)	A209705	001	Feb 27, 2024	Feb	NEWA
AP			1GM/100ML (10MG/ML)	A209705	002	Feb 27, 2024	Feb	NEWA
AP			1.5GM/100ML (15MG/ML)	A209705	003	Feb 27, 2024	Feb	NEWA
AP		BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Feb	CTNA
AP			1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Feb	CTNA
AP			1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Feb	CTNA
>D>	AP	FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Mar	DISC
>A>	@		500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Mar	DISC
>D>	AP		1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Mar	DISC
>A>	@		1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Mar	DISC
>D>	AP		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Mar	DISC
>A>	@		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Mar	DISC
AP		HIKMA	500MG/100ML (5MG/ML)	A211356	001	Feb 12, 2024	Feb	NEWA
AP			1GM/100ML (10MG/ML)	A211356	002	Feb 12, 2024	Feb	NEWA
AP			1.5GM/100ML (15MG/ML)	A211356	003	Feb 12, 2024	Feb	NEWA
		+ @ HQ SPCLT PHARMA	250MG/50ML (5MG/ML)	N202543	004	Dec 14, 2020	Feb	DISC
			SOLUTION; ORAL					
			LEVETIRACETAM					
>D>	AA	HIKMA	100MG/ML	A090601	001	Feb 28, 2012	Mar	DISC
>A>	@		100MG/ML	A090601	001	Feb 28, 2012	Mar	DISC

TABLET; ORAL

LEVETIRACETAM

>D>	AB	GRANULES	250MG	A217878	001	Jun 13, 2023	Mar	DISC
>A>	@		250MG	A217878	001	Jun 13, 2023	Mar	DISC
>D>	AB		500MG	A217878	002	Jun 13, 2023	Mar	DISC
>A>	@		500MG	A217878	002	Jun 13, 2023	Mar	DISC
>D>	AB		750MG	A217878	003	Jun 13, 2023	Mar	DISC
>A>	@		750MG	A217878	003	Jun 13, 2023	Mar	DISC
>D>	AB		1GM	A217878	004	Jun 13, 2023	Mar	DISC
>A>	@		1GM	A217878	004	Jun 13, 2023	Mar	DISC
>D>	AB	INVAGEN PHARMS	250MG	A078234	001	Jan 15, 2009	Mar	DISC
>A>	@		250MG	A078234	001	Jan 15, 2009	Mar	DISC
>D>	AB		500MG	A078234	002	Jan 15, 2009	Mar	DISC
>A>	@		500MG	A078234	002	Jan 15, 2009	Mar	DISC
>D>	AB		750MG	A078234	003	Jan 15, 2009	Mar	DISC
>A>	@		750MG	A078234	003	Jan 15, 2009	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	@	ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011	Feb	DISC
	@		750MG	A091360	002	Oct 04, 2011	Feb	DISC

LEVOCARNITINESOLUTION; ORAL
LEVOCARNITINE

>D>	AA	HIKMA	1GM/10ML	A077399	001	Oct 25, 2007	Mar	DISC
>A>	@		1GM/10ML	A077399	001	Oct 25, 2007	Mar	DISC

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		KNACK	EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jan	NEWA
AP			EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jan	NEWA
AP			EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jan	NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

>D>	@	AKORN	0.5%	A090268	001	Dec 20, 2010	Mar	CAHN
>A>	@	SAPTALIS PHARMS	0.5%	A090268	001	Dec 20, 2010	Mar	CAHN

LEVOLEUCOVORIN CALCIUMPOWDER; INTRAVENOUS
FUSILEV

>D>	AP	+	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CTEC
>A>		+		EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CTEC
>D>			LEVOLEUCOVORIN CALCIUM						
>D>	AP		MEITHEAL	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Mar	DISC
>A>		@		EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Mar	DISC

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB1, AB2, AB3, AB4	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.05MG	A207588	002	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.075MG	A207588	003	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.088MG	A207588	004	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.1MG	A207588	005	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.112MG	A207588	006	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.125MG	A207588	007	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.137MG	A207588	008	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.15MG	A207588	009	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.175MG	A207588	010	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.2MG	A207588	011	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4		0.3MG	A207588	012	May 10, 2022	Feb	CTEC

LIDOCAINE HYDROCHLORIDE

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT	PAI HOLDINGS PHARM	2%	A218138	001	Feb 20, 2024	Feb	NEWA
----	--------------------	----	---------	-----	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

>D>	AB		HIKMA	2.5%;2.5%	A076290	001	Sep 25, 2003	Mar	DISC
>A>		@		2.5%;2.5%	A076290	001	Sep 25, 2003	Mar	DISC

LIFITEGRASTSOLUTION/DROPS;OPHTHALMIC
XIIDRA

AB +! BAUSCH AND LOMB INC 5% N208073 001 Jul 11, 2016 Jan CAHN

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

>D>	AB	BIOCON PHARMA	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Mar CAHN
>A>	AB		EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Mar CAHN
	AB		EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb CAHN
>D>	AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Mar CAHN
>A>	AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Mar CAHN
	AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb CAHN
>D>	AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Mar CAHN
>A>	AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Mar CAHN
	AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb CAHN
	AB	CARNEGIE	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Jan NEWA
	AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Jan NEWA
	AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Jan NEWA

>A> LIRAGLUTIDE>A> SOLUTION;SUBCUTANEOUS
>A> SAXENDA

>A>	+!	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014	Mar CAIN
>A>		VICTOZA					
>A>	+!	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Mar CAIN

>D> LIRAGLUTIDE RECOMBINANT>D> SOLUTION;SUBCUTANEOUS
>D> SAXENDA

>D>	+!	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014	Mar CAIN
>D>		VICTOZA					
>D>	+!	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Mar CAIN

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

	@	ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023	Feb DISC
	@		20MG	A202802	002	Aug 25, 2023	Feb DISC
	@		30MG	A202802	003	Aug 25, 2023	Feb DISC
	@		40MG	A202802	004	Aug 25, 2023	Feb DISC
	@		50MG	A202802	005	Aug 25, 2023	Feb DISC
	@		60MG	A202802	006	Aug 25, 2023	Feb DISC
	@		70MG	A202802	007	Aug 25, 2023	Feb DISC
AB		HIKMA	10MG	A202827	007	Jan 17, 2024	Jan NEWA

TABLET, CHEWABLE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB		MSN	10MG	A218306	001	Feb 02, 2024	Jan NEWA
AB			20MG	A218306	002	Feb 02, 2024	Jan NEWA
AB			30MG	A218306	003	Feb 02, 2024	Jan NEWA
AB			40MG	A218306	004	Feb 02, 2024	Jan NEWA
AB			50MG	A218306	005	Feb 02, 2024	Jan NEWA
AB			60MG	A218306	006	Feb 02, 2024	Jan NEWA
	@	TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Feb DISC
	@		20MG	A215415	002	Aug 25, 2023	Feb DISC
	@		30MG	A215415	003	Aug 25, 2023	Feb DISC
	@		40MG	A215415	004	Aug 25, 2023	Feb DISC
	@		50MG	A215415	005	Aug 25, 2023	Feb DISC
	@		60MG	A215415	006	Aug 25, 2023	Feb DISC

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

	@	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb DISC	
>D>	AA	!	RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar CTEC
>A>	AA	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar NEWA
>A>	!			EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar CTEC
	AA	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb CHRS
>A>	AA		SAPTALIS PHARMS	EQ 300MG CARBONATE/5ML	A217183	001	Mar 18, 2024	Mar NEWA
	AA			EQ 300MG CARBONATE/5ML	A217183	001	Feb 29, 2024	Feb NEWA

LOMITAPIDE MESYLATECAPSULE;ORAL
JUXTAPID

+	CHIESI	EQ 5MG BASE	N203858	001	Dec 21, 2012	Jan CAHN
+		EQ 10MG BASE	N203858	002	Dec 21, 2012	Jan CAHN
+		EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan CAHN
+		EQ 30MG BASE	N203858	004	Apr 23, 2015	Jan CAHN
+	@	EQ 40MG BASE	N203858	005	Apr 23, 2015	Jan CAHN
+	@	EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan CAHN

LOMUSTINECAPSULE;ORAL
GLEOSTINE

+	@ LATINA PHARMA	5MG	N017588	004	Dec 19, 2014	Feb CAHN
+		10MG	N017588	001		Feb CAHN
+		40MG	N017588	002		Feb CAHN
+	!	100MG	N017588	003		Feb CAHN

LOPINAVIR; RITONAVIR

TABLET;ORAL

LOPINAVIR AND RITONAVIR

AB	MYLAN LABS LTD	100MG;25MG	A079074	001	Feb 07, 2024	Jan NEWA
AB		200MG;50MG	A079074	002	Feb 07, 2024	Jan NEWA

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM

>D>	AA	HIKMA	2MG/ML	A200169	001	Jan 30, 2012	Mar DISC
>A>		@	2MG/ML	A200169	001	Jan 30, 2012	Mar DISC

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

	@ AIPING PHARM INC	25MG	A090544	001	Oct 06, 2010	Feb CAHN
	@	50MG	A090544	002	Oct 06, 2010	Feb CAHN
	@	100MG	A090544	003	Oct 06, 2010	Feb CAHN
AB	CHARTWELL RX	25MG	A077424	001	Oct 06, 2010	Jan CAHN
AB		50MG	A077424	002	Oct 06, 2010	Jan CAHN
AB		100MG	A077424	003	Oct 06, 2010	Jan CAHN

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB	SLATE RUN PHARMA	20MG	A212091	001	Dec 28, 2020	Feb CAHN
AB		40MG	A212091	002	Dec 28, 2020	Feb CAHN
AB		60MG	A212091	003	Dec 28, 2020	Feb CAHN
AB		80MG	A212091	004	Dec 28, 2020	Feb CAHN
AB		120MG	A212091	005	Dec 28, 2020	Feb CAHN

>A> MACITENTAN; TADALAFIL

>A> TABLET;ORAL

>A> OPSYNVI

>A>	+	ACTELION	10MG;20MG	N218490	001	Mar 22, 2024	Mar NEWA
>A>	+	!	10MG;40MG	N218490	002	Mar 22, 2024	Mar NEWA

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

>A>	AA	TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Mar NEWA
-----	----	------	---------------------------------	---------	-----	--------------	----------

MARAVIROC

TABLET;ORAL

SELZENTRY

+	@ VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016	Jan DISC
+	@	75MG	N022128	004	Nov 04, 2016	Jan DISC

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA	+	!	CASPER PHARMA LLC	50MG	N010721	001	Jan 20, 1982	Feb	CHRS
			MECLIZINE HYDROCHLORIDE						
>D>	AA	!	AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011	Mar	CHRS
>A>	AA			50MG	A201451	003	Feb 23, 2011	Mar	CHRS
	AA	!		50MG	A201451	003	Feb 23, 2011	Feb	CMFD
>D>	AA		INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Mar	DISC
>A>		@		12.5MG	A200432	001	Feb 17, 2022	Mar	DISC
>D>	AA			25MG	A200432	002	Feb 17, 2022	Mar	DISC
>A>		@		25MG	A200432	002	Feb 17, 2022	Mar	DISC
>D>	AA			50MG	A200432	003	Feb 17, 2022	Mar	DISC
>A>		@		50MG	A200432	003	Feb 17, 2022	Mar	DISC

TABLET, CHEWABLE; ORAL

ANTIVERT

>D>	AA	+	CASPER PHARMA LLC	25MG	N010721	005		Mar	CHRS
>A>		+	!	25MG	N010721	005		Mar	CTEC
>A>	AA	+	!	25MG	N010721	005		Mar	CHRS
>D>			MECLIZINE HYDROCHLORIDE						
>D>	AA		INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Mar	DISC
>A>		@		25MG	A200791	001	Feb 17, 2022	Mar	DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

AB			HONG KONG	150MG/ML	A076553	001	Jul 28, 2004	Jan	CAHN
----	--	--	-----------	----------	---------	-----	--------------	-----	------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

>D>		@	BIONPHARMA	125MG/ML	A204688	001	Dec 01, 2017	Mar	CAHN
>A>		@	CHARTWELL	125MG/ML	A204688	001	Dec 01, 2017	Mar	CAHN
>D>	AB		HIKMA	40MG/ML	A203960	001	Jun 09, 2017	Mar	DISC
>A>		@		40MG/ML	A203960	001	Jun 09, 2017	Mar	DISC

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	!		ZYDUS PHARMS USA	15MG	A077921	002	Jul 19, 2006	Jan	CTEC
			MOBIC						
		+	@ BOEHRINGER INGELHEIM	7.5MG	N020938	001	Apr 13, 2000	Jan	DISC
		+	@	15MG	N020938	002	Aug 23, 2000	Jan	DISC

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

AB			XIAMEN LP PHARM CO	21MG	A213985	004	Feb 06, 2024	Jan	NEWA
----	--	--	--------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

AB			RENATA	5MG	A209527	001	May 07, 2018	Jan	CAHN
AB				10MG	A209527	002	May 07, 2018	Jan	CAHN

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

AA	!		EPIC PHARMA LLC	50MG	A040331	001	May 28, 1999	Feb	CTEC
				50MG	A040331	001	May 28, 1999	Feb	CHRS
AA			GENUS	50MG	A040893	001	Jun 24, 2009	Feb	CMFD
		@		50MG	A040893	001	Jun 24, 2009	Jan	CAHN
		@		75MG	A040893	002	Jun 24, 2009	Jan	CAHN
		@		100MG	A040893	003	Jun 24, 2009	Jan	CAHN
		@		150MG	A040893	004	Jun 24, 2009	Jan	CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

@	DAEWOONG PHARM CO	500MG/VIAL
@		1GM/VIAL

A204854	001	Dec 18, 2015	Feb	DISC
A204854	002	Dec 18, 2015	Feb	DISC

MESALAMINE

TABLET, DELAYED RELEASE;ORAL
MESALAMINE

AB ANNORA PHARMA 1.2GM A216334 001 Feb 05, 2024 Jan NEWA

MESNA

INJECTABLE; INTRAVENOUS
MESNA

@ RISING 100MG/ML A203364 001 Jul 18, 2014 Feb CAHN

METAPROTERENOL SULFATE

SYRUP;ORAL
METAPROTERENOL SULFATE

! GENUS 10MG/5ML A073632 001 Jul 22, 1992 Jan CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
METFORMIN HYDROCHLORIDE

>A> AB3 MACLEODS PHARMS LTD 1GM A211163 001 Mar 13, 2024 Mar NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@ CHARTWELL RX 500MG;EQ 15MG BASE A091273 001 Apr 16, 2013 Jan CAHN

@ 850MG;EQ 15MG BASE A091273 002 Apr 16, 2013 Jan CAHN

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

>D> AA AUSTARPHARMA LLC 500MG A200958 001 Oct 21, 2011 Mar CAHN

>D> AA 750MG A200958 002 Oct 21, 2011 Mar CAHN

>D> AB ! 1GM A200958 003 Dec 06, 2021 Mar CAHN

AA DBL PHARMS 500MG A203550 001 Feb 08, 2017 Feb CAHN

AA 750MG A203550 002 Feb 08, 2017 Feb CAHN

>A> AA HANGZHOU BINJIANG 500MG A200958 001 Oct 21, 2011 Mar CAHN

>A> AA 750MG A200958 002 Oct 21, 2011 Mar CAHN

>A> AB ! 1GM A200958 003 Dec 06, 2021 Mar CAHN

METHSCOPOLAMINE BROMIDE

TABLET;ORAL

METHSCOPOLAMINE BROMIDE

AA AACE PHARMS 2.5MG A216786 001 Feb 01, 2024 Jan NEWA

AA 5MG A216786 002 Feb 01, 2024 Jan NEWA

METHYLDOPA

TABLET;ORAL

METHYLDOPA

@ CHARTWELL RX 250MG N018934 001 Jun 29, 1984 Feb DISC

250MG N018934 001 Jun 29, 1984 Jan CMFD

@ 500MG N018934 002 Jun 29, 1984 Feb DISC

! 500MG N018934 002 Jun 29, 1984 Jan CMFD

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D> AA BRECKENRIDGE 5MG/5ML A201466 001 Nov 12, 2013 Mar DISC

>A> @ 5MG/5ML A201466 001 Nov 12, 2013 Mar DISC

>D> AA 10MG/5ML A201466 002 Nov 12, 2013 Mar DISC

>A> @ 10MG/5ML A201466 002 Nov 12, 2013 Mar DISC

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D> @ CEDIPROF INC 5MG A208737 001 Feb 01, 2019 Mar CMFD

>A> AB 5MG A208737 001 Feb 01, 2019 Mar CMFD

>D> @ 10MG A208737 002 Feb 01, 2019 Mar CMFD

>A> AB 10MG A208737 002 Feb 01, 2019 Mar CMFD

>D> @ 20MG A208737 003 Feb 01, 2019 Mar CMFD

>A> AB 20MG A208737 003 Feb 01, 2019 Mar CMFD

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

@ PRAXGEN

4MG

A212262 001 Jun 27, 2019 Feb DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB HONG KONG

40MG/ML

A040557 001 Feb 23, 2005 Jan CAHN

AB

80MG/ML

A040557 002 Feb 23, 2005 Jan CAHN

@ TEVA PHARMS USA

40MG/ML

A040620 001 Oct 27, 2006 Jan DISC

@

80MG/ML

A040620 002 Oct 27, 2006 Jan DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

>D> AB GRANULES

EQ 25MG TARTRATE

A216509 001 Aug 07, 2023 Mar DISC

>A>

@

EQ 25MG TARTRATE

A216509 001 Aug 07, 2023 Mar DISC

>D> AB

@

EQ 50MG TARTRATE

A216509 002 Aug 07, 2023 Mar DISC

>A>

@

EQ 50MG TARTRATE

A216509 002 Aug 07, 2023 Mar DISC

>D> AB

@

EQ 100MG TARTRATE

A216509 003 Aug 07, 2023 Mar DISC

>A>

@

EQ 100MG TARTRATE

A216509 003 Aug 07, 2023 Mar DISC

>D> AB

@

EQ 200MG TARTRATE

A216509 004 Aug 07, 2023 Mar DISC

>A>

@

EQ 200MG TARTRATE

A216509 004 Aug 07, 2023 Mar DISC

METRONIDAZOLE

GEL; VAGINAL

METRONIDAZOLE

>A> AB ENCUBE

1.3%

A216795 001 Mar 18, 2024 Mar NFTG

NUVESSA

>D> +! CHEMO RESEARCH SL

1.3%

N205223 001 Mar 24, 2014 Mar CFTG

>A> AB

+!

1.3%

N205223 001 Mar 24, 2014 Mar CFTG

TABLET; ORAL

METRONIDAZOLE

>D> AB FLAMINGO PHARMS

250MG

A207309 001 May 16, 2016 Mar DISC

>A>

@

250MG

A207309 001 May 16, 2016 Mar DISC

>D> AB

@

500MG

A207309 002 May 16, 2016 Mar DISC

>A>

@

500MG

A207309 002 May 16, 2016 Mar DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

@ FRESENIUS KABI USA

EQ 5MG BASE/ML

A208878 001 Mar 28, 2017 Jan DISC

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

@ SUN PHARM INDS LTD

EQ 45MG BASE

A091118 001 Sep 25, 2014 Jan DISC

@

EQ 65MG BASE

A091118 003 Dec 03, 2019 Jan DISC

@

EQ 80MG BASE

A091118 004 Sep 25, 2014 Jan DISC

@

EQ 90MG BASE

A091118 005 Sep 25, 2014 Jan DISC

@

EQ 105MG BASE

A091118 006 Sep 25, 2014 Jan DISC

@

EQ 115MG BASE

A091118 007 Dec 03, 2019 Jan DISC

@

EQ 135MG BASE

A091118 008 Sep 25, 2014 Jan DISC

@ ZYDUS PHARMS

EQ 45MG BASE

A203553 001 Nov 16, 2017 Jan DISC

@

EQ 55MG BASE

A203553 002 Jun 16, 2023 Jan DISC

@

EQ 65MG BASE

A203553 003 Jun 16, 2023 Jan DISC

@

EQ 80MG BASE

A203553 004 Nov 16, 2017 Jan DISC

@

EQ 90MG BASE

A203553 005 Nov 16, 2017 Jan DISC

@

EQ 105MG BASE

A203553 006 Nov 16, 2017 Jan DISC

@

EQ 115MG BASE

A203553 007 Jun 16, 2023 Jan DISC

@

EQ 135MG BASE

A203553 008 Nov 16, 2017 Jan DISC

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MIRABEGRON

AB ALKEM LABS LTD

25MG

A215948 001 Feb 12, 2024 Feb NEWA

AB

@

50MG

A215948 002 Feb 12, 2024 Feb NEWA

>D> @ ZYDUS PHARMS

25MG

A209488 001 Sep 29, 2022 Mar CMFD

>A> AB

@

25MG

A209488 001 Sep 29, 2022 Mar CMFD

>D>

@

50MG

A209488 002 Sep 29, 2022 Mar CMFD

TABLET, EXTENDED RELEASE;ORAL								
MIRABEGRON								
>A>	AB		50MG		A209488	002	Sep 29, 2022	Mar CMFD
<u>MIRTAZAPINE</u>								
TABLET;ORAL								
MIRTAZAPINE								
AB		AIPING PHARM INC	15MG		A076219	001	Jun 19, 2003	Feb CAHN
AB			30MG		A076219	002	Jun 19, 2003	Feb CAHN
AB			45MG		A076219	003	Jun 19, 2003	Feb CAHN
<u>MITOMYCIN</u>								
INJECTABLE;INJECTION								
MITOMYCIN								
>A>	AP	FRESENIUS KABI USA	5MG/VIAL		A211269	001	Apr 05, 2024	Mar NEWA
>A>	AP		20MG/VIAL		A211269	002	Apr 05, 2024	Mar NEWA
>A>	AP		40MG/VIAL		A211269	003	Apr 05, 2024	Mar NEWA
<u>MITOXANTRONE HYDROCHLORIDE</u>								
INJECTABLE;INJECTION								
MITOXANTRONE HYDROCHLORIDE								
>D>		@ MYLAN LABS LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)		A201014	001	Dec 11, 2012	Mar CAHN
>A>		@ RISING	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)		A201014	001	Dec 11, 2012	Mar CAHN
<u>MOMETASONE FUROATE</u>								
SPRAY, METERED;NASAL								
MOMETASONE FUROATE								
>A>	AB	AUROBINDO PHARMA	0.05MG/SPRAY		A215878	001	Mar 18, 2024	Mar NEWA
<u>MONTELUKAST SODIUM</u>								
GRANULE;ORAL								
MONTELUKAST SODIUM								
		@ TEVA PHARMS	EQ 4MG BASE/PACKET		A090955	001	Aug 03, 2012	Jan DISC
<u>MORPHINE SULFATE</u>								
SOLUTION;ORAL								
MORPHINE SULFATE								
>D>	AA	HIKMA	100MG/5ML		A208809	001	Jul 06, 2017	Mar DISC
>A>		@	100MG/5ML		A208809	001	Jul 06, 2017	Mar DISC
AA		WINDER LABS LLC	10MG/5ML		A211454	001	Feb 12, 2021	Jan CMFD
AA			20MG/5ML		A211454	002	Feb 12, 2021	Jan CMFD
AA			100MG/5ML		A211454	003	Feb 12, 2021	Jan CMFD
<u>MOXIFLOXACIN HYDROCHLORIDE</u>								
SOLUTION/DROPS;OPHTHALMIC								
VIGAMOX								
AT1	+	HARROW EYE	EQ 0.5% BASE		N021598	001	Apr 15, 2003	Jan CAHN
<u>MYCOPHENOLATE MOFETIL</u>								
TABLET;ORAL								
MYCOPHENOLATE MOFETIL								
		@ AMNEAL	500MG		A090606	001	Jul 16, 2010	Feb DISC
AB		AUROBINDO PHARMA	500MG		A217937	001	Feb 20, 2024	Feb NEWA
<u>MYCOPHENOLIC SODIUM</u>								
TABLET, DELAYED RELEASE;ORAL								
MYCOPHENOLIC SODIUM								
AB		AUROBINDO PHARMA LTD	EQ 180MG BASE		A218603	001	Feb 27, 2024	Feb NEWA
AB			EQ 360MG BASE		A218603	002	Feb 27, 2024	Feb NEWA
<u>NALOXONE HYDROCHLORIDE</u>								
INJECTABLE;INJECTION								
NALOXONE HYDROCHLORIDE								
>A>	AP	FRESENIUS KABI USA	0.4MG/ML		A213573	001	Apr 02, 2024	Mar NEWA
>A>	AP		1MG/ML		A213573	002	Apr 02, 2024	Mar NEWA
>A>	AP	HIKMA	0.4MG/ML		A212300	002	Mar 07, 2024	Mar NEWA
AP		MANKIND PHARMA	0.4MG/ML		A218404	001	Feb 29, 2024	Feb NEWA
AP		PAR STERILE PRODUCTS	1MG/ML		A215964	001	Jul 29, 2022	Jan CMFD

NALTREXONEFOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
NALTREXONE

@	TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023	Jan	DISC
	VIVITROL						
+	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006	Jan	CTEC

NAPROXENTABLET; ORAL
NAPROXEN

>D>	AB	INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011	Mar	DISC
>A>		@	250MG	A091305	001	Aug 24, 2011	Mar	DISC
>D>	AB		375MG	A091305	002	Aug 24, 2011	Mar	DISC
>A>		@	375MG	A091305	002	Aug 24, 2011	Mar	DISC
>D>	AB		500MG	A091305	003	Aug 24, 2011	Mar	DISC
>A>		@	500MG	A091305	003	Aug 24, 2011	Mar	DISC

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

AB	APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024	Feb	NEWA
AB		EQ 20MG BASE	A209741	002	Feb 27, 2024	Feb	NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP	NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Jan	CAHN
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Jan	CAHN

>A> NESIRITIDE>A> FOR SOLUTION; INTRAVENOUS
>A> NATRECOR

>A>		+ @ SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Mar	CAIN
-----	--	---------------	------------	---------	-----	--------------	-----	------

>D> NESIRITIDE RECOMBINANT>D> FOR SOLUTION; INTRAVENOUS
>D> NATRECOR

>D>		+ @ SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Mar	CAIN
-----	--	---------------	------------	---------	-----	--------------	-----	------

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

>A>	AB	SKG PHARMA	20MG	A218202	001	Apr 10, 2024	Mar	NEWA
>A>	AB		30MG	A218202	002	Apr 10, 2024	Mar	NEWA

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP	RK PHARMA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Feb	CMFD
----	-----------	----------------------	---------	-----	--------------	-----	------

NIRAPARIB TOSYLATE

CAPSULE; ORAL

ZEJULA

		+ @ GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Feb	DISC
--	--	---------------------	---------------	---------	-----	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

	@	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Feb	DISC
	@		50MG	A091095	002	Jun 18, 2015	Feb	DISC
	@		100MG	A091095	003	Jun 18, 2015	Feb	DISC

NITROGLYCERIN

OINTMENT; INTRA-ANAL

NITROGLYCERIN

AB	COSETTE	0.4%	A216103	001	Feb 16, 2024	Feb	NFTG	
AB	+	ABBVIE	0.4%	N021359	001	Jun 21, 2011	Feb	CFTG

NOREPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+!	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Jan	CMFD
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Jan	CMFD
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Jan	CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

@	RISING	EQ 10MG BASE	A074234	001	Jul 26, 1993	Feb	CAHN
@		EQ 25MG BASE	A074234	002	Jul 26, 1993	Feb	CAHN
@		EQ 50MG BASE	A074234	003	Jul 26, 1993	Feb	CAHN
@		EQ 75MG BASE	A074234	004	Jul 26, 1993	Feb	CAHN

NYSTATIN

POWDER;TOPICAL

NYSTATIN

>A>	AT	ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN
>D>	AT	BEOWULF ASSET	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AB		TEVA PHARMS USA INC	EQ 10MG BASE/VIAL	A210317	001	Dec 05, 2023	Jan	CTEC
AB			EQ 20MG BASE/VIAL	A210317	002	Dec 05, 2023	Jan	CTEC
AB			EQ 30MG BASE/VIAL	A210317	003	Dec 05, 2023	Jan	CTEC
AB	+	SANDOSTATIN LAR						
AB	+	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998	Jan	CTEC
AB	+		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998	Jan	CTEC
AB	+		EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998	Jan	CTEC

ODEVIXIBAT

CAPSULE;ORAL

BYLVAY

+	IPSEN	0.4MG	N215498	002	Jul 20, 2021	Jan	CAHN
+!		1.2MG	N215498	004	Jul 20, 2021	Jan	CAHN

CAPSULE, PELLETS;ORAL

BYLVAY

+	IPSEN	0.2MG	N215498	001	Jul 20, 2021	Jan	CAHN
+!		0.6MG	N215498	003	Jul 20, 2021	Jan	CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT		AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb	NEWA
----	--	--------	------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OTIC

OFLOXACIN

>D>	AT	HIKMA	0.3%	A076616	001	Mar 17, 2008	Mar	DISC
>A>		@	0.3%	A076616	001	Mar 17, 2008	Mar	DISC

OLANZAPINE

TABLET;ORAL

OLANZAPINE

>D>	AB	INDOCO	2.5MG	A206155	001	Jul 31, 2020	Mar	DISC
>A>		@	2.5MG	A206155	001	Jul 31, 2020	Mar	DISC
>D>	AB		5MG	A206155	002	Jul 31, 2020	Mar	DISC
>A>		@	5MG	A206155	002	Jul 31, 2020	Mar	DISC
>D>	AB		7.5MG	A206155	003	Jul 31, 2020	Mar	DISC
>A>		@	7.5MG	A206155	003	Jul 31, 2020	Mar	DISC
>D>	AB		10MG	A206155	004	Jul 31, 2020	Mar	DISC
>A>		@	10MG	A206155	004	Jul 31, 2020	Mar	DISC
>D>	AB		15MG	A206155	005	Jul 31, 2020	Mar	DISC
>A>		@	15MG	A206155	005	Jul 31, 2020	Mar	DISC
>D>	AB		20MG	A206155	006	Jul 31, 2020	Mar	DISC
>A>		@	20MG	A206155	006	Jul 31, 2020	Mar	DISC

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

>D>	AB	BRECKENRIDGE	5MG	A206227	001	Jan 25, 2024	Mar	CAHN
	AB		5MG	A206227	001	Jan 25, 2024	Jan	NEWA
>D>	AB		20MG	A206227	002	Jan 25, 2024	Mar	CAHN
	AB		20MG	A206227	002	Jan 25, 2024	Jan	NEWA
>D>	AB		40MG	A206227	003	Jan 25, 2024	Mar	CAHN
	AB		40MG	A206227	003	Jan 25, 2024	Jan	NEWA
>A>	AB	CHARTWELL RX	5MG	A206227	001	Jan 25, 2024	Mar	CAHN
>A>	AB		20MG	A206227	002	Jan 25, 2024	Mar	CAHN
>A>	AB		40MG	A206227	003	Jan 25, 2024	Mar	CAHN

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

>D>	AB	HIKMA	0.665MG/SPRAY	A213757	001	Aug 19, 2020	Mar	DISC
>A>	@		0.665MG/SPRAY	A213757	001	Aug 19, 2020	Mar	DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

>D>	AB	BIONPHARMA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Mar	CAHN
>A>	AB	CHARTWELL	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Mar	CAHN

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>D>	AB	AJANTA PHARMA LTD	40MG;1.1GM	A204228	002	Jul 15, 2016	Mar	CHRS
>A>	AB	!	40MG;1.1GM	A204228	002	Jul 15, 2016	Mar	CHRS
>D>		ZEGERID						
>D>	AB	+ SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Mar	DISC
>A>		+ @	20MG;1.1GM	N021849	001	Feb 27, 2006	Mar	DISC
>D>	AB	+!	40MG;1.1GM	N021849	002	Feb 27, 2006	Mar	DISC
>A>		+ @	40MG;1.1GM	N021849	002	Feb 27, 2006	Mar	DISC

FOR SUSPENSION; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>D>	AB	AJANTA PHARMA LTD	40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Mar	CHRS
>A>	AB	!	40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Mar	CHRS
>D>		ZEGERID						
>D>	AB	+ SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Mar	DISC
>A>		+ @	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Mar	DISC
>D>	AB	+!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Mar	DISC
>A>		+ @	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Mar	DISC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

@ SUN PHARM INDS LTD

4MG

A078602

001

Feb 24, 2011

Jan DISC

@

8MG

A078602

002

Feb 24, 2011

Jan DISC

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

@ PHARM ASSOC

EQ 4MG BASE/5ML

A078127

001

Jun 25, 2007

Feb DISC

OSPEMIFENE

TABLET; ORAL

OSPEMIFENE

AB HETERO LABS LTD V

60MG

A215574

001

Feb 13, 2024

Feb NFTG

AB OSPHENA

60MG

N203505

001

Feb 26, 2013

Feb CFTG

OXALIPLATININJECTABLE; INTRAVENOUS
OXALIPLATIN

AP	KINDOS	50MG/10ML (5MG/ML)	A217348	001	Jan 11, 2024	Jan NEWA
AP		100MG/20ML (5MG/ML)	A217348	002	Jan 11, 2024	Jan NEWA

OXAPROZINTABLET; ORAL
OXAPROZIN
@ TEVA

		600MG	A075849	001	Jul 03, 2002	Jan DISC
--	--	-------	---------	-----	--------------	----------

OXCARBAZEPINESUSPENSION; ORAL
OXCARBAZEPINE

>A>	AB	ALKEM LABS LTD	300MG/5ML	A213183	001	Mar 18, 2023	Mar NEWA
>D>	AB	CARNEGIE	300MG/5ML	A218278	001	Mar 01, 2024	Mar CAHN
	AB		300MG/5ML	A218278	001	Mar 01, 2024	Feb NEWA
	AB	MEDLEY PHARMS	300MG/5ML	A217782	001	Feb 14, 2024	Feb NEWA
>A>	AB	RISING	300MG/5ML	A218278	001	Mar 01, 2024	Mar CAHN

TABLET; ORAL

OXCARBAZEPINE

AB	RUBICON	150MG	A207717	001	Mar 05, 2024	Feb NEWA
AB		300MG	A207717	002	Mar 05, 2024	Feb NEWA
AB		600MG	A207717	003	Mar 05, 2024	Feb NEWA
	@ ZYDUS	150MG	A211747	001	Jul 03, 2023	Jan DISC
	@	300MG	A211747	002	Jul 03, 2023	Jan DISC
	@	600MG	A211747	003	Jul 03, 2023	Jan DISC

TABLET, EXTENDED RELEASE; ORAL

OXCARBAZEPINE

AB	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Feb NEWA
AB		300MG	A217659	002	Feb 22, 2024	Feb NEWA
AB		600MG	A217659	003	Feb 22, 2024	Feb NEWA
	OXTELLAR XR					
AB	+ SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012	Feb CTEC
AB	+	300MG	N202810	002	Oct 19, 2012	Feb CTEC
AB	+!	600MG	N202810	003	Oct 19, 2012	Feb CTEC

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

OXYBUTYNIN CHLORIDE
@ PHARM ASSOC

		5MG/5ML	A075137	001	Dec 18, 1998	Feb DISC
--	--	---------	---------	-----	--------------	----------

TABLET; ORAL

OXYBUTYNIN CHLORIDE

>D>	BX	EYWA	5MG	A211062	001	Feb 06, 2019	Mar DISC
>A>		@	5MG	A211062	001	Feb 06, 2019	Mar DISC

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

>D>	AA	HIKMA	5MG/5ML	A208817	001	Aug 10, 2017	Mar DISC
>A>		@	5MG/5ML	A208817	001	Aug 10, 2017	Mar DISC
>D>	AA		100MG/5ML	A208795	001	Aug 07, 2017	Mar DISC
>A>		@	100MG/5ML	A208795	001	Aug 07, 2017	Mar DISC
>D>		@ PHARMOBEDIANT CNSLTG	5MG/5ML	A206456	001	Jun 16, 2015	Mar CAHN
>A>		@ XTTRIUM LABS INC	5MG/5ML	A206456	001	Jun 16, 2015	Mar CAHN

OZANIMOD HYDROCHLORIDE

CAPSULE; ORAL

ZEPOSIA

+	BRISTOL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	Jan CAHN
+		EQ 0.46MG BASE	N209899	002	Mar 25, 2020	Jan CAHN
+	!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	Jan CAHN

PACLITAXELPOWDER; INTRAVENOUS
ABRAXANE

AB	+!	BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005	Jan CTEC
AB	+!	TEVA PHARMS INC	100MG/VIAL	N216338	001	May 11, 2023	Jan CMFD

PALBOCICLIBTABLET; ORAL
IBRANCE

	+	PFIZER	75MG	N212436	001	Nov 01, 2019	Jan	CTEC
	+		100MG	N212436	002	Nov 01, 2019	Jan	CTEC
	+	!	125MG	N212436	003	Nov 01, 2019	Jan	CTEC

PALIPERIDONETABLET, EXTENDED RELEASE; ORAL
INVEGA

>D>	AB	+	JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Mar	DISC
>A>		+	@	1.5MG	N021999	006	Aug 26, 2008	Mar	DISC

PANTOPRAZOLE SODIUMINJECTABLE; INTRAVENOUS
PANTOPRAZOLE SODIUM

>D>	AP		ACIC PHARMS	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Mar	CAHN
>A>	AP		HANGZHOU ZHONGMEI	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Mar	CAHN
			@ SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Feb	DISC

SOLUTION; INTRAVENOUS
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

	+	!	BAXTER HLTHCARE CORP	EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML)	N217512	001	Feb 14, 2024	Feb	NEWA
	+	!		EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML)	N217512	002	Feb 14, 2024	Feb	NEWA
	+	!		EQ 80MG BASE/100ML (EQ 0.8MG BASE/ML)	N217512	003	Feb 14, 2024	Feb	NEWA

PATROMER SORBITE X CALCIUMPOWDER; ORAL
VELTASSA

	+	@	VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Feb	DISC
--	---	---	--------------	--------------------	---------	-----	--------------	-----	------

PENICILLIN V POTASSIUMTABLET; ORAL
PENICILLIN V POTASSIUM

AB	!	AUROBINDO PHARMA	EQ 500MG BASE	A065435	002	Apr 29, 2008	Jan	CHRS
		@ SANDOZ	EQ 250MG BASE	A064071	001	Nov 30, 1995	Jan	DISC
		@	EQ 500MG BASE	A064071	002	Nov 30, 1995	Jan	DISC

PENTOBARBITAL SODIUMSUPPOSITORY; RECTAL
NEMBUTAL

>D>		@	AKORN	30MG	A083247	001	Jan 25, 1982	Mar	CAHN
>D>		@		60MG	A083247	002	Jan 25, 1982	Mar	CAHN
>D>		@		120MG	A083247	003	Jan 25, 1982	Mar	CAHN
>D>		@		200MG	A083247	004	Jan 25, 1982	Mar	CAHN
>A>		@	SAPTALIS PHARMS	30MG	A083247	001	Jan 25, 1982	Mar	CAHN
>A>		@		60MG	A083247	002	Jan 25, 1982	Mar	CAHN
>A>		@		120MG	A083247	003	Jan 25, 1982	Mar	CAHN
>A>		@		200MG	A083247	004	Jan 25, 1982	Mar	CAHN

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB			ANI PHARMS	400MG	A074878	001	Jul 09, 1997	Jan	CMFD
----	--	--	------------	-------	---------	-----	--------------	-----	------

PERMETHRINCREAM; TOPICAL
PERMETHRIN

		@	DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jan	DISC
--	--	---	-------------------	----	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL
ADIPEX-P

	+	@	TEVA	37.5MG	A088023	001	Aug 02, 1983	Feb	DISC
--	---	---	------	--------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

>D>	AA		INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Mar	DISC
>A>		@		15MG	A202858	001	Feb 14, 2014	Mar	DISC
>D>	AA			30MG	A202858	002	Feb 14, 2014	Mar	DISC
>A>		@		30MG	A202858	002	Feb 14, 2014	Mar	DISC
>D>	AA			30MG	A204414	001	May 05, 2014	Mar	DISC

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

>A>	@	30MG	A204414	001	May 05, 2014	Mar	DISC
>D>	AA	37.5MG	A202846	001	Feb 05, 2014	Mar	DISC
>A>	@	37.5MG	A202846	001	Feb 05, 2014	Mar	DISC
AA	!	NUVO PHARM	A205017	001	Sep 25, 2014	Feb	CHRS

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

>D>	AA	INVAGEN PHARMS	A202942	001	Feb 05, 2014	Mar	DISC
>A>	@		A202942	001	Feb 05, 2014	Mar	DISC

PHENTOLAMINE MESYLATE

SOLUTION;OPHTHALMIC

RYZUMVI

+	!	FAMYGEN LIFE SCI	EQ 0.75% BASE	N217064	001	Sep 25, 2023	Jan	CAHN
---	---	------------------	---------------	---------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

>A>	AP1	HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Mar	NEWA
>A>	AP1		50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Mar	NEWA
>A>	AP1		100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Mar	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

>D>	AA	HIKMA	5MG/5ML;6.25MG/5ML	A040675	001	Dec 23, 2014	Mar	DISC
>A>	@		5MG/5ML;6.25MG/5ML	A040675	001	Dec 23, 2014	Mar	DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

@	PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Feb	DISC
---	--------------------	-----------	---------	-----	--------------	-----	------

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

NUPLAZID

AB	+	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018	Jan	CFTG
		PIMAVANSERIN						
		@ MSN	EQ 34MG BASE	A214925	001	Jan 16, 2024	Feb	DISC
AB			EQ 34MG BASE	A214925	001	Jan 16, 2024	Jan	NEWA
AB		ZYDUS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan	CAHN
AB		ZYDUS PHARMS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan	NEWA

TABLET;ORAL

NUPLAZID

AB	+	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018	Jan	CFTG
		PIMAVANSERIN						
AB		ZYDUS	EQ 10MG BASE	A214502	001	Jan 16, 2024	Jan	CAHN
AB		ZYDUS PHARMS	EQ 10MG BASE	A214502	001	Jan 16, 2024	Jan	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

@	FRESENIUS KABI USA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018	Feb	DISC
---	--------------------	--------------------------------------	---------	-----	--------------	-----	------

PIROXICAM

CAPSULE;ORAL

PIROXICAM

>D>	AB	FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Mar	DISC
>A>	@		10MG	A207938	001	Sep 09, 2016	Mar	DISC
>D>	AB		20MG	A207938	002	Sep 09, 2016	Mar	DISC
>A>	@		20MG	A207938	002	Sep 09, 2016	Mar	DISC

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP		ADRASTEIA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb	CAHN
----	--	------------------	----------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

@ ANCHEN PHARMS 8MEQ
@ 10MEQA202886 001 Dec 26, 2013 Feb DISC
A202886 002 Dec 26, 2013 Feb DISC

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA STRIDES PHARMA 20MEQ/15ML

A211665 002 Jan 16, 2024 Jan NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB @ TORRENT 5MEQ
5MEQ
@ 10MEQ
AB 10MEQ
@ 15MEQ
AB 15MEQA213986 001 Feb 06, 2024 Feb DISC
A213986 001 Feb 06, 2024 Jan NEWA
A213986 002 Feb 06, 2024 Feb DISC
A213986 002 Feb 06, 2024 Jan NEWA
A213986 003 Feb 06, 2024 Feb DISC
A213986 003 Feb 06, 2024 Jan NEWAPRALSETINIB

CAPSULE;ORAL

GAVRETO

+! BLUEPRINT MEDICINES 100MG

N213721 001 Sep 04, 2020 Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>D> AB GLENMARK GENERICS 0.125MG
>D> AB ! 0.25MG
>D> AB 0.5MG
>D> AB 0.75MG
>D> AB 1MG
>D> AB 1.5MG
>A> AB GLENMARK PHARMS LTD 0.125MG
>A> AB ! 0.25MG
>A> AB 0.5MG
>A> AB 0.75MG
>A> AB 1MG
>A> AB 1.5MGA090781 001 Oct 08, 2010 Mar CAHN
A090781 002 Oct 08, 2010 Mar CAHN
A090781 003 Oct 08, 2010 Mar CAHN
A090781 006 Sep 11, 2015 Mar CAHN
A090781 004 Oct 08, 2010 Mar CAHN
A090781 005 Oct 08, 2010 Mar CAHN
A090781 001 Oct 08, 2010 Mar CAHN
A090781 002 Oct 08, 2010 Mar CAHN
A090781 003 Oct 08, 2010 Mar CAHN
A090781 006 Sep 11, 2015 Mar CAHN
A090781 004 Oct 08, 2010 Mar CAHN
A090781 005 Oct 08, 2010 Mar CAHNPREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

>D> AA HIKMA 15MG/5ML
>A> @ 15MG/5ML
@ PHARM ASSOC 15MG/5MLA040401 001 Feb 27, 2003 Mar DISC
A040401 001 Feb 27, 2003 Mar DISC
A040399 001 Mar 05, 2003 Feb DISCPREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

>D> AA HIKMA EQ 5MG BASE/5ML
>A> @ EQ 5MG BASE/5ML
>D> PHARM ASSOC EQ 30MG BASE/5ML
>A> @ EQ 30MG BASE/5MLA075183 001 Mar 26, 2003 Mar DISC
A075183 001 Mar 26, 2003 Mar DISC
A204962 001 Mar 11, 2020 Mar DISC
A204962 001 Mar 11, 2020 Mar DISCPREDNISONE

SOLUTION;ORAL

PREDNISONE INTENSOL

+! HIKMA 5MG/ML

A088810 001 Feb 20, 1985 Jan CRLD

TABLET;ORAL

PREDNISONE

@ GENEYORK PHARMS 1MG
@ 2.5MG
@ 5MG
@ 10MG
@ 20MG
@ 50MGA211496 001 Dec 28, 2018 Feb DISC
A210525 004 Dec 07, 2018 Feb DISC
A210525 005 Dec 07, 2018 Feb DISC
A210525 001 Dec 04, 2018 Feb DISC
A210525 002 Dec 04, 2018 Feb DISC
A210525 003 Dec 04, 2018 Feb DISC

PREGABALINCAPSULE;ORAL
PREGABALIN

AB	ACI	25MG	A215755	001	Apr 26, 2023	Feb	CMFD
AB		50MG	A215755	002	Apr 26, 2023	Feb	CMFD
AB		75MG	A215755	003	Apr 26, 2023	Feb	CMFD
AB		100MG	A215755	004	Apr 26, 2023	Feb	CMFD
AB		150MG	A215755	005	Apr 26, 2023	Feb	CMFD
AB		200MG	A215755	006	Apr 26, 2023	Feb	CMFD
AB		225MG	A215755	007	Apr 26, 2023	Feb	CMFD
AB		300MG	A215755	008	Apr 26, 2023	Feb	CMFD
	@ CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023	Jan	DISC
	@	50MG	A206452	002	Jul 12, 2023	Jan	DISC
	@	75MG	A206452	003	Jul 12, 2023	Jan	DISC
	@	100MG	A206452	004	Jul 12, 2023	Jan	DISC
	@	150MG	A206452	005	Jul 12, 2023	Jan	DISC
	@	200MG	A206452	006	Jul 12, 2023	Jan	DISC
	@	225MG	A206452	007	Jul 12, 2023	Jan	DISC
	@	300MG	A206452	008	Jul 12, 2023	Jan	DISC
AB	STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024	Jan	NEWA
AB		50MG	A209883	002	Jan 24, 2024	Jan	NEWA
AB		75MG	A209883	003	Jan 24, 2024	Jan	NEWA
AB		100MG	A209883	004	Jan 24, 2024	Jan	NEWA
AB		150MG	A209883	005	Jan 24, 2024	Jan	NEWA
AB		200MG	A209883	006	Jan 24, 2024	Jan	NEWA
AB		225MG	A209883	007	Jan 24, 2024	Jan	NEWA
AB		300MG	A209883	008	Jan 24, 2024	Jan	NEWA
	@ SUN PHARM	25MG	A091157	001	Nov 29, 2019	Jan	DISC
	@	50MG	A091157	002	Nov 29, 2019	Jan	DISC
	@	75MG	A091157	003	Nov 29, 2019	Jan	DISC
	@	100MG	A091157	004	Nov 29, 2019	Jan	DISC
	@	150MG	A091157	005	Nov 29, 2019	Jan	DISC
	@	200MG	A091157	006	Nov 29, 2019	Jan	DISC
	@	225MG	A091157	007	Nov 29, 2019	Jan	DISC
	@	300MG	A091157	008	Nov 29, 2019	Jan	DISC

PRIMIDONESUSPENSION;ORAL
MYSOLINE

+ @ FHTA 250MG/5ML

N010401 001 Jan CAHN

TABLET;ORAL
PRIMIDONE

AB	CARNEGIE	50MG	A218366	001	Jan 23, 2024	Jan	NEWA
AB		250MG	A218366	002	Jan 23, 2024	Jan	NEWA

PROPAFENONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

>D>	AB	SCINOPHARM TAIWAN	225MG	A212928	001	Jun 18, 2020	Mar	CAHN
>D>	AB		325MG	A212928	002	Jun 18, 2020	Mar	CAHN
>D>	AB		425MG	A212928	003	Jun 18, 2020	Mar	CAHN
>A>	AB	TWI PHARMS	225MG	A212928	001	Jun 18, 2020	Mar	CAHN
>A>	AB		325MG	A212928	002	Jun 18, 2020	Mar	CAHN
>A>	AB		425MG	A212928	003	Jun 18, 2020	Mar	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

AB	ANI PHARMS	60MG	A040512	001	Oct 08, 2003	Jan	CMFD	
>D>	AB	EYWA	30MG	A211181	002	May 14, 2019	Mar	CAHN
>D>	AB		60MG	A211181	001	Jul 20, 2018	Mar	CAHN
>A>	AB	MLV	30MG	A211181	002	May 14, 2019	Mar	CAHN
>A>	AB		60MG	A211181	001	Jul 20, 2018	Mar	CAHN

QUETIAPINE FUMARATETABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

	@ PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Feb	DISC
	@	EQ 150MG BASE	A090482	002	May 09, 2017	Feb	DISC
	@	EQ 200MG BASE	A090482	003	May 09, 2017	Feb	DISC
	@	EQ 300MG BASE	A090482	004	May 09, 2017	Feb	DISC
	@	EQ 400MG BASE	A090482	005	May 09, 2017	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

>A> AB PRINSTON INC EQ 400MG BASE A208781 005 Mar 11, 2024 Mar NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

>D> AB INVAGEN PHARMS EQ 5MG BASE A078457 001 Aug 24, 2007 Mar DISC
>A> @ EQ 5MG BASE A078457 001 Aug 24, 2007 Mar DISC
>D> AB EQ 10MG BASE A078457 002 Aug 24, 2007 Mar DISC
>A> @ EQ 10MG BASE A078457 002 Aug 24, 2007 Mar DISC
>D> AB EQ 20MG BASE A078457 003 Aug 24, 2007 Mar DISC
>A> @ EQ 20MG BASE A078457 003 Aug 24, 2007 Mar DISC
>D> AB EQ 40MG BASE A078457 004 Aug 24, 2007 Mar DISC
>A> @ EQ 40MG BASE A078457 004 Aug 24, 2007 Mar DISC

RANITIDINE HYDROCHLORIDE

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

>D> AA LANNETT CO INC EQ 15MG BASE/ML A091288 001 Dec 09, 2010 Mar DISC
>A> @ EQ 15MG BASE/ML A091288 001 Dec 09, 2010 Mar DISC
>D> AA ! PHARM ASSOC EQ 15MG BASE/ML A077405 001 Sep 21, 2007 Mar DISC
>A> @ EQ 15MG BASE/ML A077405 001 Sep 21, 2007 Mar DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ PAR PHARM

@

EQ 150MG BASE

EQ 300MG BASE

A075180 001 Jan 28, 1999 Feb DISC

A075180 002 Jan 28, 1999 Feb DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

@ PIRAMAL HLTHCARE UK

@

500MG

1GM

A213085 001 Jul 25, 2023 Jan DISC

A213085 002 Jul 25, 2023 Jan DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

>A> AB SKG PHARMA EQ 0.5MG BASE A218163 001 Apr 09, 2024 Mar NEWA
>A> AB EQ 1MG BASE A218163 002 Apr 09, 2024 Mar NEWA

RESMETIROM

>A> TABLET;ORAL

>A> REZDIFFRA

>A> + MADRIGAL 60MG N217785 001 Mar 14, 2024 Mar NEWA

>A> + 80MG N217785 002 Mar 14, 2024 Mar NEWA

>A> +! 100MG N217785 003 Mar 14, 2024 Mar NEWA

RIFAMPIN

CAPSULE;ORAL

RIFAMPIN

>D> AB HIKMA 150MG A065028 001 Mar 14, 2001 Mar DISC

>A> @ 150MG A065028 001 Mar 14, 2001 Mar DISC

>D> AB 300MG A065028 002 Mar 14, 2001 Mar DISC

>A> @ 300MG A065028 002 Mar 14, 2001 Mar DISC

RILPIVIRINE HYDROCHLORIDE

>A> TABLET, FOR SUSPENSION;ORAL

>A> EDURANT PED

>A> +! JANSSEN PRODS EQ 2.5MG BASE N219016 001 Mar 15, 2024 Mar NEWA

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

>A> RISVAN

>A> + LABS FARMS ROVI SA 75MG N214835 001 Mar 29, 2024 Mar NEWA

>A> +! 100MG N214835 002 Mar 29, 2024 Mar NEWA

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

AB + JANSSEN PHARMS 12.5MG/VIAL N021346 004 Apr 12, 2007 Jan CMS1

AB +! 25MG/VIAL N021346 001 Oct 29, 2003 Jan CMS1

AB + 37.5MG/VIAL N021346 002 Oct 29, 2003 Jan CMS1

AB + 50MG/VIAL N021346 003 Oct 29, 2003 Jan CMS1

INJECTABLE; INTRAMUSCULAR

RISPERIDONE

AB	TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan CMS1
AB		25MG/VIAL	A214068	002	Dec 05, 2023	Jan CMS1
AB		37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan CMS1
AB		50MG/VIAL	A214068	004	Dec 05, 2023	Jan CMS1

SOLUTION; ORAL

RISPERIDONE

>D>	AA	HIKMA	1MG/ML	A076904	001	Jul 29, 2009	Mar DISC
>A>		@	1MG/ML	A076904	001	Jul 29, 2009	Mar DISC
		@ PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Feb DISC

TABLET; ORAL

RISPERIDONE

AB	RENATA	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
AB		1MG	A078707	003	Dec 29, 2008	Feb CAHN
AB		2MG	A078707	004	Dec 29, 2008	Feb CAHN
AB		3MG	A078707	005	Dec 29, 2008	Feb CAHN
AB		4MG	A078707	006	Dec 29, 2008	Feb CAHN

RITONAVIR

CAPSULE; ORAL

RITONAVIR

	MYLAN	100MG	A205024	001	Feb 16, 2024	Feb NEWA
--	-------	-------	---------	-----	--------------	----------

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

	@ SANDOZ	EQ 5MG BASE	A079171	001	Jul 19, 2016	Jan DISC
	@	EQ 10MG BASE	A079171	002	Jul 19, 2016	Jan DISC
	@	EQ 20MG BASE	A079171	003	Jul 19, 2016	Jan DISC
	@	EQ 40MG BASE	A079171	004	Jul 19, 2016	Jan DISC

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

SAXAGLIPTIN

	@ AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb DISC
	@	EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb DISC

SILODOSIN

CAPSULE; ORAL

SILODOSIN

>A>	AB	CHARTWELL RX	4MG	A204726	001	Mar 31, 2017	Mar CAHN
>A>	AB		8MG	A204726	002	Mar 31, 2017	Mar CAHN
>D>	AB	SANDOZ	4MG	A204726	001	Mar 31, 2017	Mar CAHN
>D>	AB		8MG	A204726	002	Mar 31, 2017	Mar CAHN

SILVER SULFADIAZINE

CREAM; TOPICAL

SSD

AB	+!	DR REDDYS LA	1%	N018578	001	Feb 25, 1982	Jan CRLD
AB	!		1%	N018578	001	Feb 25, 1982	Jan CHRS

SODIUM ACETATE

INJECTABLE; INJECTION

SODIUM ACETATE

>D>	AP	+!	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Mar CDFR
>D>	AP		MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Mar CDFR

SOLUTION; INTRAVENOUS

SODIUM ACETATE

>A>	AP	HIKMA	40MEQ/20ML (2MEQ/ML)	A216920	001	Mar 15, 2024	Mar NEWA	
>A>	AP		100MEQ/50ML (2MEQ/ML)	A216920	002	Mar 15, 2024	Mar NEWA	
>A>	AP		200MEQ/100ML (2MEQ/ML)	A216920	003	Mar 15, 2024	Mar NEWA	
>A>	AP	+!	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Mar CDFR
>A>	AP	+!	40MEQ/20ML (2MEQ/ML)	N018893	001	May 04, 1983	Mar CPOT	
>A>	AP	+!	100MEQ/50ML (2MEQ/ML)	N018893	002	Sep 02, 2014	Mar CMS1	
>A>	AP	+!	200MEQ/100ML (2MEQ/ML)	N018893	003	Sep 02, 2014	Mar CMS1	
>A>	AP	MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Mar CDFR	
>A>	AP		40MEQ/20ML (2MEQ/ML)	A214805	004	Jan 22, 2024	Mar CMS1	
>A>	AP		100MEQ/50ML (2MEQ/ML)	A214805	001	May 04, 2021	Mar CPOT	
>A>	AP		200MEQ/100ML (2MEQ/ML)	A214805	003	May 04, 2021	Mar CMS1	

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D>	AB	AUROBINDO PHARMA	200MG/5ML;40MG/5ML	A 091348	001	Jun 08, 2010	Mar	CHRS
>A>	AB	!	200MG/5ML;40MG/5ML	A 091348	001	Jun 08, 2010	Mar	CHRS
>D>	AB	! HIKMA	200MG/5ML;40MG/5ML	A 074650	001	Dec 29, 1997	Mar	DISC
>A>		@	200MG/5ML;40MG/5ML	A 074650	001	Dec 29, 1997	Mar	DISC

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX

	+	@ GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	001	Dec 28, 1992	Jan	DISC
AP	!	EUGIA PHARMA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 202758	001	Apr 23, 2013	Jan	CHRS
		@ PAR PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 077332	001	Oct 09, 2009	Feb	DISC

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

>A>	AB	EUGIA PHARMA	EQ 12.5MG BASE	A 218615	001	Mar 14, 2024	Mar	NEWA
>A>	AB		EQ 25MG BASE	A 218615	002	Mar 14, 2024	Mar	NEWA
>A>	AB		EQ 37.5MG BASE	A 218615	003	Mar 14, 2024	Mar	NEWA
>A>	AB		EQ 50MG BASE	A 218615	004	Mar 14, 2024	Mar	NEWA
		@ NOVUGEN	EQ 12.5MG BASE	A 218012	001	Aug 21, 2023	Feb	DISC
		@	EQ 25MG BASE	A 218012	002	Aug 21, 2023	Feb	DISC
		@	EQ 37.5MG BASE	A 218012	003	Aug 21, 2023	Feb	DISC
		@	EQ 50MG BASE	A 218012	004	Aug 21, 2023	Feb	DISC

TACROLIMUS

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

AB	+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jan	CFTG
AB	+		EQ 1MG BASE	N204096	002	Jul 19, 2013	Jan	CFTG
AB	+	!	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jan	CFTG
		TACROLIMUS						
AB		CHENGDU	EQ 0.5MG BASE	A 215012	001	Jan 25, 2024	Jan	NFTG
AB			EQ 1MG BASE	A 215012	002	Jan 25, 2024	Jan	NFTG
AB			EQ 5MG BASE	A 215012	003	Jan 25, 2024	Jan	NFTG

TADALAFIL

TABLET;ORAL

TADALAFIL

>D>	AB1	AUSTARPHARMA	2.5MG	A 208824	001	Oct 27, 2020	Mar	CAHN
>D>	AB1		5MG	A 208824	002	Oct 27, 2020	Mar	CAHN
>D>	AB1		10MG	A 208824	003	Oct 27, 2020	Mar	CAHN
>D>	AB1		20MG	A 208824	004	Oct 27, 2020	Mar	CAHN
>A>	AB1	HANGZHOU BINJIANG	2.5MG	A 208824	001	Oct 27, 2020	Mar	CAHN
>A>	AB1		5MG	A 208824	002	Oct 27, 2020	Mar	CAHN
>A>	AB1		10MG	A 208824	003	Oct 27, 2020	Mar	CAHN
>A>	AB1		20MG	A 208824	004	Oct 27, 2020	Mar	CAHN
	AB1	SHANDONG	20MG	A 216279	001	Mar 04, 2024	Feb	NEWA

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST

>A>	AT	INGENUS PHARMS LLC	0.0015%	A 218002	001	Apr 05, 2024	Mar	NEWA
-----	----	--------------------	---------	----------	-----	--------------	-----	------

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

>A>	+	PFIZER	EQ 0.1MG BASE	N 217439	001	Mar 07, 2024	Mar	NEWA
>A>	+		EQ 0.25MG BASE	N 217439	002	Mar 07, 2024	Mar	NEWA
>A>	+		EQ 0.35MG BASE	N 217439	003	Mar 07, 2024	Mar	NEWA
>A>	+		EQ 0.5MG BASE	N 217439	004	Mar 07, 2024	Mar	NEWA
>A>	+		EQ 0.75MG BASE	N 217439	005	Mar 07, 2024	Mar	NEWA
>A>	+	!	EQ 1MG BASE	N 217439	006	Mar 07, 2024	Mar	NEWA

TAVABOROLE

SOLUTION;TOPICAL

>D> KERYDIN

>D> AB +! ANACOR PHARMS INC 5% N204427 001 Jul 07, 2014 Mar DISC

>A> + @ 5% N204427 001 Jul 07, 2014 Mar DISC

TAVABOROLE

>D> AB ENCUBE 5% A211297 001 Oct 13, 2020 Mar CHRS

>A> AB ! 5% A211297 001 Oct 13, 2020 Mar CHRS

>A> TEDUGLUTIDE

>A> POWDER;SUBCUTANEOUS

>A> GATTEX KIT

>A> +! TAKEDA PHARMS USA 5MG/VIAL N203441 001 Dec 21, 2012 Mar CAIN

>D> TEDUGLUTIDE RECOMBINANT

>D> POWDER;SUBCUTANEOUS

>D> GATTEX KIT

>D> +! TAKEDA PHARMS USA 5MG/VIAL N203441 001 Dec 21, 2012 Mar CAIN

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB CHARTWELL RX 15MG A071427 001 Jan 12, 1988 Jan CAHN

AB 30MG A071428 001 Jan 12, 1988 Jan CAHN

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

TENOFOVIR ALAFENAMIDE FUMARATE

>A> AB APOTEX EQ 25MG BASE A213867 001 Mar 21, 2024 Mar NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB MYLAN LABS LTD 300MG A079071 001 Feb 29, 2024 Feb NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB BIONPHARMA EQ 1MG BASE A075667 001 Jul 28, 2000 Jan CMFD

AB EQ 2MG BASE A075667 002 Jul 28, 2000 Jan CMFD

AB EQ 5MG BASE A075667 003 Jul 28, 2000 Jan CMFD

AB EQ 10MG BASE A075667 004 Jul 28, 2000 Jan CMFD

TERBINAFINE

GEL;TOPICAL

LAMISIL

@ KARO HLTHCARE 1% N020846 001 Apr 29, 1998 Feb CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL

@ KARO HLTHCARE 1% N020749 001 Oct 17, 1997 Feb CAHN

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

>D> AB CIPLA EQ 250MG BASE A077137 001 Jul 02, 2007 Mar DISC

>A> @ EQ 250MG BASE A077137 001 Jul 02, 2007 Mar DISC

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

>D> AB GLENMARK PHARMS 7MG A209663 001 Nov 15, 2018 Mar CAHN

>A> AB 7MG A209663 001 Nov 15, 2018 Mar CAHN

>D> AB 14MG A209663 002 Nov 15, 2018 Mar CAHN

>A> AB 14MG A209663 002 Nov 15, 2018 Mar CAHN

>A> AB TORRENT 7MG A209697 001 Apr 04, 2024 Mar NEWA

>A> AB 14MG A209697 002 Apr 04, 2024 Mar NEWA

TESTOSTERONE

		GEL, METERED; TRANSDERMAL						
		FORTESTA						
		+ @ ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jan	DISC
		TESTOSTERONE						
		! ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan	CTEC
AB		!	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan	CHRS
		SOLUTION, METERED; TRANSDERMAL						
		TESTOSTERONE						
>D>	AT	DASH PHARMS	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Mar	CAHN
>A>	AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Mar	CAHN

TESTOSTERONE ENANTHATE

		INJECTABLE; INJECTION						
		TESTOSTERONE ENANTHATE						
AO		EUGIA PHARMA	200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA
AO			200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA

TESTOSTERONE UNDECANOATE

		CAPSULE; ORAL						
		TLANDO						
		+! VERITY	112.5MG	N208088	001	Mar 28, 2022	Jan	CAHN

TETRABENAZINE

		TABLET; ORAL						
		TETRABENAZINE						
AB		SLATE RUN PHARMA	12.5MG	A213316	001	Jan 22, 2020	Feb	CAHN
AB			25MG	A213316	002	Jan 22, 2020	Feb	CAHN

TETRACYCLINE HYDROCHLORIDE

		TABLET; ORAL						
		SUMYCIN						
		STRIDES PHARMA	250MG	A061147	001		Jan	CMFD
		!	500MG	A061147	004		Jan	CMFD

TIOPRONIN

		TABLET; ORAL						
		TIOPRONIN						
>D>	AB	PAR PHARM INC	100MG	A216198	001	Jun 02, 2022	Mar	DISC
>A>		@	100MG	A216198	001	Jun 02, 2022	Mar	DISC
		TABLET, DELAYED RELEASE; ORAL						
		THIOLA EC						
AB		+ MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019	Jan	CFTG
		TIOPRONIN						
AB		TORRENT	100MG	A216990	001	Jan 30, 2024	Jan	NFTG
AB			300MG	A216990	002	Jan 30, 2024	Jan	NEWA

TIRZEPATIDE

		SOLUTION; SUBCUTANEOUS						
		MOUNJARO						
		+! ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	007	Jul 28, 2023	Jan	NEWA
		+!	5MG/0.5ML (5MG/0.5ML)	N215866	008	Jul 28, 2023	Jan	NEWA
		+!	7.5MG/0.5ML (7.5MG/0.5ML)	N215866	009	Jul 28, 2023	Jan	NEWA
		+!	10MG/0.5ML (10MG/0.5ML)	N215866	010	Jul 28, 2023	Jan	NEWA
		+!	12.5MG/0.5ML (12.5MG/0.5ML)	N215866	011	Jul 28, 2023	Jan	NEWA
		+!	15MG/0.5ML (15MG/0.5ML)	N215866	012	Jul 28, 2023	Jan	NEWA
		MOUNJARO (AUTOINJECTOR)						
		+! ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	Jan	CTNA
		+!	5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	Jan	CTNA
		+!	7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	Jan	CTNA
		+!	10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	Jan	CTNA
		+!	12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	Jan	CTNA
		+!	15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	Jan	CTNA
>D>		ZEPBOUND						
>D>		+! ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023	Mar	CTNA
>A>		+!	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	007	Mar 28, 2024	Mar	NEWA
>D>		+!	5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023	Mar	CTNA
>A>		+!	5MG/0.5ML (5MG/0.5ML)	N217806	008	Mar 28, 2024	Mar	NEWA
>D>		+!	7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023	Mar	CTNA
>A>		+!	7.5MG/0.5ML (7.5MG/0.5ML)	N217806	009	Mar 28, 2024	Mar	NEWA
>D>		+!	10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023	Mar	CTNA

SOLUTION;SUBCUTANEOUS

>A>		ZEPBOUND							
>A>	+	10MG/0.5ML	(10MG/0.5ML)	N217806	010	Mar 28,	2024	Mar	NEWA
>D>	+	12.5MG/0.5ML	(12.5MG/0.5ML)	N217806	005	Nov 08,	2023	Mar	CTNA
>A>	+	12.5MG/0.5ML	(12.5MG/0.5ML)	N217806	011	Mar 28,	2024	Mar	NEWA
>D>	+	15MG/0.5ML	(15MG/0.5ML)	N217806	006	Nov 08,	2023	Mar	CTNA
>A>	+	15MG/0.5ML	(15MG/0.5ML)	N217806	012	Mar 28,	2024	Mar	NEWA
>A>		ZEPBOUND (AUTOINJECTOR)							
>A>	+	2.5MG/0.5ML	(2.5MG/0.5ML)	N217806	001	Nov 08,	2023	Mar	CTNA
>A>	+	5MG/0.5ML	(5MG/0.5ML)	N217806	002	Nov 08,	2023	Mar	CTNA
>A>	+	7.5MG/0.5ML	(7.5MG/0.5ML)	N217806	003	Nov 08,	2023	Mar	CTNA
>A>	+	10MG/0.5ML	(10MG/0.5ML)	N217806	004	Nov 08,	2023	Mar	CTNA
>A>	+	12.5MG/0.5ML	(12.5MG/0.5ML)	N217806	005	Nov 08,	2023	Mar	CTNA
>A>	+	15MG/0.5ML	(15MG/0.5ML)	N217806	006	Nov 08,	2023	Mar	CTNA

TOLCAPONE

TABLET;ORAL

TOLCAPONE

>D>	AB	PAR PHARM INC	100MG	A204584	001	Mar 26,	2015	Mar	DISC
>A>		@	100MG	A204584	001	Mar 26,	2015	Mar	DISC

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

@	AJANTA PHARMA LTD	25MG	A215663	001	Aug 15,	2023	Feb	DISC
@		50MG	A215663	002	Aug 15,	2023	Feb	DISC
@		100MG	A215663	003	Aug 15,	2023	Feb	DISC
@		200MG	A215663	004	Aug 15,	2023	Feb	DISC

TABLET;ORAL

TOPIRAMATE

@	AIPING PHARM INC	25MG	A078499	001	Jan 07,	2010	Feb	CAHN
@		50MG	A078499	002	Jan 07,	2010	Feb	CAHN
@		100MG	A078499	003	Jan 07,	2010	Feb	CAHN
@		200MG	A078499	004	Jan 07,	2010	Feb	CAHN
@	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27,	2009	Jan	DISC
@		100MG	A076327	002	Mar 27,	2009	Jan	DISC
@		200MG	A076327	003	Mar 27,	2009	Jan	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

>D>		@ MYLAN LABS LTD	EQ 4MG BASE/VIAL	A091542	001	Aug 28,	2012	Mar	CAHN
>A>		@ RISING	EQ 4MG BASE/VIAL	A091542	001	Aug 28,	2012	Mar	CAHN

TORSEMIDE

>D>	INJECTABLE;INJECTION								
>D>	DEMADEX								
>D>	+	@ ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23,	1993	Mar	CDFR
>D>	+	@	20MG/2ML (10MG/ML)	N020137	001	Aug 23,	1993	Mar	CDFR
>D>	TORSEMIDE								
>D>		@ AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21,	2010	Mar	CDFR
>D>		@	50MG/5ML (10MG/ML)	A090656	002	Apr 21,	2010	Mar	CDFR
>D>		@ WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11,	2008	Mar	CDFR
>D>		@	50MG/5ML (10MG/ML)	A078007	002	Jun 11,	2008	Mar	CDFR
>A>	SOLUTION;INTRAVENOUS								
>A>	DEMADEX								
>A>	+	@ ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23,	1993	Mar	CDFR
>A>	+	@	20MG/2ML (10MG/ML)	N020137	001	Aug 23,	1993	Mar	CDFR
>A>	TORSEMIDE								
>A>		@ AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21,	2010	Mar	CDFR
>A>		@	50MG/5ML (10MG/ML)	A090656	002	Apr 21,	2010	Mar	CDFR
>A>		@ WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11,	2008	Mar	CDFR
>A>		@	50MG/5ML (10MG/ML)	A078007	002	Jun 11,	2008	Mar	CDFR

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

>A>		RUBICON	75MG	A208708	004	Apr 04,	2024	Mar	NFTG
-----	--	---------	------	---------	-----	---------	------	-----	------

TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

@ AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020	Jan CAHN
@	0.5%	A211315	002	Mar 18, 2020	Jan CAHN

SPRAY;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	SAPTALIS PHARMS	0.147MG/GM	A207094	001	Dec 07, 2016	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

TRIAZOLAM

TABLET;ORAL

TRIAZOLAM

@ HIKMA	0.125MG	A074224	001	Jun 01, 1994	Feb DISC
@	0.25MG	A074224	002	Jun 01, 1994	Feb DISC

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

>A> AB	BRECKENRIDGE	EQ 25MG BASE	A208127	001	Apr 15, 2016	Mar CAHN
>A> AB	!	EQ 50MG BASE	A208127	002	Apr 15, 2016	Mar CAHN
>A> AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Mar CAHN
>D> AB	CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Mar CAHN
>D> AB	!	EQ 50MG BASE	A208127	002	Apr 15, 2016	Mar CAHN
>D> AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Mar CAHN

TROSPIUM CHLORIDE

TABLET;ORAL

TROSPIUM CHLORIDE

AB	ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb CAHN
----	---------------	------	---------	-----	--------------	----------

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+!	GLAXO GRP ENGLAND	EQ 0.0625MG BASE/INH	N205382	001	Apr 30, 2014	Jan CPOT
----	-------------------	----------------------	---------	-----	--------------	----------

>A> VADADUSTAT

TABLET;ORAL

VAFSEO

>A>	+ AKEBIA	150MG	N215192	001	Mar 27, 2024	Mar NEWA
>A>	+	300MG	N215192	002	Mar 27, 2024	Mar NEWA
>A>	+!	450MG	N215192	003	Mar 27, 2024	Mar NEWA

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

>D>	+ NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017	Mar CFTG
>A> AB	+	EQ 40MG BASE	N209241	001	Apr 11, 2017	Mar CFTG
>D>	+!	EQ 80MG BASE	N209241	002	Oct 04, 2017	Mar CFTG
>A> AB	+!	EQ 80MG BASE	N209241	002	Oct 04, 2017	Mar CFTG

VALBENAZINE TOSYLATE

>A> AB	LUPIN LTD	EQ 40MG BASE	A216064	001	Apr 05, 2024	Mar NFTG
>A> AB		EQ 80MG BASE	A216064	002	Apr 05, 2024	Mar NFTG

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

>D> BX	EYWA	250MG	A207611	001	Aug 05, 2019	Mar DISC
>A>	@	250MG	A207611	001	Aug 05, 2019	Mar DISC

SYRUP;ORAL

VALPROIC ACID

>D> AA	HIKMA	250MG/5ML	A074060	001	Jan 13, 1995	Mar DISC
>A>	@	250MG/5ML	A074060	001	Jan 13, 1995	Mar DISC
AA	QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Jan CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

@ PAI HOLDINGS PHARM	EQ 125MG BASE	A065478	001	Apr 09, 2012	Feb DISC
@	EQ 250MG BASE	A065478	002	Apr 09, 2012	Feb DISC

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

@	PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	DISC
@		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	DISC
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CTNA
+		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CTNA
+		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CTNA

SOLUTION; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N050671	001	Apr 29, 1993	Feb	CPOT
+		EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CDFR
+		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N050671	002	Dec 20, 2010	Feb	CPOT
+		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CDFR
+		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N050671	003	Mar 01, 1999	Feb	CPOT
+		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CDFR
+		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N050671	004	Jan 25, 2024	Feb	NEWA
+		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N050671	005	Jan 25, 2024	Feb	NEWA

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

>A>	AB	AJANTA PHARMA LTD	EQ 0.5MG BASE	A213019	001	Mar 19, 2024	Mar	NEWA
>A>	AB		EQ 1MG BASE	A213019	002	Mar 19, 2024	Mar	NEWA
	AB	AVALANCHE PHARM	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Feb	NEWA
	AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Feb	NEWA
	AB	MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Feb	NEWA
	AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Feb	NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

AP		GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)	A216963	001	Feb 09, 2024	Feb	NEWA
----	--	------------------	-------------------------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

>D>		@ MYLAN LABS LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Mar	CAHN
>A>		@ RISING	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Mar	CAHN

VORICONAZOLE

INJECTABLE; INTRAVENOUS

VORICONAZOLE

>A>	AP	ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Mar	NEWA
-----	----	--------	------------	---------	-----	--------------	-----	------

ZOLMITRIPTAN

SPRAY; NASAL

ZOLMITRIPTAN

AB	!	PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Feb	CHRS
----	---	----------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

ZOLMITRIPTAN

>D>	AB	INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar	DISC
>A>		@	2.5MG	A204284	001	Apr 09, 2014	Mar	DISC
>D>	AB		5MG	A204284	002	Apr 09, 2014	Mar	DISC
>A>		@	5MG	A204284	002	Apr 09, 2014	Mar	DISC

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

>D>	AB	INVAGEN PHARMS	5MG	A078184	001	Sep 07, 2007	Mar	DISC
>A>		@	5MG	A078184	001	Sep 07, 2007	Mar	DISC
>D>	AB		10MG	A078184	002	Sep 07, 2007	Mar	DISC
>A>		@	10MG	A078184	002	Sep 07, 2007	Mar	DISC

ACETAMINOPHEN

SUPPOSITORY;RECTAL

>D>	ACEPHEN						
>D>	COSETTE	120MG	N018060	001		Mar	DISC
>A>	@	120MG	N018060	001		Mar	DISC
>D>		325MG	A072344	001	Mar 27, 1992	Mar	DISC
>A>	@	325MG	A072344	001	Mar 27, 1992	Mar	DISC
>D>		650MG	A072237	001	Mar 27, 1992	Mar	DISC
>A>	@	650MG	A072237	001	Mar 27, 1992	Mar	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN; IBUPROFEN

>A>	AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024	Mar	NEWA
-----	----------------------	-------------	---------	-----	--------------	-----	------

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

	GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024	Feb	NEWA
--	------------------	-------	---------	-----	--------------	-----	------

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

	DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024	Feb	NFTG
--	-------------------	--------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb	CDFR
@	APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Feb	CDFR
	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb	CDFR
	BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb	CDFR
	CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb	CDFR
@	CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb	CDFR
@	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb	CDFR
	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	CDFR
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb	CDFR
		5MG/5ML	A090254	002	Apr 09, 2008	Feb	CDFR
@	PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb	CDFR
	QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb	CDFR
@	RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb	CDFR
	TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb	CDFR
		5MG/5ML	A201546	001	May 20, 2011	Feb	CDFR
@	TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb	CDFR

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb	CDFR
@	APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Feb	CDFR
	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb	CDFR
	BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb	CDFR
	CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb	CDFR
@	CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb	CDFR
@	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb	CDFR
	PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb	CDFR
@	PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb	CDFR
@	RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Feb	CDFR
	TARO	5MG/5ML	A090182	001	Apr 22, 2008	Feb	CDFR
		5MG/5ML	A201546	002	May 20, 2011	Feb	CDFR
@	TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Feb	CDFR

CHILDREN'S ZYRTEC ALLERGY

+!	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Feb	CDFR
----	----------------------	---------	---------	-----	--------------	-----	------

CHILDREN'S ZYRTEC HIVES RELIEF

+!	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Feb	CDFR
----	----------------------	---------	---------	-----	--------------	-----	------

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	SUN PHARM	5MG	A090142	001	Aug 30, 2011	Mar	DISC
>A>	@	5MG	A090142	001	Aug 30, 2011	Mar	DISC
>D>			A090142	003	Aug 30, 2011	Mar	DISC
>A>	@		A090142	003	Aug 30, 2011	Mar	DISC

CLOTRIMAZOLECREAM;VAGINAL
TRIVAGIZOLE 3

>D>	TARO	2%	N021143	001	Apr 12, 2000	Mar	CAHN
>A>		2%	N021143	001	Apr 12, 2000	Mar	CAHN

DICLOFENAC SODIUMGEL;TOPICAL
DICLOFENAC SODIUM

>D>	HIKMA	1%	A209484	001	Nov 21, 2018	Mar	DISC
>A>	@	1%	A209484	001	Nov 21, 2018	Mar	DISC

DOCOSANOLCREAM;TOPICAL
DOCOSANOL

>D>	AUROBINDO PHARMA LTD	10%	A217090	001	Mar 01, 2024	Feb	NEWA
>D>	ENCUBE	10%	A212385	001	Oct 07, 2022	Mar	CAHN
>A>	P AND L DEVELOPMENT	10%	A212385	001	Oct 07, 2022	Mar	CAHN

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

GUARDIAN DRUG EQ 20MG BASE

A216149 001 Mar 15, 2023 Feb CAHN

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

@ AUROBINDO PHARMA LTD EQ 20MG BASE

A214473 001 Jul 12, 2023 Jan DISC

FAMOTIDINETABLET;ORAL
FAMOTIDINE

>A>	GRAVITI PHARMS	10MG	A218461	001	Mar 14, 2024	Mar	NEWA
>A>		20MG	A218461	002	Mar 14, 2024	Mar	NEWA

FLUTICASONE PROPIONATESPRAY, METERED;NASAL
FLUTICASONE PROPIONATE

>D>	HIKMA	0.05MG/SPRAY	A208024	001	Apr 17, 2019	Mar	DISC
>A>	@	0.05MG/SPRAY	A208024	001	Apr 17, 2019	Mar	DISC

IBUPROFENCAPSULE;ORAL
IBUPROFEN

>D>	AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A215777	001	Sep 14, 2023	Mar	DISC
>A>	@	EQ 200MG FREE ACID AND POTASSIUM SALT	A215777	001	Sep 14, 2023	Mar	DISC
>D>	PATHEON SOFTGELS	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Mar	CAHN
>A>		EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Mar	CAHN
		EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Feb	NEWA

SUSPENSION/DROPS;ORAL

IBUPROFEN

>A>	AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024	Mar	NEWA
-----	----------------------	---------	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDESOLUTION;ORAL
LOPERAMIDE HYDROCHLORIDE

@ SAPTALIS PHARMS 1MG/5ML

A074352 001 Nov 17, 1995 Jan CAHN

NAPROXEN SODIUMTABLET;ORAL
NAPROXEN SODIUM

@ SUN PHARM INDS LTD 220MG

A091183 001 May 20, 2011 Jan DISC

NICOTINE POLACRILEXTROCHE/LOZENGE; ORAL
NICORETTE

+	HALEON US HOLDINGS	EQ 2MG BASE	N022360	001	May 18, 2009	Jan	CAHN
+	!	EQ 4MG BASE	N022360	002	May 18, 2009	Jan	CAHN

NORGESTRELTABLET; ORAL
OPILL

+	!	LABORATOIRE HRA	0.075MG	N017031	001		Feb	CMFD
---	---	-----------------	---------	---------	-----	--	-----	------

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

@	SAPTALIS PHARMS	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Jan	CAHN
---	-----------------	--------------	---------	-----	--------------	-----	------

POVIDONE-IODINESPONGE; TOPICAL
E-Z SCRUB 201

+	@	BECTON DICKINSON	20%	N019240	001	Nov 29, 1985	Feb	DISC
---	---	------------------	-----	---------	-----	--------------	-----	------

+	@	BECTON DICKINSON	10%	N019476	001	Jan 07, 1987	Feb	DISC
---	---	------------------	-----	---------	-----	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

>D>		THINQ PHARM-CRO PVT	EQ 75MG BASE	A210250	001	Aug 30, 2019	Mar	DISC
-----	--	---------------------	--------------	---------	-----	--------------	-----	------

>A>	@		EQ 75MG BASE	A210250	001	Aug 30, 2019	Mar	DISC
-----	---	--	--------------	---------	-----	--------------	-----	------

TERBINAFINEGEL; TOPICAL
LAMISIL AT

+	!	KARO HLTHCARE	1%	N021958	001	Jul 24, 2006	Feb	CAHN
---	---	---------------	----	---------	-----	--------------	-----	------

TERBINAFINE HYDROCHLORIDECREAM; TOPICAL
LAMISIL

+	!	KARO HLTHCARE	1%	N020980	001	Mar 09, 1999	Feb	CAHN
---	---	---------------	----	---------	-----	--------------	-----	------

+	!	KARO HLTHCARE	1%	N021124	001	Mar 17, 2000	Feb	CAHN
---	---	---------------	----	---------	-----	--------------	-----	------

+	!	KARO HLTHCARE	1%	N021124	002	Mar 17, 2000	Feb	CAHN
---	---	---------------	----	---------	-----	--------------	-----	------

+	!	KARO HLTHCARE	1%	N021124	002	Mar 17, 2000	Feb	CAHN
---	---	---------------	----	---------	-----	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 3 MARCH 2024

NO MARCH 2024 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001	>A> 11918693	Jul 09, 2041	DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	>A> 11896567	Oct 26, 2031	U-3744			
	>A> 11896567	Oct 26, 2031	U-3745			
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361 001					CGT	Jun 12, 2024
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-3809		>A> I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-3809		>A> I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-3809		>A> I-937	Jan 18, 2027
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	>A> 11903908	Dec 04, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	>A> 11903908	Dec 04, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	11890261	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	11890261	Feb 15, 2038	U-2497			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	>A> 11918685	Oct 06, 2037	U-3447			
	>A> 11918685	Oct 06, 2037	U-3448			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11878011	May 27, 2042	U-3816			
	>A> 11931463	Feb 12, 2034	DP U-3866			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	11896562	Mar 10, 2037	U-3299			
<u>APREPITANT - APONVIE</u>						
N 216457 001	11878074	Sep 18, 2035	U-3787			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	>A> 11925704	Jun 07, 2037	DP U-3853			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	Jul 28, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		>A> NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	>A> 11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	>A> 11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	>A> 11931328	Jul 29, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	>A> 11925648	Apr 21, 2041	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
	>A> 11896759	Jan 26, 2038	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
	>A> 11896759	Jan 26, 2038	DP			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001					I-931	Dec 14, 2026
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	>A> 11926584	Jun 19, 2040	U-3873			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	>A> 11926584	Jun 19, 2040	U-3873			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040	U-3357			
	11877997	Feb 19, 2040	U-3356			
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034	U-3797		NCE	Jan 05, 2029
	10258564	Nov 22, 2034	U-3798			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034	U-3799			
	10265334	Jul 03, 2032	DP			
	10322081	Jul 10, 2035	U-3793			
	10322081	Jul 10, 2035	U-3794			
	10322081	Jul 10, 2035	U-3795			
	10322081	Jul 10, 2035	U-3796			
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035	U-3790			
	10736839	Jul 10, 2035	U-3791			
	10736839	Jul 10, 2035	U-3792			
	11040006	Jul 10, 2035	DP U-3789			
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP U-3788			
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP U-3803			
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030	U-3802			
	9855211	Feb 27, 2034	DP U-3800			
	9855211	Feb 27, 2034	DP U-3801			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					>A> ODE-468	Feb 23, 2031
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	>A> 7390791	Apr 17, 2025	DS DP		>A> ODE-468	Feb 23, 2031
	>A> 7390791*PED	Oct 17, 2025				
	>A> 8754065	Aug 15, 2032	DS DP U-257			
	>A> 8754065*PED	Feb 15, 2033				
	>A> 9296769	Aug 15, 2032	DS DP U-257			
	>A> 9296769*PED	Feb 15, 2033				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2025	DS DP			
<u>BIRCH TRITERPENES - FILSUVEZ</u>						
N 215064 001	11083733	Jan 04, 2039	DP		>A> NCE	Dec 18, 2028
	11266660	Jan 04, 2039	U-3811		ODE-460	Dec 18, 2030
	8828444	Jun 21, 2025	DP			
	9352041	Nov 24, 2030	U-3811			
	9827214	Nov 24, 2030	U-3811			
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	11903993	May 20, 2039	U-3817			
	11918622	May 20, 2039	U-3817			
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027 001					PC	Jul 06, 2024
<u>BUDESONIDE - EOHILIA</u>						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		>A> ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028	U-3820			
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039	U-3820			
	8324192	Aug 03, 2029	U-3820			
	8497258	Nov 09, 2026	U-3820			
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026	U-3820			
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026	U-3820			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	11896719	Jan 23, 2043	U-3810		>A> ODE-464	Dec 20, 2030
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	>A> 11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	>A> 11925706	Jan 22, 2041	DP U-3380			
	>A> 11931459	Mar 17, 2042	U-3839			
	>A> 11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	>A> 11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	>A> 11925706	Jan 22, 2041	DP U-3380			
	>A> 11931459	Mar 17, 2042	U-3839			
	>A> 11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001					>A> I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002					>A> I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003					>A> I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004					>A> I-933	Jan 23, 2027
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11883373	Jan 23, 2043	U-3419			
	11896563	Dec 01, 2041	U-3419			
	>A> 11925636	Jan 20, 2043	U-3419			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11154509	Apr 25, 2028	U-3815			
	9498486	Apr 25, 2028	U-3814			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11865102	Apr 26, 2039	DS DP U-2781			
	11865102	Apr 26, 2039	DS DP U-3236			
	11865102	Apr 26, 2039	DS DP U-3277			
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001					>A> NCE	Jul 21, 2028
<u>CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM - EXBLIFEP</u>						
N 216165 001	>A> 11124526	Nov 07, 2034	U-3852		>A> NCE	Feb 22, 2029
	>A> 7687488	Dec 03, 2027	DS DP U-3851		>A> GAIN	Feb 22, 2034
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
N 218158 001	>A> 10588913	May 09, 2036	DP		>A> NP	Mar 04, 2027
	>A> 11376262	May 09, 2036	DP U-19			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	>A> 11944594	Nov 01, 2033	U-3864			
	>A> 11944595	Nov 01, 2033	U-3867			
	>A> 11944595	Nov 01, 2033	U-3868			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP	Y		
	8633162	Aug 27, 2024	U-1479	Y		
	8642556	Aug 27, 2024	DP	Y		
	8648048	Aug 27, 2024	U-1483	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8685930	Aug 27, 2024	DP	Y		
	9248191	Aug 27, 2024	U-1479	Y		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	11504333*PED	Dec 29, 2038			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP		PED	Sep 16, 2026
	7994185*PED	Jul 20, 2030			PED	Sep 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-3565			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-3565			
	8835443*PED	Dec 10, 2025				
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	>A> 7456254	Jun 30, 2025	U-2139			
	>A> 8431685	Apr 13, 2025	U-2139			
	>A> 8461105	Apr 13, 2025	U-2139			
	>A> 9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	>A> 11903955	Mar 09, 2040	U-3825			
	>A> 7456254	Jun 30, 2025	U-2139			
	>A> 8431685	Apr 13, 2025	U-2139			
	>A> 8461105	Apr 13, 2025	U-2139			
	>A> 9238076	Apr 15, 2024	U-2139			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040	U-3756			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11890272	Jul 17, 2040	U-3756			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8168209	Nov 22, 2025	DP	Y		
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641	Y		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641	Y		
	8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP	Y		
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641	Y		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641	Y		
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP	Y		
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641	Y		
	8362085*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8598233	Nov 22, 2025	DP	Y		
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8168209	Nov 22, 2025	DP	Y		
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641	Y		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641	Y		
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP	Y		
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641	Y		
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP	Y		
	8598233*PED	May 22, 2026				
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001					>A> ODE-144	May 12, 2029
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11872218	Jan 03, 2028	U-1969			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001					>A> NP ODE-462	Dec 13, 2026 Dec 13, 2030
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	7419983	Jul 06, 2029	DS DP			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002					ODE-457	Jan 07, 2029
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	10683499	Aug 25, 2034	DS DP U-2378		NCE	Dec 21, 2028
	8101743	Apr 01, 2025	DS DP		ODE-461	Dec 21, 2030
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	>A> 10898482	Feb 09, 2036	DP U-2518		I-930	Jan 19, 2027
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
	>A> 10898482	Feb 09, 2036	DP U-3805			
	>A> 10898482	Feb 09, 2036	DP U-3806			
	>A> 10898482	Feb 09, 2036	DP U-3807			
	>A> 11077106	Feb 02, 2038	U-3196			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	>A> 11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	>A> 10898482	Feb 09, 2036	DP U-2518		I-930	Jan 19, 2027
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
	>A> 10898482	Feb 09, 2036	DP U-3805			
	>A> 10898482	Feb 09, 2036	DP U-3806			
	>A> 10898482	Feb 09, 2036	DP U-3807			
	>A> 11077106	Feb 02, 2038	U-3196			
	>A> 11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	>A> 10898482	Feb 09, 2036	DP U-2518		I-930	Jan 19, 2027
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
	>A> 10898482	Feb 09, 2036	DP U-3805			
	>A> 10898482	Feb 09, 2036	DP U-3806			
	>A> 10898482	Feb 09, 2036	DP U-3807			
	>A> 11077106	Feb 02, 2038	U-3196			
	>A> 11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039	U-3785			
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001	11884626	Jun 21, 2036	U-3731			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	RE49826	Jul 29, 2035	DS			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	RE49826	Jul 29, 2035	DS			
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	>A> 8168615	Jul 13, 2029	DP			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001					NCE	Nov 30, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002					NCE	Nov 30, 2028
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	>A> 8969336	Nov 28, 2032	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	>A> 11891372	Apr 13, 2036			U-3254	
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	>A> 11891372	Apr 13, 2036			U-3254	
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032		U-1383	Y	
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	>A> 11938217	Oct 25, 2038	DP			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266 001					PC	Jun 24, 2024
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HYDROXYUREA - XROMI</u>						
N 216593 001					>A> ODE-470	Apr 04, 2031
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8754090	Jun 03, 2031	U-1456	Y		
	8754090*PED	Dec 03, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8754090	Jun 03, 2031	U-1456	Y		
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	>A> 10004746	Jun 03, 2031	U-3846			
	>A> 10004746	Jun 03, 2031	U-3847			
	>A> 10004746	Jun 03, 2031	U-3848			
	>A> 10004746	Jun 03, 2031	U-3849			
	>A> 10016435	Jun 03, 2031	U-3845			
	>A> 10463668	Oct 24, 2034	U-2970			
	>A> 10478439	Jun 03, 2031	U-2666			
	>A> 10478439	Jun 03, 2031	U-2970			
	>A> 10478439	Jun 03, 2031	U-3422			
	>A> 10478439	Jun 03, 2031	U-3842			
	>A> 10478439	Jun 03, 2031	U-3843			
	>A> 10478439	Jun 03, 2031	U-3844			
	>A> 10478439	Jun 03, 2031	U-3845			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 10695350	Oct 24, 2034	U-2970			
	>A> 10751342	Jun 03, 2031	U-2666			
	>A> 10751342	Jun 03, 2031	U-3842			
	>A> 10751342	Jun 03, 2031	U-3843			
	>A> 10751342	Jun 03, 2031	U-3844			
	>A> 11672803	Jun 03, 2031	U-2666			
	>A> 11672803	Jun 03, 2031	U-3842			
	>A> 11672803	Jun 03, 2031	U-3843			
	>A> 11672803	Jun 03, 2031	U-3844			
	>A> 8476284	Dec 28, 2026	U-3843			
	>A> 8476284	Dec 28, 2026	U-3844			
	>A> 8476284	Dec 28, 2026	U-3845			
	>A> 8497277	Dec 28, 2026	U-2666			
	>A> 8497277	Dec 28, 2026	U-2970			
	>A> 8497277	Dec 28, 2026	U-3422			
	>A> 8497277	Dec 28, 2026	U-3842			
	>A> 8497277	Dec 28, 2026	U-3843			
	>A> 8497277	Dec 28, 2026	U-3844			
	>A> 8497277	Dec 28, 2026	U-3845			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8563563	Apr 26, 2027	U-2666			
	>A> 8563563	Apr 26, 2027	U-3842			
	>A> 8563563	Apr 26, 2027	U-3843			
	>A> 8563563	Apr 26, 2027	U-3844			
	>A> 8563563	Apr 26, 2027	U-3845			
	>A> 8703780	Dec 28, 2026	U-2666			
	>A> 8703780	Dec 28, 2026	U-3842			
	>A> 8952015	Dec 28, 2026	U-2666			
	>A> 8952015	Dec 28, 2026	U-3842			
	>A> 8952015	Dec 28, 2026	U-3843			
	>A> 8952015	Dec 28, 2026	U-3844			
	>A> 8952015	Dec 28, 2026	U-3845			
	>A> 8999999	Jun 03, 2031	U-2666			
	>A> 8999999	Jun 03, 2031	U-3842			
	>A> 8999999	Jun 03, 2031	U-3843			
	>A> 8999999	Jun 03, 2031	U-3844			
	>A> 9125889	Jun 03, 2031	U-3845			
	>A> 9795604	Oct 24, 2034	U-2970			
	>A> 9795604	Oct 24, 2034	U-3422			
	>A> 9795604*PED	Apr 24, 2035				
	>A> 9801881	Jun 03, 2031	U-3846			
	>A> 9801881	Jun 03, 2031	U-3847			
	>A> 9801883	Jun 03, 2031	U-2666			
	>A> 9801883	Jun 03, 2031	U-3842			
	>A> 9801883	Jun 03, 2031	U-3843			
	>A> 9801883	Jun 03, 2031	U-3844			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	001				NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	002				NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	003				NPP	May 11, 2026
<u>ILOPROST - AURLUMYN</u>						
N 217933	001				>A> NP >A> ODE-465	Feb 13, 2027 Feb 13, 2031
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	001	11850245	Apr 30, 2030	U-1455		
		11850245	Apr 30, 2030	U-172		
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883	001				CGT	Jul 10, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276	001				NCE ODE-456	Dec 05, 2028 Dec 05, 2030
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793	001	>A> 11344552	Aug 19, 2036	U-3824	>A> I-932 >A> ODE-463	Feb 13, 2027 Feb 13, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	001				NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	002				NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501	001				NPP ODE-453 ODE-459 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>LATANOPROST - IYUZEH</u>						
N 216472	001	8637054	Jul 08, 2031	DP U-446		
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795	001	>A> 8058467	Feb 21, 2029	DS U-2144		
<u>LEMBorexant - DAYVIGO</u>						
N 212028	001	>A> 10702529	Oct 21, 2035	DP		
		>A> 11026944	Oct 21, 2035	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	>A> 10702529	Oct 21, 2035	DP			
	>A> 11026944	Oct 21, 2035	DP			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	>A> 10259791	Aug 26, 2035	DS		>A> I-868	Aug 10, 2024
	>A> 10259791*PED	Feb 26, 2036			>A> M-269	Jul 21, 2024
	>A> 10407393	Aug 26, 2035	DS		>A> M-272	Dec 19, 2024
	>A> 10407393*PED	Feb 26, 2036			>A> ODE-196	Aug 15, 2025
	>A> 11090386	Feb 23, 2036		U-3519	>A> PED	Feb 15, 2026
	>A> 11090386*PED	Aug 23, 2036				
	>A> 11186547	Aug 26, 2035	DS			
	>A> 11186547*PED	Feb 26, 2036				
	>A> 7253286	Oct 24, 2025	DS DP			
	>A> 7253286*PED	Apr 24, 2026				
	>A> 7612208	Sep 19, 2026	DS DP			
	>A> 7612208*PED	Mar 19, 2027				
	>A> 9006256	Jul 27, 2027		U-1695		
	>A> 9006256*PED	Jan 27, 2028				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	>A> 10259791	Aug 26, 2035	DS		>A> I-868	Aug 10, 2024
	>A> 10259791*PED	Feb 26, 2036			>A> M-269	Jul 21, 2024
	>A> 10407393	Aug 26, 2035	DS		>A> M-272	Dec 19, 2024
	>A> 10407393*PED	Feb 26, 2036			>A> ODE-196	Aug 15, 2025
	>A> 11090386	Feb 23, 2036		U-3519	>A> PED	Feb 15, 2026
	>A> 11090386*PED	Aug 23, 2036				
	>A> 11186547	Aug 26, 2035	DS			
	>A> 11186547*PED	Feb 26, 2036				
	>A> 7253286	Oct 24, 2025	DS DP			
	>A> 7253286*PED	Apr 24, 2026				
	>A> 7612208	Sep 19, 2026	DS DP			
	>A> 7612208*PED	Mar 19, 2027				
	>A> 9006256	Jul 27, 2027		U-1695		
	>A> 9006256*PED	Jan 27, 2028				
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	RE46791	Jan 18, 2029	DS DP			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	>A> 11903940	Mar 02, 2040		U-3821		
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	11850182	Sep 14, 2029	DP	U-3819		
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11850182	Sep 14, 2029	DP	U-3819		
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11850182	Sep 14, 2029	DP	U-3819		
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	>A> 11911388	Apr 10, 2030		U-3854		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	>A> 11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	>A> 11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	>A> 11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	>A> 11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	>A> 11911388	Apr 10, 2030	U-3854			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	8598119	Dec 28, 2029	U-543	Y		
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	>A> 11904027	Jul 25, 2038	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	>A> 10512657	Oct 26, 2032	U-3850		>A> I-938	Mar 13, 2027
	>A> 11229661	Oct 26, 2032	U-3850			
	>A> 11918578	Feb 12, 2040	U-3290			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	>A> 11918559	Jul 29, 2039	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					M-303	Jan 08, 2027
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					M-303	Jan 08, 2027
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	>A> 11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	>A> 11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	>A> 11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	>A> 11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	>A> 11911518	Mar 23, 2032	U-2357			
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11903938	Aug 17, 2038	DS	U-2371		
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001 >A>	11944634	Oct 16, 2032	DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041		U-3782		
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041		U-3782		
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041		U-3782		
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11903918	Feb 27, 2035		U-1384		
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043		U-3754	NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	>A> 11925619	May 19, 2043		U-3754		
	>A> 11925620	May 19, 2043		U-3754		
	>A> 11938116	May 19, 2043		U-3754		
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					CGT	Aug 21, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001 >A>	8361977	Dec 23, 2030	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036		U-3784		
	11890316	Dec 28, 2040		U-3232		
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	7449464	Sep 08, 2027	DS DP			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001 >A>	11931350	Mar 23, 2032	DS	U-2986		
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002 >A>	11931350	Mar 23, 2032	DS	U-2986		
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003 >A>	11931350	Mar 23, 2032	DS	U-2986		
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001 >A>	11919838	Apr 20, 2029		U-3862		
	>A> 11919838	Apr 20, 2029		U-3863		
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001 >A>	11911473	Jul 16, 2039		U-623		
	>A> 11911473	Jul 16, 2039		U-624		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	>A> 11911473	Jul 16, 2039	U-623			
	>A> 11911473	Jul 16, 2039	U-624			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	>A> 10357468	May 27, 2035	U-2812		Y	
	>A> 10583130	Mar 31, 2030	U-3869			
	>A> 8168793	Apr 02, 2029	DS DP U-3869			
	>A> 8524746	Jul 14, 2029	U-3869			
	>A> 9550759	Jul 26, 2026	U-3870			
	>A> 9550759	Jul 26, 2026	U-3871			
	>A> 9550759	Jul 26, 2026	U-3872			
	>A> 9630955	Dec 12, 2032	DS DP U-3869			
	>A> 9745290	Oct 10, 2027	DP U-3869			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	>A> 10357468	May 27, 2035	U-2812		Y	
	>A> 10583130	Mar 31, 2030	U-3869			
	>A> 8168793	Apr 02, 2029	DS DP U-3869			
	>A> 8524746	Jul 14, 2029	U-3869			
	>A> 9550759	Jul 26, 2026	U-3870			
	>A> 9550759	Jul 26, 2026	U-3871			
	>A> 9550759	Jul 26, 2026	U-3872			
	>A> 9630955	Dec 12, 2032	DS DP U-3869			
	>A> 9745290	Oct 10, 2027	DP U-3869			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	>A> 10183020	Jan 02, 2035	DP U-1777			
	>A> 10183020	Jan 02, 2035	DP U-2289			
	>A> 10183020	Jan 02, 2035	DP U-3016			
	>A> 10183020	Jan 02, 2035	DP U-3823			
	>A> 8946235	Aug 08, 2032	DS DP U-1777			
	>A> 8946235	Aug 08, 2032	DS DP U-2289			
	>A> 8946235	Aug 08, 2032	DS DP U-3016			
	>A> 8946235	Aug 08, 2032	DS DP U-3823			
	>A> 9732058	Jul 25, 2032	DS DP U-1777			
	>A> 9732058	Jul 25, 2032	DS DP U-2289			
	>A> 9732058	Jul 25, 2032	DS DP U-3016			
	>A> 9732058	Jul 25, 2032	DS DP U-3823			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	>A> 10183020	Jan 02, 2035	DP U-1777			
	>A> 10183020	Jan 02, 2035	DP U-2289			
	>A> 10183020	Jan 02, 2035	DP U-3016			
	>A> 10183020	Jan 02, 2035	DP U-3823			
	>A> 8946235	Aug 08, 2032	DS DP U-1777			
	>A> 8946235	Aug 08, 2032	DS DP U-2289			
	>A> 8946235	Aug 08, 2032	DS DP U-3016			
	>A> 8946235	Aug 08, 2032	DS DP U-3823			
	>A> 9732058	Jul 25, 2032	DS DP U-1777			
	>A> 9732058	Jul 25, 2032	DS DP U-2289			
	>A> 9732058	Jul 25, 2032	DS DP U-3016			
	>A> 9732058	Jul 25, 2032	DS DP U-3823			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534 001					M-14	Jul 21, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535	001				M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535	002				M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194	001				M-14	Jul 21, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899	001 >A>	10239846	Nov 15, 2030	U-3740		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899	002 >A>	10239846	Nov 15, 2030	U-3740		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899	003 >A>	10239846	Nov 15, 2030	U-3740		
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014	001	11844841	Dec 09, 2038	DP U-3172		
		11844841	Dec 09, 2038	DP U-3173		
		11844841	Dec 09, 2038	DP U-3174		
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171	001 >A>	11903994	Feb 22, 2037	U-3826		
	>A>	11903994	Feb 22, 2037	U-3827		
	>A>	11903994	Feb 22, 2037	U-3828		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	001 >A>	6949571	May 23, 2025	DS DP U-106		
	>A>	6949571	May 23, 2025	DS DP U-2088		
	>A>	6949571	May 23, 2025	DS DP U-2089		
	>A>	6949571	May 23, 2025	DS DP U-2428		
	>A>	6949571	May 23, 2025	DS DP U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	002 >A>	6949571	May 23, 2025	DS DP U-106		
	>A>	6949571	May 23, 2025	DS DP U-2088		
	>A>	6949571	May 23, 2025	DS DP U-2089		
	>A>	6949571	May 23, 2025	DS DP U-2428		
	>A>	6949571	May 23, 2025	DS DP U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	003 >A>	6949571	May 23, 2025	DS DP U-106		
	>A>	6949571	May 23, 2025	DS DP U-2088		
	>A>	6949571	May 23, 2025	DS DP U-2089		
	>A>	6949571	May 23, 2025	DS DP U-2428		
	>A>	6949571	May 23, 2025	DS DP U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	004 >A>	6949571	May 23, 2025	DS DP U-106		
	>A>	6949571	May 23, 2025	DS DP U-2088		
	>A>	6949571	May 23, 2025	DS DP U-2089		
	>A>	6949571	May 23, 2025	DS DP U-2428		
	>A>	6949571	May 23, 2025	DS DP U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	005 >A>	6949571	May 23, 2025	DS DP U-106		
	>A>	6949571	May 23, 2025	DS DP U-2088		
	>A>	6949571	May 23, 2025	DS DP U-2089		
	>A>	6949571	May 23, 2025	DS DP U-2428		
	>A>	6949571	May 23, 2025	DS DP U-2429		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	>A> 6949571	May 23, 2025	DS DP U-106			
	>A> 6949571	May 23, 2025	DS DP U-2088			
	>A> 6949571	May 23, 2025	DS DP U-2089			
	>A> 6949571	May 23, 2025	DS DP U-2428			
	>A> 6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	>A> 6949571	May 23, 2025	DS DP U-106			
	>A> 6949571	May 23, 2025	DS DP U-2088			
	>A> 6949571	May 23, 2025	DS DP U-2089			
	>A> 6949571	May 23, 2025	DS DP U-2428			
	>A> 6949571	May 23, 2025	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037		U-665		
	>A> 11925695	Mar 16, 2037		U-665		
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037		U-665		
	>A> 11925695	Mar 16, 2037		U-665		
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034		DP		
	10772829	Jan 31, 2034		DP		
	11090261	Jan 31, 2034		DP		
	11400077	Oct 25, 2039		U-3804		
	11844858	Jan 31, 2034		DP		
	9795560	Jan 31, 2034		DP		
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031		U-3685		
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP U-3130			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					ODE-451	Dec 01, 2030
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002					ODE-451	Dec 01, 2030
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001				>A> I-934		Mar 19, 2027
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002				>A> I-934		Mar 19, 2027
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003				>A> I-934		Mar 19, 2027
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004				>A> I-934		Mar 19, 2027
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11872192	Apr 03, 2039	U-2952			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	>A> 10695361	Sep 16, 2036	U-3831		PED	Jul 21, 2025
	>A> 10695361	Sep 16, 2036	U-3832		PED	Oct 25, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	>A> 10695361*PED	Mar 16, 2037			PED	Apr 22, 2026
	>A> 11007208	Sep 16, 2036	U-3831		PED	Jan 13, 2027
	>A> 11007208	Sep 16, 2036	U-3832			
	>A> 11007208*PED	Mar 16, 2037				
	>A> 11266681	Jul 10, 2038	U-3831			
	>A> 11266681	Jul 10, 2038	U-3832			
	>A> 11266681*PED	Jan 10, 2039				
	>A> 11382926	Sep 16, 2036	U-3831			
	>A> 11382926	Sep 16, 2036	U-3832			
	>A> 11382926*PED	Mar 16, 2037				
	>A> 11491169	May 28, 2041	U-3835			
	>A> 11491169	May 28, 2041	U-3836			
	>A> 11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	>A> 11903953	May 28, 2041	U-3835			
	>A> 11903953	May 28, 2041	U-3836			
	>A> 11903953*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	>A> 10695361	Sep 16, 2036	U-3829		NCE	Oct 22, 2025
	>A> 10695361	Sep 16, 2036	U-3830		NPP	Apr 25, 2025
	>A> 10695361*PED	Mar 16, 2037			PED	Jul 21, 2025
	>A> 11007208	Sep 16, 2036	U-3829		PED	Oct 25, 2025
	>A> 11007208	Sep 16, 2036	U-3830		PED	Apr 22, 2026
	>A> 11007208*PED	Mar 16, 2037			PED	Jan 13, 2027
	>A> 11382926	Sep 16, 2036	U-3829			
	>A> 11382926	Sep 16, 2036	U-3830			
	>A> 11382926*PED	Mar 16, 2037				
	>A> 11491169	May 28, 2041	U-3833			
	>A> 11491169	May 28, 2041	U-3834			
	>A> 11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	>A> 11903953	May 28, 2041	U-3837			
	>A> 11903953	May 28, 2041	U-3838			
	>A> 11903953*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001					>A> NCE ODE-455	Nov 15, 2028 Nov 15, 2030
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	>A> 10376517	Sep 17, 2033	U-3861		>A> NCE	Mar 14, 2029
	>A> 11564926	Sep 17, 2033	DS DP U-3861			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	>A> 7452882	Sep 12, 2026	DS DP			
	>A> 9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	>A> 10376517	Sep 17, 2033	U-3861		>A> NCE	Mar 14, 2029
	>A> 11564926	Sep 17, 2033	DS DP U-3861			
	>A> 7452882	Sep 12, 2026	DS DP			
	>A> 9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	>A> 10376517	Sep 17, 2033	U-3861		>A> NCE	Mar 14, 2029
	>A> 11564926	Sep 17, 2033	DS DP U-3861			
	>A> 7452882	Sep 12, 2026	DS DP			
	>A> 9266861	Sep 17, 2033	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
	7125879*PED	Oct 21, 2025				
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	>A> 11911370	Dec 30, 2040	DP			
	>A> 11918564	Dec 30, 2040	DP			
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	>A> 7157456	Aug 28, 2024	DS DP			
	>A> 7157456*PED	Feb 28, 2025				
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001					NP	Dec 15, 2026
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					>A> I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					>A> I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					>A> I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004					>A> I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005					>A> I-935	Mar 08, 2027
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					>A> ODE-469	Jan 31, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	11896572	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	11896572	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	11896572	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	11896572	Jul 21, 2037	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001	>A> 10189837	Oct 20, 2031	DS DP			
	>A> 10780088	Jul 27, 2029	U-3651			
	>A> 8012976	Oct 19, 2029	DS DP			
	>A> 8420650	Jul 27, 2029	DS DP			
	>A> 8735392	Oct 20, 2031	DS DP			
	>A> 9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002	>A> 10189837	Oct 20, 2031	DS DP			
	>A> 10780088	Jul 27, 2029	U-3651			
	>A> 8012976	Oct 19, 2029	DS DP			
	>A> 8420650	Jul 27, 2029	DS DP			
	>A> 8735392	Oct 20, 2031	DS DP			
	>A> 9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	>A> 10189837	Oct 20, 2031	DS DP			
	>A> 10780088	Jul 27, 2029	U-3651			
	>A> 8012976	Oct 19, 2029	DS DP			
	>A> 8420650	Jul 27, 2029	DS DP			
	>A> 8735392	Oct 20, 2031	DS DP			
	>A> 9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004	>A> 10189837	Oct 20, 2031	DS DP			
	>A> 10780088	Jul 27, 2029	U-3651			
	>A> 8012976	Oct 19, 2029	DS DP			
	>A> 8420650	Jul 27, 2029	DS DP			
	>A> 8735392	Oct 20, 2031	DS DP			
	>A> 9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005	>A> 10189837	Oct 20, 2031	DS DP			
	>A> 10780088	Jul 27, 2029	U-3651			
	>A> 8012976	Oct 19, 2029	DS DP			
	>A> 8420650	Jul 27, 2029	DS DP			
	>A> 8735392	Oct 20, 2031	DS DP			
	>A> 9820985	Jul 27, 2029	U-2437			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006	>A> 10189837	Oct 20, 2031	DS DP			
	>A> 10780088	Jul 27, 2029			U-3651	
	>A> 8012976	Oct 19, 2029	DS DP			
	>A> 8420650	Jul 27, 2029	DS DP			
	>A> 8735392	Oct 20, 2031	DS DP			
	>A> 9820985	Jul 27, 2029			U-2437	
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	>A> 11826339	Jan 25, 2033			U-3342	
	>A> 11826339	Jan 25, 2033			U-3343	
	>A> 11918556	Jan 25, 2033			U-3342	
	>A> 11918556	Jan 25, 2033			U-3343	
	>A> 11918557	Apr 07, 2033			U-3003	
	>A> 11918557	Apr 07, 2033			U-3865	
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	>A> 11826339	Jan 25, 2033			U-3342	
	>A> 11918556	Jan 25, 2033			U-3342	
	>A> 11918557	Apr 07, 2033			U-3003	
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031			U-2736	
	10420775	Sep 12, 2031			U-2736	
	10420775	Sep 12, 2031			U-2852	
	10420775	Sep 12, 2031			U-2853	
	11052093	Apr 13, 2032	DS DP		U-2736	
	11052093	Apr 13, 2032	DS DP		U-2852	
	11052093	Apr 13, 2032	DS DP		U-2853	
	11491163	Apr 11, 2033			U-2736	
	11491163	Apr 11, 2033			U-2852	
	11491163	Apr 11, 2033			U-2853	
	8765732	Sep 12, 2031			U-2852	
	8765732	Sep 12, 2031			U-2853	
	9090562	Sep 12, 2031	DS DP			
	9549931	Sep 12, 2031			U-2736	
	9549931	Sep 12, 2031			U-2852	
	9549931	Sep 12, 2031			U-2853	
	9855275	Sep 12, 2031			U-2736	
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	11890270	Aug 08, 2032			U-2346	
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033			U-2418	
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033			U-2418	
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033			U-2418	
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP		U-3378	
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP		U-3378	
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP		U-3378	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	>A> 11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	>A> 11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	>A> 11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	>A> 11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	>A> 11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	>A> 11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007					>A> NCE	May 13, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008					>A> NCE	May 13, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009					>A> NCE	May 13, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010					>A> NCE	May 13, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011					>A> NCE	May 13, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012					>A> NCE	May 13, 2027
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	7166722	Nov 16, 2024	DS DP			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	>A> 11911362	Aug 21, 2040	DP U-3413			
	>A> 11911362	Aug 21, 2040	DP U-3414			
	>A> 11911362	Aug 21, 2040	DP U-3415			
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001					NP	Dec 13, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	>A> 11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	>A> 11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	>A> 11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	>A> 11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	>A> 11826327	Feb 03, 2042	U-3749			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324 11666572	Apr 27, 2038 Apr 27, 2038	U-3783 U-3783			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324 11666572	Apr 27, 2038 Apr 27, 2038	U-3783 U-3783			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11857542	Dec 22, 2041	U-3786			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	>A> 7811595 >A> 8343952	Mar 13, 2028 Aug 14, 2027	DS DP DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	>A> 7811595 >A> 8343952	Mar 13, 2028 Aug 14, 2027	DS DP DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	>A> 7811595 >A> 8343952	Mar 13, 2028 Aug 14, 2027	DS DP DS DP			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	>A> 11903941 >A> 11903942 >A> 11903943 >A> 11911380	Oct 19, 2035 Oct 19, 2035 Oct 19, 2035 Oct 19, 2035	U-1900 DP U-1900 U-1900			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	>A> 10570139 >A> 10570139 >A> 10570139 >A> 10570139 >A> 10570139 >A> 10570139 >A> 10570139 >A> 10570139 >A> 10570139 >A> 10570139 >A> 10570139 >A> 10570139 >A> 11142528 >A> 11142528 >A> 11142528 >A> 11142528 >A> 11142528	Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034 Apr 22, 2034	U-1745 U-2145 U-2537 U-2666 U-3063 U-3486 U-3856 U-3857 U-3858 U-3859 U-3860 DP U-1745 DP U-2145 DP U-2537 DP U-2666 DP U-3063	>A> I-936 >A> ODE-467	Mar 07, 2027 Mar 07, 2031	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	>A> 11142528	Apr 22, 2034	DP U-3486			
	>A> 11142528	Apr 22, 2034	DP U-3856			
	>A> 11142528	Apr 22, 2034	DP U-3857			
	>A> 11142528	Apr 22, 2034	DP U-3858			
	>A> 11142528	Apr 22, 2034	DP U-3860			
	>A> 11701357	Jun 24, 2039	U-3860			
	>A> 11786531	Jan 19, 2043	U-3715			
	>A> 11786531	Jan 19, 2043	U-3716			
	>A> 11786531	Jan 19, 2043	U-3717			
	>A> 11786531	Jan 19, 2043	U-3718			
	>A> 11786531	Jan 19, 2043	U-3719			
	>A> 11786531	Jan 19, 2043	U-3720			
	>A> 11786531	Jan 19, 2043	U-3860			
	11851437	Aug 15, 2037	DS DP			
	>A> 11884674	Aug 15, 2037	U-1745			
	>A> 11884674	Aug 15, 2037	U-2145			
	>A> 11884674	Aug 15, 2037	U-2537			
	>A> 11884674	Aug 15, 2037	U-2666			
	>A> 11884674	Aug 15, 2037	U-3063			
	>A> 11884674	Aug 15, 2037	U-3486			
	>A> 11884674	Aug 15, 2037	U-3860			
	>A> 11896596	Jan 19, 2043	U-3715			
	>A> 11896596	Jan 19, 2043	U-3716			
	>A> 11896596	Jan 19, 2043	U-3717			
	>A> 11896596	Jan 19, 2043	U-3718			
	>A> 11896596	Jan 19, 2043	U-3719			
	>A> 11896596	Jan 19, 2043	U-3720			
	>A> 11896596	Jan 19, 2043	U-3860			
	>A> 11911386	Jan 19, 2043	U-3715			
	>A> 11911386	Jan 19, 2043	U-3716			
	>A> 11911386	Jan 19, 2043	U-3717			
	>A> 11911386	Jan 19, 2043	U-3718			
	>A> 11911386	Jan 19, 2043	U-3719			
	>A> 11911386	Jan 19, 2043	U-3720			
	>A> 11911386	Jan 19, 2043	U-3860			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Dec 24, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm